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Abstract 
Close to 40-percent of new pharmaceuticals and over 30-percent of pipeline drugs exhibit poor water 
solubility which provides challenges in drug delivery, such as the delivery of therapeutic levels of 
drugs to specific biological targets to achieve a desired therapeutic outcome. The challenge of 
increasing drug therapeutic efficacy, with a concurrent minimization of side effects, can be tackled 
through proper design and engineering of a suitable drug delivery system (DDS). There is a high 
demand for DDS that are easy to prepare in the absence of non-pharmaceutical solvents, can carry a 
variety of drugs, have appropriate pharmacokinetic properties including stability under biological 
conditions and/or can deliver a drug to a particular tissue or receptor. The development of 
nanotechnology and bioengineered nanomaterials has greatly increased the potential of nanocarriers for 
drug delivery. Motivated by the challenges experienced with modular design of effective nanocarrier, 
this PhD project aims to develop a platform tailorable nanocarrier emulsion (TNE) with combined long 
circulating and target specific properties, using only biological components and facile processes. 
Nanoemulsions are a promising nanocarrier class for enhancement of solubility and bioavailability of 
poorly soluble drugs. They are emulsions that have extremely small droplet size ranging from 10 nm to 
200 nm with narrow size distribution. The enormous interfacial area formed by nano-sized droplets 
provides further engineering opportunities for sustained and controlled drug delivery. Peptide 
surfactant AM1 was shown to have good emulsification properties and can stabilize oil-in-water 
emulsions prepared from a range of oils. Recent works from our laboratory have shown that AM1 
stabilized emulsion can be used to deliver a hydrophobic molecule to knock down an intracellular 
protein target in vitro. In this PhD work, we tested our hypotheses that a recently-reported biosurfactant 
protein DAMP4, which comprises four repeating sequences closely related to AM1, could be used to 
functionalize the interface of AM1 stabilized oil-in-water emulsion through non-covalent self-assembly 
by addressing the following: (1) Utilization of DAMP4 modified with polyethylene glycol (PEG) to 
investigate whether DAMP4 can display PEG at the interface and impart altered cell association to the 
nanoemulsion; (2) Utilization of DAMP4 modified with monoclonal antibody (mAb) against the CD8+ 
dendritic cells (DCs) specific receptor Clec9A to design a nanocarrier emulsion that is able to target 
Clec9A+ DCs; (3) Encapsulation of a model antigen within the immune evading and Clec9A+ DCs 
targeting emulsion to investigate the immune function in a relevant animal model. This work, to our 
best knowledge, introduces the first DC targeting and immune-evading tailorable nanocarrier emulsion 
(TNE) made using only biological components and assembled in a bottom-up fashion. Simple top-
ii 
 
down sequential addition of immune evading and receptor-specific Ab elements conjugated to DAMP4 
promotes self-assembly at an interface previously formed in the presence of peptide surfactant AM1, 
leading to a functional display at the interface through non-covalent molecular self-assembly. Model 
antigen delivered by TNE can be presented by both MHC I and II molecules, leading to CD4 and CD8 
T cell activation in vivo. Knowledge gained from this work lays a foundation on which to develop a 
TNE platform for vaccines to deliver both humoral and T cell mediated immunity. 
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Chapter 1  Introduction 
1.1. Background 
Biotechnology and biomedical advances have led to the discovery and development of new drugs that 
will change the way we treat disease.  The most common small molecule drugs (SMDs), which are 
normally chemically-manufactured molecular substances, are traditionally processed into ingestible 
tablets or capsules for oral administration. Upon administration, the SMDs dissolve in the 
gastrointestinal (GI) tract, penetrate the intestinal wall and reach their active biological site through the 
blood stream. A majority (~ 90 %) of new chemical entities (NCEs) are discovered to be lipophilic and 
exhibit poor water solubility (Hauss, 2007). In addition, most SMDs used in or designed for cancer and 
autoimmune disease treatments possess unfavourable side effects. Increased systemic administration of 
these anti-cancer SMDs increases potential for adverse side effects.  
 
Another hot topic in pharmaceutical research and development (R&D) is biomolecular drugs (also 
referred to biologics), which make up more than 30 % of the current licensed pharmaceutical products 
(Leader et al., 2008, Swinney and Anthony, 2011). This class of drugs are mostly active components 
created through biotechnology, such as monoclonal antibodies (mAbs), protein therapeutics, growth 
factors and cytokines (Sathish et al., 2013).  Nevertheless, wide adoption of biologics in clinical 
application is limited by their intrinsic instability. Furthermore, most of these drugs cannot be packaged 
into traditional capsules for oral administration as they are susceptible to in vivo enzymatic degradation 
(Sathish et al., 2013).  
 
Owing to the issues stated above, two strategies for improving the therapeutic efficacy of drugs have 
emerged over the past several decades. The first is to design new derivatives of therapeutics with 
enhanced pharmacological properties, e.g. solubility and bioavailability (Collins and Workman, 2006). 
These new derivatives have significantly extended R&D timeframes and require high financial input. 
The other more feasible and economical strategy is to formulate therapeutics with novel drug delivery 
systems (DDS) so that they can be used to cater for specific medication needs (Duncan, 2006, Ferrari, 
2005, Peer et al., 2007).   
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DDS are vehicles by which therapeutic substances are introduced to the body and shuttled to their site 
of action. They are designed to improve therapeutic efficacy and reduce the potential of side-effects. In 
addition to the demand of suitable DDS for new drugs, pharmaceutical companies are also looking to 
re-package blockbuster drugs that are approaching the end of patent life into new DDS in order to 
maintain their lead in the market. The global DDS market in 2010 was $131.6 billion and is expected to 
reach $224.2 billion by the end of 2017 (2011). There is great demand for novel DDS and the prospects 
for this market are truly promising.  
 
1.2. Colloidal nanocarriers for drug delivery   
The challenge of increasing drug therapeutic efficacy, with a concurrent minimization of side effects, 
can be tackled through proper design and engineering of a suitable DDS. The development of 
nanotechnology and bioengineered nanomaterials has greatly increased the potential of nanocarriers for 
drug delivery. An ideal nanocarrier can protect delicate drugs from enzymatic degradation, prolong 
circulation half-life, with targeting characteristics that allow for site-specific delivery. Rational design 
of advanced nanocarrier DDS requires the coordinating behaviour of three components, the vehicle that 
carriers the drug, a targeting or/and immune-evading moiety that recognizes and binds the target, and 
the drug that provides therapeutic action at the specific site. 
 
Colloidal nanocarriers DDS holds great promise to address the stated requirements above (Ferrari, 
2005, Moghimi et al., 2005, Boyd, 2008). Drugs with poor water-solubility and instability under 
external or enzymatic environments can be encapsulated within the hydrophobic compartments of the 
nanocarriers, such as liposomes, emulsions and micelles (Yekollu et al., 2011, Ashley et al., 2011, Han 
et al., 2013, Howell et al., 2013). Obstacles arising from aberrant side effects and inability to cross 
biological barriers could be tackled by surface engineering with immune evading polymers and 
biologically reactive ligands (Boyd, 2008). Current well-studied DDS nanocarriers include but are not 
limited to liposomes, nanoparticles, micelles, nanocapsules, nanospheres and emulsions (Hu et al., 
2011, Ashley et al., 2011, Kaaki et al., 2011, Kukowska-Latallo et al., 2005, Liu et al., 2010, Mathew 
et al., 2012, Reddy et al., 2006, Yoshida et al., 2012, Shroff and Kokkoli, 2012). Doxil® was the first 
FDA approved liposome based therapeutic nanocarrier for cancer treatment (Petros and DeSimone, 
2010). 
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1.2.1. Potential of nanoemulsions for drug delivery 
While liposomes and nanoparticles laid the foundation for nanocarriers research and represent well-
studied platforms for cell-specific delivery, they often require complex preparation procedures, use 
solvents not suitable for pharmaceutical use and/or result in polydisperse structures that are difficult to 
define and characterize to a level that allows simple pharmaceutical registration.  The compositional 
complexity of these delivery systems also hinders FDA approval for clinical application.  At the other 
end of the application spectrum, nanoemulsions are a promising nanocarrier class for enhancement of 
solubility and bioavailability of poorly soluble drugs (Anton et al., 2008, Anton et al., 2010, 
Constantinides et al., 2004, Constantinides et al., 2000, Davis et al., 1987, Ganta and Amiji, 2009, Ghai 
and Sinha, 2012). They are emulsions that have an extremely small droplet size ranging from 10 nm to 
200 nm with narrow size distribution (Solans et al., 2003). Nanoemulsions are non-equilibrium 
systems, which means they have a tendency to separate into the constituent phases (Gutiérrez et al., 
2008). Nevertheless, nanoemulsions can stay kinetically stable over a long period of time (Solans et al., 
2003). Compared to common polymeric micellar nanocarriers, nanoemulsions have higher drug 
loading capacity and longer shelf life (Sadurní et al., 2005, Tadros et al., 2004). Lipophilic drugs can be 
solubilized within the oil droplets to increase their bioavailability and enable facile packaging. The 
enormous interfacial area formed by nano-sized droplets provides further engineering opportunities for 
sustained and controlled drug delivery (Thanos et al., 2003, Chuan et al., 2011). 
 
1.3. Previous relevant research in the lab and hypothesis 
Emulsions and nanoemulsions have already found widespread use in clinical application. However, in 
most cases they do not encode sophisticated function, for example the ability to specifically target a 
given cell population in vivo (Ganta and Amiji, 2009, Santos-Magalhães et al., 2000, Makidon et al., 
2008, Kukowska-Latallo et al., 2005, Sigward et al., 2013). This limitation arises from the difficulty of 
engineering the emulsion interface, which is usually populated by mixed chemical species including 
surfactants, and is less physically and chemically defined than the solid counterpart. The challenges of 
developing a targeted nanocarrier emulsion lie in 1) the ease of manufacturing steps in the absence of 
non-pharmaceutical solvents; 2) the ability to deliver a variety of pharmaceuticals with appropriate 
pharmacokinetic properties to their site of action; 3) controlled and target specific delivery of 
concentrated pharmaceutical ingredients to the site of desired action. In this thesis I develop a new 
DDS that overcomes these challenges, as follows. 
4 
 
 
Peptide surfactant AM1 (Dexter et al., 2006) belongs to a biosurfactant family developed in the Centre 
for Biomolecular Engineering (CBE) at The University of Queensland, and is a short helix-forming 
sequence based on the peptide Lac21(Middelberg et al., 2000) which only differs from Lac21 by two 
histidine residues.  The histidine residues within AM1 allow binding of transition metal ions, eg. Zn(II), 
which enhance intermolecular interactions to create a cohesive interfacial network having measurable 
mechanical properties and known structure (Middelberg et al., 2008). Surface active peptides (SAP) 
like AM1 exhibit stimuli-responsive interfacial behavior in that they are capable of converting between 
a cohesive ‘film state’ and a mobile ‘detergent state’ at a fluid-fluid interface (Dexter and Middelberg, 
2007). At neutral pH in the presence of Zn (II), AM1 has good emulsification properties and can 
stabilize oil-in-water emulsions prepared from a range of oils. In addition, a tunable emulsion interface 
can be achieved by changing either the sequence of these SAP or the physical conditions of the buffer, 
e.g. pH and ionic character (Malcolm et al., 2009). AM1 comes with the possibility of low-cost bio-
production which offers the combined advantages of biocompatibility and sustainability (Kaar et al., 
2009).  
 
Using an AM1-stabilised nanoemulsion, we reported the preparation of a tailorable nanocarrier 
emulsion (TNE) for the co-delivery of a small lipophilic drug and an animal model relevant antigen to 
antigen presenting cells (APCs) in vitro (Chuan et al., 2011). The reported TNE comprised a core that 
is a pharmaceutical-grade oil stabilized by AM1 (Dexter et al., 2006), rendered stable in physiological 
conditions by electrostatic deposition of the antigen of interest onto the TNE outer surface using a well-
established layer-by-layer approach. The chosen excipient for this first-generation TNE (Miglyol® 812) 
is a medium-chain fatty acid triglyceride approved by the FDA and commonly used as an excipient in 
pharmaceutical formulations (Chuan et al., 2011). The study showed successful packaging of a 
hydrophobic molecule within the oil droplet and co-delivery to cells, with dose-dependent knock-down 
of an intracellular protein target. 
 
While this first TNE study showed successful delivery to cells, it did not encode stealth or targeting 
capability which would be necessary for effective in vivo use. The in vivo function of the TNE will 
likely be limited by the rapid uptake of intravenously injected colloidal drug carriers by cells in the 
mononuclear phagocyte system (MPS) (Klibanov et al., 1990, Mosqueira et al., 2001). Secondly, it will 
be desirable to specifically deliver active cargo to a target site to minimize unnecessary side effects 
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associated with uptake by non-target cells. Additionally, layer-by-layer assembly confused the cargo 
and stabilizing functions (the delivered model antigen, BSA, was also used to provide colloidal 
stability). The research challenge addressed in this thesis was to devise new approaches not dependent 
on layer-by-layer assembly that would allow an AM1-stabilised nanoemulsion to deliver active 
ingredient to cells, in vivo, in a way that evades non-specific uptake yet targets a specific subset of cells. 
Additionally, it was desired to not confuse the cargo and stabilization functions, so that the active 
compound is encapsulated within the oil core rather than located on the colloidal surface. 
 
Several mechanisms of surface functionalization for nanocarriers are available in the literature, but 
typically involve the physical or chemical addition of agents to the surface of a nanocarrier (Kamphuis 
et al., 2010, Wang et al., 2010). These options are available for the TNE, as the surface is based on 
peptides thus the tools of protein conjugation are available. However, such an approach would require 
complex chemical steps and may still require the use of protein for colloidal stabilization.  
 
Inspired by the chemical similarity of a recently-reported protein biosurfactant DAMP4 (Middelberg 
and Dimitrijev-Dwyer, 2011), Professor Anton Middelberg, who is also the principal supervisor of this 
PhD project, hypothesized that DAMP4 would integrate into or onto the surface of an AM1-stabilised 
oil-water interface, and that modification of DAMP4 with another entity (e.g. antibody or polymer) 
would enable display of that entity at the interface by non-covalent “click chemistry” self-assembly. 
Neutron reflectometry studies, subsequent to the start of this doctoral research, confirmed interfacial 
mixing of DAMP4 with a small peptide surfactant closely related to AM1 (Dwyer et al., 2013). The 
hypothesis that DAMP4 could be used to engineer the interface of the TNE through non-covalent self-
assembly laid the foundation for this doctoral project. Figure 1-1 shows the schematic representation of 
such hypothesis.  
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Figure 1-1. Schematic representation of hypothesis that DAMP4 could be used to engineer a TNE 
interface. a) Rapid adsorption of peptide surfactant AM1 (red) onto the oil-water interface results in a 
stable TNE oil core (yellow). Incorporating the oil-solubilized protein antigen (light green) into oil 
phase at the time of emulsion formation enables its facile packaging; b) Functional groups conjugated 
to DAMP4 protein (dark blue) introduced to a solution containing the preformed AM1 peptide 
stabilized TNE oil core results in c) DAMP4 integration to the oil-water interface and functional 
display of its conjugated group at the interface. 
 
1.4. Project aims and objectives 
The overall aim of this doctoral work was to explore the above hypothesis and solve obvious 
challenges along the way, to ultimately decouple the biological (cargo) and physical design 
(stabilization) criteria for nanoemulsions through an entirely novel emulsion nano-engineering 
approach based on non-covalent self-assembly at the oil-water interface. This aim was achieved 
through the following objectives: 
 
1. to investigate whether DAMP4 modified with functional moieties (e.g. the polymer PEG) can 
display those moieties at the interface and impart function (e.g. altered cell binding) to the 
nanoemulsion; 
2. to design a stable, long circulating nanocarrier emulsion able to target dendritic cells, using 
DAMP4 as an interfacial anchor;  
3. to investigate the cellular uptake efficiency of the resulting nanoemulsion and conduct 
formulation optimization to enhance target specificity; 
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4. to encapsulate a model antigen within the nanoemulsion and evaluate immune function in a 
relevant animal model; 
5. to assess the possibility of tuning the immune response elicited by antigen-loaded nanoemulsion 
by varying suitable design parameters.  
 
As an initial test of the hypothesis, I modified DAMP4 with polyethylene glycol (PEG, a non-toxic and 
non-immunogenic highly elastic polymer) and evaluated the immune evading ability of a nanoemulsion 
modified with the PEG-DAMP4 hybrid molecule. PEG is a well-studied polymer that has been 
approved by the US Food and Drug Administration (FDA) for pharmaceutical use (Harris et al., 2001), 
thus it was selected in this work as the immune evading molecule. If the hypothesis is correct, 
conjugation of PEG to DAMP4 prior to introduction of such a hybrid molecule to a preformed AM1-
stabilized TNE core would result in a TNE having an elastic interface and enhanced immune-evading 
characteristics. For the targeting moiety, I decorated the nanoemulsion with DAMP4 modified with 
antibody against Clec9A, a recently-identified surface receptor highly exclusive to a subset of DCs in 
both human and mouse (Caminschi et al., 2008, Lahoud et al., 2011, Sancho et al., 2009). Antibody 
bound to Clec9A has been found to be internalized efficiently and in vivo delivery of antigen coupled 
to this antibody results in antigen cross presentation by CD8+ DCs (Caminschi et al., 2008, Sancho et 
al., 2009). This background made Clec9A a superior targeting choice for delivering drugs to DCs. 
 
1.5. Thesis structure 
Following this introduction, this thesis is comprised of five main chapters including a literature review 
and four experimental chapters.  
 
Chapter 2 presents a critical review of the topics relevant to this research project and provides the 
relevant conceptual background needed. 
 
The comprehensive development of a new TNE is documented in Chapters 3 to 6, organized by the 
increased complexity of the TNE composition. Chapter 3 addressed objective 1 by describing a simple, 
unique chemistry that allows for one-step non-covalent conjugation of PEG to the AM1 pre-stabilized 
TNE core for enhanced immune evading function. We first evaluate the hypothesis of DAMP4 
mediating TNE functionalization by conducting sudden bubble contraction experiments. PEG-modified 
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DAMP4 formed an elastic film on an AM1 pre-occupied oil-water interface, suggesting a flexible layer 
of PEG was anchoring on the interface via DAMP4. A PEGylated TNE was prepared from PEG 
modified DAMP4 via sequential reagent addition process. In vitro stability and the immune evading 
ability of such PEGylated TNE are also described in this chapter. 
 
Having proved DAMP4 was able to bring conjugated PEG into a pre-formed AM1 stabilized oil-water 
interface, an immune-evading TNE was fabricated using a top-down non-covalent click chemistry 
strategy. With this in mind, Chapter 4 addressed objectives 2 and 3 by examining whether the same 
method could be applied to add a target-specific homing characteristic to the TNE. In vitro TNE-cell 
association and the formulation optimization of the constructed TNE is discussed in this chapter.  
 
The need for highly-efficient DDS for vaccines led us to consider this system for delivery of protein 
based therapeutics. Hence we address objectives 4 and 5 in Chapters 5 and 6. The PEG layer of the 
TNE is expected to promote passive targeting through enhanced permeability and retention (EPR) 
effect, while the targeting mAb allowed highly specific delivery to DCs to activate the required 
immune response. Chapter 5 describes the process of incorporating a model protein antigen (Ag) 
ovalbumin (OVA) into the TNE. The efficiency of TNE targeting delivery of Ag to dendritic cells 
(DCs) was evaluated by by an in vitro T cell proliferation assay. Having in mind in vivo drug delivery 
applications, such studies are an essential first steps to assess the potential of TNE for the delivery of 
protein and drugs.  
 
Chapter 6 assesses the efficiency of TNE delivering Ag to DCs in vivo. Ag encapsulated within TNE 
was specifically delivered to DCs, correctly processed and cross-presented to Ag specific T cell 
subsets. Cytotoxic T lymphocytes (CTL) assay revealed that Ag delivered by TNE to CD8+ DCs leads 
to endogenous production of effectors CTLs. Tunable immune response could be obtained by varying 
the TNE formulation composition.  
 
Finally, the major outcomes of developing a TNE, the potential of further development for translating 
the TNE platform into clinical application and the shortcomings of such a platform are summarized in 
Chapter 7.  
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The patented research (Middelberg and Zeng) findings in this body of work are related to the 
development of a new drug delivery system that has the potential to be exploited in further clinical 
application. The use of top-down non-covalent click self-assembly to form a nanoemulsion harnessing 
the chemical similarity of novel surface peptide surfactant may eventually form the basis of flexible 
drug delivery platform that can be tailored to address unmet medical need in a personalized fashion.  
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Chapter 2  Literature Review 
2.1. Background 
2.1.1. Nanotechnology 
The emergence of nanotechnology was spawned by expanding knowledge and the enhanced ability to 
manipulate materials at the nanoscale. Worldwide annual public funding into nanotechnology research 
has ballooned exponentially from under $500 million in 1997 to $17.8 billion in 2011 (John, 2013). 
Nanotechnology is an interdisciplinary field that covers a wide range of areas, including physics, 
chemistry, biology, engineering and medicine (Roco, 2004). The conceptual foundation of 
nanotechnology was laid by physicist Richard Feynman in his 1959 lecture, where he stated “There’s 
plenty of room at the bottom”.  
 
The prefix “nano” derives from the Greek word for “dwarf” (Emerich and Thanos, 2003). The National 
Nanotechnology Initiative (NNI) of the United States government defines nanotechnology as “research 
and technology development at the atomic, molecular or macromolecular scale, leading to the 
controlled creation and use of structures, devices and systems with a length of 1-100 nm” (McNeil, 
2005, Medina et al., 2007). One nanometer is equal to 10 Ångström, or one-billionth of a meter. 
Nanotechnologies have great potential to bring benefits in a myriad of areas, ranging from water 
decontamination, information and communication technologies, mining, chemical products and drug 
development. A complete list of the potential application of nanotechnologies is too diverse to discuss 
in detail, but without doubt nanotechnology is beneficial for developing new and effective medical 
treatments (Shaffer, 2005, Peer et al., 2007, Safari and Zarnegar, 2014). The ability to manipulate 
materials at the nano-scale had catalyzed the development of novel diagnostics and imaging devices for 
treating disease in a way that has never before been possible.  
 
2.1.2. Nanotechnology in medicine 
Drug delivery system (DDS) are formulations or devices that enable the introduction of a therapeutic 
substance at the biological site of action with enhanced efficacy and safety in a controlled manner, 
while minimizing interactions with the rest of the body. An ideal DDS requires the interactions from 
three aspects: the administration of the therapeutic substance, the release of active ingredients from 
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delivery the vehicle and the subsequent transportation of the active ingredients across biological 
barriers to the site of action. Better design of DDS provides better treatments for diseases. For example, 
in cancer therapy, systemic administration of cytotoxic anti-cancer drugs leads to substantial 
indiscriminant toxicity to tissues other than tumor tissues (Scripture and Figg, 2006). Administration of 
chemotherapeutic agents to treat cancer can benefit from repacking these highly toxic molecules into a 
more favorably distributing DDS (Sharma and Straubinger, 1994, Zamboni, 2005). Moreover, 
advancements in biotechnology have led to the discovery and rational design of new drug candidates. 
However, the translation of these drug candidates into clinical applications has been limited by their 
poor solubility, high toxicity, nonspecific delivery, low bioavailability and short circulating half-lives. 
Effective drug delivery has become the key factor for better treatment. The need to develop specific 
drug delivery methods to promote the utilization of these new drugs in clinical effectiveness has 
become greater than ever.  
 
Nanomedicine is defined as the use of nanoscale materials in medicine, by harnessing their unique 
properties when applied in medical application (Wagner et al., 2006). Nanomedicine covers a broad 
range of research areas, ranging from nanocarriers for drug delivery, self-assembled bionanomaterials 
for tissue regeneration, to nanoscale device for in vivo imaging and disease detection (Wagner et al., 
2006, Kabanov and Gendelman, 2007, Bawa and Johnson, 2007). Drug delivery is currently 
dominating the field of nanomedicine research, comprising the highest number of scientific papers and 
patents (Wagner et al., 2006). Nanotechnology has great potential to revolutionize traditional DDS, by 
enabling the development of functionalized nanocarriers acting as a vehicle for the drug payload with 
release by a controlled mechanism at a specific biological site of action. Nanocarriers such as 
liposomes have been shown to be a biocompatible DDS with increased bioavailability, provided by the 
prolonged circulation time of drugs and higher accumulation of drugs at the target site due to the 
enhanced permeability and retention (EPR) effect. Furthermore, the enormous surface area of these 
nanocarriers provides opportunities for surface engineering with a homing device, such as a ligand 
specific for receptors over-expressed at pathological sites or to facilitate receptor-mediated endocytosis 
into targeted tissues.      
 
Various nanocarriers had been constructed from a variety of materials, including polymers, lipids and 
metals. Therapeutics can be encapsulated either within the internal compartments, adsorbed or grafted 
onto the surface of the nanocarriers. The characteristics regarding drug loading capacity and stability, 
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target specificity and drug release rate differ for these nanocarriers; however, therapeutic nanocarriers 
should satisfy the following essential criteria: biodegradability, biocompatibility, non-immunogenicity 
and physical stability in blood for an intravenously injected formulation. The concept of the “magic 
bullet” proposed a century ago by Paul Enrlich (Strebhardt and Ullrich, 2008) inspired the development 
of targeting drugs for better treatment, which has been made possible by using various types of 
nanomaterials.   Since the first therapeutic liposome was introduced by Gregoriadis in 1974 
(Gregoriadis et al., 1974), research in the field of therapeutic nanocarriers had grown tremendously. A 
few of the therapeutic nanocarriers under intensive study are discussed here.  
 
2.1.2.1. Liposome 
Liposomes are spherical vesicles comprising one or multiple bilayered phospholipid membrane 
(Torchilin, 2005) (Figure 2-1). The predominant physical and chemical properties of a liposome are 
determined by the net properties of the constituent phospholipids (Bawarski et al., 2008). Amphiphilic 
phospholipids self-assemble into bilayers and form liposomes spontaneously. The biphasic character of 
liposomes makes them ideal carriers for both lipophilic and hydrophilic drugs. The nature of their 
amphipathic membrane structure enables liposomes to encapsulate hydrophobic or lipophilic molecules 
between two phospholipid layers; meanwhile, any hydrophilic molecule can be incorporated within the 
aqueous core. Drugs can be loaded into liposomes through: i) conventional methods such as thin-film 
rehydration and the freezing-and-thawing method, where liposomes were formed in the aqueous phase 
saturated with soluble drugs (Szoka and Papahadjopoulos, 1980, Lasic, 1988, Woodle and 
Papahadjopoulos, 1989) or ii) the more widely used remote or active loading approach, where drugs are 
loaded into a preformed liposome by a driving force caused by the trans-membrane gradient (Clerc and 
Barenholz, 1995, Clerc and Barenholz, 1998, Haran et al., 1993). Using such a method, various drugs 
had been successfully loaded into liposome based on pH (Nichols and Deamer, 1976, Qiu et al., 2008, 
Dos Santos et al., 2004, Swenson et al., 2001) or ion gradient (Lasic et al., 1995, Wasserman et al., 
2007, Clerc and Barenholz, 1998). Intravenously injected liposomes are varied in size, but most of 
them are smaller than 400 nm to facilitate extravasation into the interstitial space from the bloodstream. 
One of the drawbacks of using liposomal formulations is the rapid elimination from the blood by the 
mononuclear phagocyte system (MPS) system. Polyethylene glycol (PEG) is often incorporated within 
the formulation to create a repulsive barrier and to reduce opsonization and the subsequent clearance of 
liposomes (Klibanov et al., 1990). Doxil®, which is a long-circulating PEGylated liposomal 
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formulation of the anti-cancer drug doxorubicin, is one of the exceptional success stories (Gabizon, 
2001, Uziely et al., 1995, Barenholz et al., 1993, Barenholz et al., 1996, Emanuel et al., 1996). By 
modifying the phospholipid structure, monoclonal antibodies (mAbs) fragments or ligands could be 
grafted onto the liposome surface and form “immunoliposomes” to enhance selective accumulation of 
therapeutics at desired biological sites (Chang et al., 2009, Wang et al., 2012, Penate Medina et al., 
2011). 
 
 
 
Figure 2-1. Drugs with varying solubility and their incorporation site within liposomal carrier. Taken 
from (Gulati et al., 1998). 
 
Although it has been almost 50 years since the concept of the liposome was introduced (Bangham et al., 
1965), only a handful of successful liposome-based drug formulations have entered the drug market 
(Mross et al., 2004, Moen et al., 2009, Jaeckle et al., 2002). Myocet® and Caelyx® are doxorubicin 
liposomal formulations for the treatment of metastatic ovarian cancer and breast cancer respectively 
(Gabizon and Papahadjopoulos, 1988). Marqibo® was the latest vincristine sulfate encapsulated 
liposome approved by the FDA in 2012 for the treatment of adult patients with lymphoblastic leukemia 
(O’Brien et al., 2012). Major limitations of the manufacturing and development of liposome are related 
to their stability, poor batch-to-batch reproducibility, difficulties in sterilization and poor drug loading 
capacity.  
 
2.1.2.2. Polymeric nanoparticles  
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Polymer-based nanoparticles have been studied extensively as drug delivery vehicles. Most polymeric 
nanoparticles are engineered from biocompatible and biodegradable polymers, with functional moieties 
for active targeting anchoring on the surface. A number of synthetic and natural polymers such as 
polylactide (PLA) (Essa et al., 2010), lactide co-glycolide (PLGA) (Danhier et al., 2012), chitosan 
(Agnihotri et al., 2004) and alginate (Sæther et al., 2008) have been exploited to formulate 
nanoparticles for the sustained release of a drug at a target site. The polymeric nanoparticle surface 
facilitates the conjugation of functional groups and ligands to target specific drug delivery (Gu et al., 
2009, Swami et al., 2012). According to the stucture of the nanoparticles, loading of drugs can be 
achieved via either i) entrapment of water soluble drugs within the nanoscale structure such as 
nanocapsules and nanospheres (Bajpai et al., 2008) or ii) chemical linkage of drugs to the polymer 
backbone so that they can be hydrolyzed in vivo for subsequent drug release. Polymeric nanoparticles 
have shown some potential as DDS (Cho et al., 2012, Hu et al., 2011, Mieszawska et al., 2013). Wide 
adoption of nanoparticles into clinical application has been limited by the tedious preparation steps, 
which require harsh chemical solvents that can potentially compromise therapeutic activities, as well as 
the low drug loading capacity. 
 
2.1.2.3.  Mesoporous silica nanoparticles 
Ordered mesoporous silica materials were first reported over 20 years ago (Kresge et al., 1992). Since 
then, significant developments have been made in this field regarding control of morphology, pore size 
adjustment and composition variation (Wan and Zhao, 2007, Ying et al., 1999). Using mesoporous 
silica nanoparticles (MSP) as drug nanocarriers is of particular interest. The exceptionally high surface 
area of MSP enables the encapsulation of a relatively high level of drugs with MSP compared to other 
nanocarriers, such as liposomes or micelles. The tunable surface chemistry makes possible for further 
surface engineering for enhanced biofunctionality. Functional groups can be introduced into the MSP 
by covalent bonding or electrostatic interactions (Ferris et al., 2011, Xia et al., 2009). Due to the high 
pore capacity, MSPs have been used to deliver drugs that are poorly soluble in water or with low 
bioavailability (Meng et al., 2011b, Chen et al., 2009, Lu et al., 2007, Gu et al., 2010). Target specific 
delivery of MSPs can be facilitated by attaching targeting moieties to the surface of MSPs (Liong et al., 
2008, Rosenholm et al., 2008, Ferris et al., 2011).  MSPs have shown great potential as nanocarriers,  
and it is encouraging that multimodal silica nanoparticles have been approved by the FDA for the first-
ever clinical trial (Friedman, 2011, Benezra et al., 2011). However, the clinical application of MSPs 
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still has a long way to go, as issues related to safety and therapeutic efficacy are yet to be addressed 
(Mai and Meng, 2012).  
 
2.1.2.4. Polymeric micelles 
Polymeric micelles are nano-sized closed lipid monolayers with a hydrophobic core and hydrophilic 
shell. Micelles are usually formed spontaneously by self-assembly of an amphiphilic polymer in a 
liquid as a result of hydrophobic or ion pair interactions between polymer segments. Polyethylene 
glycol (PEG) is commonly used as the hydrophilic block while poly (propylene oxide) and poly (ester) 
are mostly used as the hydrophobic blocks (Miyata et al., 2011, Torchilin et al., 1995). Micelles are 
ideal nanocarriers for delivering water insoluble molecules with improved stability (Batrakova and 
Kabanov, 2008, Marczylo et al., 2007, Sahu et al., 2011). These aspects probably contribute to their 
nanoscale size and hydrophobic shells that impair the uptake by the RES. NK105 is a polymeric 
micellar paclitaxel formulation under phase III evaluation (Hamaguchi et al., 2005, Kato et al., 2012). 
NK105 was constructed from a block copolymer consisting of PEG and polyaspartate (Hamaguchi et 
al., 2005). NK106, which has paclitaxel encapsulating its inner hydrophobic core, was evaluated for 
treating gastric cancer (Kato et al., 2012). Another micellar carrier NK911, which contains 
doxorubicin, was evaluated for metastatic pancreatic cancer treatment (Matsumura et al., 2004). One of 
the shortcomings of using micelles as drug nanocarriers is their relatively low drug loading capacity 
and drug molecules may gradually diffuse out of the micelles before they reach the site of action (Kim 
et al., 2010). In addition, micelles are unstable upon high dilution, for example intravenous 
administration, under which circumstance micelles may be diluted below their critical micelle 
concentration (CMC) and disassemble into individual copolymers (Torchilin, 2001) . There are several 
issues that need to be addressed before translating micellar nanocarrier research into clinical 
applications. 
 
In summary, each of the systems discussed above has advantages and disadvantages regarding the 
versatile requirements for therapeutic applications. With the rapid development of nanotechnology, the 
range of building blocks that can be applied for nanocarrier platforms has also expanded tremendously 
over the past few decades. Each nanocarrier platform has its own unique advantage and intrinsic 
limitations, such as insufficient drug loading capacity or low stability. Thus a DDS with combined 
advantageous characteristics is in high demand. 
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2.2. Nanocarrier emulsions for drug delivery 
2.2.1. Background of emulsion science  
Emulsions are colloidal dispersions of immiscible fluids, with one fluid phase dispersed as droplet 
within the other (Becher, 2001 , Walstra, 2003, Schramm, 2006). The dispersed phase is called the 
“dispersed/internal phase” and therefore the other one is called the continuous/external phase (Barnes 
and Gentle, 2005).  An oil-in-water (O/W) emulsion can be described as  oil droplets (dispersed phase) 
dispersed in water (continuous phase); vise versa for an water-in-oil (W/O) emulsion (Becher, 2001 ). 
In addition to the normal two phase emulsions, there are also the so-called “double emulsion” systems 
consist of multiple phase, such as a W/O/W emulsion (Hanson et al., 2008, Pradhan and Rousseau, 
2012, Benichou et al., 2004) (Figure 2-2). Emulsions are thermodynamically unfavorable systems, in 
which the dispersed phase tends to coalesce and flocculate over time. Thus a third component called 
emulsifier or surfactant is needed to stabilize the emulsion. Surfactants can lower the interfacial tension 
and reduce the thermodynamic forces driving towards coalescence, resulting in long-term stability 
exceeding that of liposomal formulaitons (Barnes and Gentle, 2005, Becher, 2001 ).  
 
Figure 2-2. Different types of emulsions according to the nature of the dispersed and continuous 
phases. 
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Nowadays, emulsions are used in a wide range of industrial applications and products ranging from 
mineral ore extraction, food products, domestic cleaning products and pharmaceuticals. Particularly in 
the pharmaceutical industry, parenteral emulsions are used for a variety of purpose, namely, nutrition, 
controlled delivery of drugs and as vaccine adjuvant (Pan et al., 2003, Tamilvanan, 2004, Makidon et 
al., 2008, Stanberry et al., 2012, Lawrence and Rees, 2000). 
 
2.2.2. Nanoemulsions 
Over the past few decades, there has been a growing interest in the field of nanoemulsion research, as 
evidenced by a large number of research papers and comprehensive literature reviews (Solans and Solé, 
2012, Gutiérrez et al., 2008, Fryd and Mason, 2012, Anton et al., 2008). Particularly, nanoemulsions 
have been intensively studied for pharmaceutical and food applications (Beck-Broichsitter et al., 2010, 
Anton et al., 2010, Calderó et al., 2011, Morral-Ruíz et al., 2012, Ghai and Sinha, 2012, MacHado et 
al., 2012, Rao and McClements, 2010, Henry et al., 2010, Silva et al., 2012). The term nanoemulsion 
has been quite widely used, but not with a consistent definition. It is often used interchangeably with 
different terms such as submicron emulsion, unstable microemulsions, miniemulisions and ultrafine 
emulsions in the literatures (Flanagan and Singh, 2006, Gutiérrez et al., 2008). Most studies agree that 
nanoemulsions are emulsions with an extremely small droplet size ranging from 10 nm to 200 nm with 
a narrow size distribution (Solans et al., 2003). Nanoemulsions are non-equilibrium or 
thermodynamically unstable systems, which means that such systems have a tendency to separate into 
the constituent phases (Gutiérrez et al., 2008). Nevertheless, nanoemulsions can be kinetically stable, 
provided an optimized composition and surfactants are in place (Solans et al., 2003). The distinction 
between conventional emulsions and nanoemulsions is not arbitrary. The advantages or properties of 
nanoemulsion systems over conventional emulsions include: 
• Superior stability against creaming/sedimentation: the small droplet sizes of nanoemulsion 
significantly reduce the gravity force, leading to increased Brownian motion to overcome 
gravity (Izquierdo et al., 2002). 
• The small droplet size of a nanoemulsion provides a higher surface area, which potentially 
provides a higher drug adsorption rate (Tadros et al., 2004). The small size distribution also 
provides the possibility of intravenous administration of nanoemulsion drug formulations. 
Conventional emulsions with a size distribution over 4 µm will cause vascular blockage and 
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affect blood pressure (Floyd, 1999, Nielloud and Marti-Mestres, 2000b). Emulsion formulations 
for intravenous injection must be below 500 nm in diameter (Driscoll et al., 2009), making 
nanoemulsion an ideal candidate.  
 
2.2.3. Therapeutic nanoemulsion 
Advanced DDS are required to be compatible with processes in the body as well as with the drug to be 
delivered. A DDS alters the biodistribution and pharmacokinetics of the associated drug; that is, the 
time-dependent percentage of the administered dose in different organs of the body. Furthermore, 
obstacles arising from low drug solubility, environmental or enzymatic degradation, rapid clearance 
rates, non-specific toxicity, the inability to cross biological barriers, just to mention a few, can be 
addressed by DDS. Nanoemulsions share many properties with liposomes as drug carriers, but are 
superior to liposome regarding the aspects of production cost and formulation stability. DDS based on 
nanoemulsions that are currently on the market are listed in Table 2-1 (Bunjes, 2010, Hippalgaonkar et 
al., 2010, Marti-Mestres and Nielloud, 2002, Tamilvanan, 2009). The major advantages of 
nanoemulsions as DDS include:  
• Production of a nanoemulsion is easy to scale up, as equipment has been developed in the food 
and cosmetics sectors. Also, nanoemulsions are relatively cost-effective compared to other DDS. 
• Nanoemulsion formulations are insensitive to dilution. On the other hand, micellar systems 
become unstable when diluted below their CMC, leading to drug leakage, making them 
unsuitable for certain routes of administration that require dilution, e.g. oral and intravenous. 
• The system composition of a nanoemulsion is relatively less complicated than other lipid 
systems. Nanoemulsions usually present less complex physicochemical behavior (Bunjes, 2010). 
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Table 2-1. Nanoemulsion drug formulations in the market.  
 
In recent decades, research has been performed to investigate nanoemulsions as DDS for the prevention 
and treatment for cancer (Anuchapreeda et al., 2012, Ganta and Amiji, 2009, Trang et al., 2011), 
inflammatory disease (M. H. F et al., 2010, Chuan et al., 2011), and infectious disease (Hwang et al., 
2013, Makidon et al., 2008). Nanoemulsions have been shown to be effective in delivering aqueous 
insoluble or lipophilic molecules (Ganta and Amiji, 2009, Ganta et al., 2010, Patlolla and Vobalaboina, 
2005). Using nanoemulsion formulations for controlled drug delivery and targeting is of particular 
interest. However, current applications of therapeutic nanoemulsion often employ egg lecithin or 
Cremorphor EL as the surfactant. For example, Texol®, one of the most effective anticancer drugs on 
the market is formulated with Cremophor® EL (polyethoxylated caster oil). Cremophor® EL, a 
commonly used surfactant for lipophilic compounds, has been associated with bronchospasms, 
hypotension and other hypersensitivity reaction (Constantinides et al., 2004). Also, it is important to 
24 
 
note that there are individuals who are allergic to egg lecithin, the most common surfactant for lipid-
based therapeutic nanoemulsion formulation (Hofer et al., 2003). Additionally, these standard 
formulations make it difficult to do anything other than create a “not-so-smart” emulsion; the full 
power of nanotechnology cannot be brought to bear by adding targeting domains in a controlled 
fashion. Thus, there is a need for new formulations of nanoemulsions that are efficacious and less toxic 
than currently available commercial products. 
 
2.3. Emulsion stability 
2.3.1. Emulsion destabilization process 
Emulsions are thermodynamically unstable systems; however, nanoemulsions can remain highly 
kinetically stable over a long period of time. Generally speaking, emulsions and nanoemulsions can be 
destabilized by the following mechanisms: creaming or sedimentation (Becher, 2001 ), flocculation 
(Petsev et al., 1995, Verwey and Overbeek, 1948), coalescence (Kabalnov and Wennerstrom, 1996) 
and Ostwald ripening (Taylor, 1998) (Figure 2-3). 
 
Creaming or sedimentation (Figure 2-3 i) is caused by the density differences of the two immiscible 
liquids, which leads to the formation of a layer with an increased concentration of dispersed phase 
droplets (Schramm, 2006). For instance, creaming may occur in an o/w emulsion where the oil phase 
has a lower density than the aqueous phase. Creaming is often followed by flocculation and/or 
coalescence as droplets come into close proximity, depending on the colloidal barriers that exist in a 
given system. 
 
Flocculation (Figure 2-3 ii) is the process whereby disperse droplets come together and form 
aggregates without losing their integrity as individual droplets (Schramm, 2006). The term flocculation 
is often interchangeable with coagulation or aggregation, but in some studies, flocculation refers to the 
formation of a loose aggregation of disperse droplets whereas coagulation refers to the formation of a 
closer aggregation of the dispersed phase (Barnes and Gentle, 2005). 
 
Ostwald ripening (Figure 2-3 iii) occurs in an emulsion in which the dispersed phase has limited 
solubility in the continuous phase, whereby larger droplets grow at the expense of smaller ones. This 
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occurs due to the transfer of the soluble liquid from the smaller droplets to the larger ones through the 
continuous phase (Schramm, 2006). Ostwald ripening primarily affects nanoemulsions and is the main 
instability process of nanoemulsion (Tadros et al., 2004). Ostwald ripening can be minimized as in this 
thesis by choosing two phases that are highly immiscible. 
 
Coalescence (Figure 2-3 iv) is a phenomenon whereby discrete droplets merge and create larger 
droplets, thereby reducing the total interfacial area of the system (Schramm, 2006). The ultimate end-
point of coalescence is complete phase separation. In coalescence, discrete droplets first become 
closely associated with sufficient energy to overcome any barriers to droplet approaches, and this leads 
to droplet fusion if insufficient resistance to colliding droplets is provided by the surfactant layer. 
Coalescence of a nanoemulsion can be prevented by a thick surfactant film adsorbed at the interface, 
which inputs electrostatic and steric stabilization. (Fast and Mecozzi, 2009). 
 
Figure 2-3. Schematic representation of emulsion stabilization. i) In creaming or sedimentation, the 
droplets rise to the surface or settle at the bottom of the continuous phase, depending on the density 
gradient between the two phases. ii) In flocculation, droplets come together and form aggregates. iii) 
Ostwald ripening occurs when large droplets grow and smaller droplets decrease in size and is 
prevalent when the dispersed phase is partly soluble in the continuous phase allowing molecular 
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movement. iv) Coalescence is a phenomenon where droplets merge to create larger droplets, thereby 
reducing the interfacial area of the system. 
 
It is worth noting that the mechanisms discussed above can also combine and influence each other, e.g. 
creaming and flocculation can lead to coalescence as droplets are brought into close contact; 
flocculation can lead to creaming as the aggregates of droplets are large enough to be influenced by 
gravity rather than by Brownian motion. Thus mechanisms of destabilization are well understood, and 
can all be controlled by appropriate formulations.  
 
2.3.2. DLVO theory 
Generally speaking, the formation of an emulsion requires the presence of a surfactant to lower the 
interfacial tension. However, the stabilization of an emulsion is related to more factors than just the 
surfactant, and such factors can be termed as colloidal interaction theory. The DLVO theory on the 
stability of colloidal dispersion, which was developed based on the fundamental work performed by 
Derjaguin, Landau, Vervey and Overbeek (Derjaguin and Landau, 1941, Verwey and Overbeek, 1948), 
can be applied to emulsion stability (Barnes and Gentle, 2005, Becher, 2001 ). In DLVO theory, the net 
interaction energy between two particles is taken as a summation of the van der Waals forces of 
attraction and the electrostatic forces of repulsion arising from the presence of electrical double-layers. 
Hence, the total energy of interaction (VT) is calculated as the sum of two components: an attractive one 
(VA) and a repulsive one (VR): 
 
VT = VR + VA 
 Equation 2-1 
 
The resulting VT is dependent on the distance between the particles and is the decisive factor for the 
stability of colloidal system (Figure 2-4). The net energy potential indicates whether the interaction 
between two particles will be repulsive (i.e. favor colloid stability) or attractive (i.e. favor colloid 
aggregation). The combined forces acting on two interacting particles is repulsive at greater distances, 
while the attractive force dominates the repulsive force when the distance between particles approaches 
zero.  
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Figure 2-4. Representation of DLVO theory. Figure taken from Thomas and Judd (Thomas et al., 
1999). The net energy can be summarized as the sum of the electrostatic repulsion and the van der 
Waals attractive forces that particles experience as they approach one another. 
 
2.3.3. Emulsion stabilization 
Based on DLVO theory, in order to maintain the stability of a colloidal system like an emulsion, the 
repulsive force needs to be dominant. There are two major mechanisms that contribute to the stability 
of a colloidal system: steric stabilization and electrostatic stabilization. 
 
2.3.3.1. Steric stabilization 
Steric hindrance is one of the major factors that contributes to the stability of emulsion droplets against 
aggregation and coalescence (Barnes and Gentle, 2005). Steric hindrance is caused by the increase in 
the free energy that occurs when two colloidal particles which are fully covered by strongly attached 
polymer appoach each other (Goodwin, 2009). Steric stabilization is achieved by attaching polymer-
like moieties to the surface of emulsion droplets to form a corona, which provides a repulsive force and 
prevents droplets from coming into close contact (Goodwin, 2009) (Figure 2-5).  
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Figure 2-5. Steric stabilization by adsorption of a polymer onto nanoparticles (Aiken Iii and Finke, 
1999). The presence of a polymer corona around the particle provides a large barrier preventing particle 
interaction.  
 
2.3.3.2. Electrostatic stabilization 
Emulsions stabilized by ionic surfactants will have an electric charge on the droplet surface and thus 
attract a layer of counter-ions from the continuous phase, known as an electric double layer (Birdi, 
2010). The electric double layer consists of three parts: i) the surface charge caused by charged ions 
adsorbed on the particle surface; ii) the Stern layer, which is the counter-ions attracted to the particle 
surface by the electrostatic force; and iii) the diffuse layer, which is the remaining region of charge 
adjacent to the particle, which contains free ions with a higher concentration of counterions (Birdi, 
2010). When emulsion droplets move within the continuous phase, a layer of the surrounding liquid 
remains attached to the particle; the boundary of this layer called the slipping plane. The zeta-potential 
(ζ potential) is defined as the value of the electric potential at the slipping plane (Goodwin, 2009). The 
ζ potential is a useful indicator of the degree of repulsion between emulsion droplets in the continuous 
phase. Strong electrical repulsion between droplets leads to a high ζ potential, which suggests a stable 
suspension. When the ζ potential is close to zero, emulsion droplets may approach each other to a point 
where they will be attracted by van der Waals forces, i.e. when there is no steric hindrance present in 
the system.  
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2.4. Surfactants 
2.4.1. Overview 
Although nanoemulsions are thermodynamically unstable, the presence of a surfactant can keep this 
system kinetically stable by lowering the interfacial tension and preventing droplets from fusing 
together. Surfactants are surface active species that tend to accumulate at an interface due to their 
intrinsic amphiphilic nature (Barnes and Gentle, 2005). An amphiphile is a substance that contains both 
hydrophilic (water soluble) and hydrophobic (water insoluble) moieties and will adsorb at an interface 
to move the hydrophobic moieties away from the aqueous phase. In general, surfactants of industrial 
importance fall into two categories: (i) low molecular weight surfactants (LMWS) including chemical 
surfactants and detergents, and (ii) proteins and other high molecular weight surfactants (Schramm, 
2006, McClements, 2005, Walstra, 2003, Dalgleish, 1997). LMWS, e.g. polysorbates and lecithins, 
have molecular masses in the range of 500-1300 Da, while proteins surfactants have molecular masses 
of tens of kDa (Dalgleish, 1997).  
 
Common LMWS are usually synthetic organic compounds consisting of a hydrophilic head group and 
a hydrophobic tail. LMWS tends to quickly adsorb at interface (e.g. air-water or oil-water) by arranging 
the hydrophilic head in the water phase and leaving the hydrophobic tail in the non-aqueous phase. 
This group of surfactants efficiently stabilizes foams or emulsions by reducing the interfacial tension 
(Pugnaloni et al., 2004). Compared to LMWS, protein surfactants are complex amphiphilic 
macromolecules consisting of a chain of amino acids (Garrett and Grisham, 2005, Wilde et al., 2004, 
Dickinson, 1999, A. Bos and van Vliet, 2001). The polar, non-polar and ionic amino acids constitute 
the hydrophilic and hydrophobic groups of proteins. In an aqueous solution, a protein tends to fold in a 
coil-like structure known as tertiary structure; this maximizes the exposure of its hydrophilic groups 
(Berg et al., 2002). Due to their structural complexity, proteins take a longer amount of time to diffuse 
and adsorb onto an interface compared to LMWS. When adsorbed at an interface, proteins have the 
potential to partially unfold and orientate their hydrophobic groups towards the non-aqueous phase. A 
cohesive protein network forms at the interface as a result of the large degree of intermolecular 
interactions with the interfacially adsorbed protein, including van der Waals forces, covalent bonds, 
hydrophobic attractions and metal ion coordination (A. Bos and van Vliet, 2001, Dickinson, 1999, 
Dickinson, 2001). Such a cohesive protein network is essential for long-term stability of emulsions and 
foams (Martin et al., 2002, Rouimi et al., 2005). 
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2.4.2. Surface active peptides and proteins  
Due to the non-renewable and non-biodegradable nature of petrochemical-based chemical surfactants 
and high petroleum prices, industries are looking for greener and more eco-friendly alternatives. 
However, combining high performance with cheaper and sustainable surfactants remains a hurdle for 
researchers. Recent advancement in biotechnology and nanotechnology have opened up opportunities 
for developing new classes of peptide surfactants through rational design. Peptides and small 
polypeptides are less complicated in structure than proteins, and display characteristics of both LMWS 
and proteins; these characteristics make them promising building blocks for the self-assembly of 
stimuli-responsive materials (Constantinides et al., 2000, Mart et al., 2006).  
 
A group of surface active peptide or protein surfactants are of specific relevance to this PhD project. 
The design of these surface active peptides was inspired by the peptide Lac21 (Ac-MKQLADS 
LMQLARQ VSRLESA-CONH2), which was derived from the naturally-occurring bacteria Lac 
repressor protein (Fairman et al., 1995). Lac21 contains a seven residue repeating motif with 
hydrophobic residues that enable this peptide to form an α-helical structure when adsorbed at an air-
water or oil-water interface (Figure 2-6 a).  Middelberg et al. showed that even though Lac21 was 
highly surface active, it did not form a mechanical strong interfacial network required for stabilizing 
foams and emulsions (Middelberg et al., 2000, Jones and Middelberg, 2002, Dexter and Middelberg, 
2007). The sequence of peptide AM1 (Ac-MKQLADS LHQLARQ VSRLEHA-CONH2) was designed 
based on the sequence of Lac21, but with the 9th and 20th residues replaced with metal ion binding 
histidine residues (Figure 2-6 b) (Dexter et al., 2006). The histidine residues were strategically placed 
within the AM1 sequence such that they will be oriented towards neighboring adsorbed peptides, 
allowing cross-linkage with other peptides via metal ion bridging. In the presence of zinc ions, AM1 
shows greater interfacial elasticity and foam stabilization ability than Lac21, and such characteristics 
were switchable by changing the bulk solution pH or the addition of metal chelating agent such as 
EDTA (Dexter et al., 2006). Despite being a promising peptide surfactant, the application of chemically 
synthesized AM1 at the industrial scale is restrained by its production cost. The bio-production of 
GAM1, which is molecularly equivalent to AM1, requires this small peptide to be produced first as a 
recombinant protein followed by downstream removal of its high molecular weight fusion tag (Kaar et 
al., 2009). This is a common procedure in small peptide production in a biofactory system in order to 
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avoid issues related to low expression rates and cytotoxicity to the host system (Anangi et al., 2012, 
Wright et al., 2012, Meng et al., 2011a). However, it is not an economical or sustainable choice as the 
removal of the large fusion tag not only complicated the production process, but also generates a large 
amount of waste.  
 
 
 
Figure 2-6. Diagram showing the 3D structure of the peptide Lac21 (a) and AM1 (b). Diagram 
adopted from Dexter and Middelberg 2007 (Dexter and Middelberg, 2007). Hydrophobic residues 
(methionine, leucine and valine) are shown in yellow and metal-binding histidine residues in green. 
 
Inspired by the interfacial activities of AM1 and motivated by the need to address the aforementioned 
issues relate to small peptide production, a new generation biosurfactant protein DAMP4, was designed 
based on AM1. DAMP4 comprises four repeating sequences closely related to AM1 (named DAMP1) 
linked by an acid cleavable aspartyl proline serine (DPS) side: MD(PSMKQLADS LHQLARQ 
VSRLEHAD)4 (Figure 2-7 a, b) (Dimitrijev-Dwyer et al., 2012, Middelberg and Dimitrijev-Dwyer, 
2011). DAMP4 can be mass-produced from the industrially relevant bacterium E.coli without a 
recombinant expression fusion tag (Dimitrijev Dwyer et al., 2014). DAMP4 is surface active and 
produces stable foams under alkaline conditions which can be controlled through a small pH shift 
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(Middelberg and Dimitrijev-Dwyer, 2011). The acid cleavable DPS linker within the DAMP4 sequence 
allows down-stream cleavage for the production of peptides similar to AM1. Neutron reflectometry 
studies have shown that DAMP4 forms a monolayer with similar thickness that formed by DAMP1 at 
an air-water interface, suggesting that the DAMP4 four-helix bundle unfolds into a chain of four 
DAMP1 chain at an air-water interface (Dwyer et al., 2013). Using the same techniques, it was also 
revealed as that despite having a slower adsorption rate compared to DAMP1 due to its higher 
molecular weight, the free energy of adsorption of DAMP4 was similar to its monomer DAMP1 
(Dwyer et al., 2013). DAMP4 is able to co-populate an interface with DAMP1 and at equilibrium the 
interfacial composition mirrors that in the underlying bulk solution (Figure 2-7 c). These findings 
support the hypothesis that motivated this PhD project: DAMP4 should be able to adsorb onto the 
interface pre-formed by AM1, as it shares similar chemistry with the DAMP4 monomer DAMP1. If 
DAMP4 was pre-conjugated to a molecule of interest (e.g. a targeting mAb or stealth agent), the 
adsorption of DAMP4 to the interface should lead to the functional display of its conjugated molecule. 
The biofunctionalization of an AM1-stabilized emulsion core can be facilitated by surface engineering 
with different functional moieties, using DAMP4 as an anchor.  
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Figure 2-7. Cartoon image of the front (a) and top (b) view of the DAMP4 four-helix bundle, 
generated using VMC software, available at: http://www.ks.uiuc.edu/research/vmd. (c) Cartoon of the 
DAMP4 four-helix bundle unfolding at an interface. DAMP4 unfolds from a four-helix bundle in the 
bulk into a chain of four connected DAMP1 monomers. Unstructured DAMP1 and unfolded DAMP4 
co-adsorb at an air-water interface. The figure was adopted from Dwyer et al (Dwyer et al., 2013). 
 
2.4.2.1. Peptide surfactant-stabilized emulsion for delivering lipophilic drugs  
Our lab reported a new approach to drug delivery based on surface peptide AM1-stabilized emulsions, 
motivated by the need to co-deliver a protein antigen and a lipophilic drug for specific inhibition of 
nuclear factor kappa B (NF-κB) in antigen presenting cells (APCs) (Chuan et al., 2011). Curcumin is a 
lipophilic molecule and inhibits NE-κB activity, which is closely associated with inflammation, making 
curcumin an ideal candidate drug for treating rheumatoid arthritis (Bharti et al., 2003, Singh and 
Aggarwal, 1995). However, curcumin in its free form exhibits low bioavailability and is poorly soluble 
in water (Cheng et al., 2001). Thus, there is a great need to encapsulate curcumin within a nanocarrier 
for enhanced delivery efficacy.  We used AM1 to prepare a nano-sized emulsion with defined surface 
properties predictable from its sequence. Incorporating curcumin into the oil phase at the time 
of emulsion formation enabled its facile packaging. AM1 simultaneously charged the stabilized 
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interface, enabling the addition of an animal model-relevant antigen via electrostatic deposition 
(Figure 2-8 upper panel). In vitro data showed that the tailorable nanocarrier emulsion (TNE) prepared 
in this way was internalized and well-tolerated by a model APC RAW 264.7 (Figure 2-8 lower panel), 
and good suppression of nuclear factor- κB (NE-κB) expression was achieved. This work reports a new 
type of nanotechnology-based carrier emulsion, which can potentially be tailored for co-delivery of 
multiple therapeutic components, and can be made using simple methods using only biocompatible 
materials.  
 
 
Figure 2-8. Schematic representation of a tailorable nanocarrier emulsion (TNE) for delivering a small 
lipophilic drug molecule. Upper panel: TNE was assembled through electrostatic adsorption of auto-
immune relevant antigens onto charged emulsion droplets stabilized by a designer peptide surfactant. A 
lipophilic small molecule drug, curcumin, was incorporated within the TNE oil core. Lower panel: 
Confocal image showing the TNE (red) internalized by model cells. The cell membrane is shown in 
white and the nucleus is shown in blue.  
 
As stated in Section 1.3 of Chapter 1, the first generation TNE did not possess the stealth or targeting 
capability required for effective in vivo use. A more sophisticated approach that was not dependent on 
layer-by-layer assembly for delivering an active ingredient to cells became the central research 
challenge for this PhD project.    
  
2.5. Nanoemulsion formation 
High energy and low energy methods can be used to prepare nanoemulsion. With the high energy 
methods, nanoemulsions are prepared using an apparatus (e.g. ultrasound sonicator or high pressure 
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homogenizer) able to produce intense disruptive forces to increase the oil/water interfacial area 
(Meleson et al., 2004). In this process, the oil and water phases of an emulsion are brought into contact 
with each other in the presence of an emulsifying agent, then high speed mixing or vigorous agitation is 
applied to break one of the phases into small droplets and disperse into the other one (Meleson et al., 
2004, McClements, 2005). High-pressure homogenizers are the most popular machine for 
emulsification in industry, as they provide homogeneous flow for emulsification in at short period of 
time (Solans et al., 2005). Ultrasound sonication is also very efficient in producing nanoemulsions, but 
it is not suitable for scaled-up manufacturing processes. In contrast, low energy emulsification methods 
harness the internal chemical energy of the system, and allow the formation of nano-size emulsions by 
spontaneous emulsification without any high energy input (Anton et al., 2008, Sajjadi, 2006, Forgiarini 
et al., 2001). The phase inversion temperature (PIT) method is the most widely used low-energy 
emulsification method in industry (Shinoda and Saito, 1968, Förster and Rybinski 1998). Nevertheless, 
both types of methods can be used to produce homogenous nanoemulsions by choosing the optimal 
system and composition variables (Yang et al., 2012). However, low energy emulsification methods 
have attracted considerable research interest in recent years as they are thought to be more energy 
efficient than the established high energy methods. 
 
2.6. Considerations for nanoemulsion formulation: 
Nanoemulsions are ideal DDS to increase the bioavailability and efficacy of lipophilic compounds 
(Ganta et al., 2008, Ganta et al., 2010, Patlolla and Vobalaboina, 2005). Thus, this section will discuss 
the formulation considerations for designing nanocarriers emulsions. Therapeutic nanocarriers 
emulsions are required to be sterile, isotonic, biodegradable and physicochemically stable (Benita and 
Levy, 1993).  The selection of the excipient, as well as emulsion characterization including assessments 
of the size distribution and surface charge should be carefully considered, as these factors could affect 
the pharmaceutical performance of the emulsion.  
 
2.6.1. Excipient selection 
The excipient of an emulsion, such as the oil phase and emulsifiers, need to be carefully selected so that 
the resulting formulation will comply with the requirements for a therapeutic emulsion. The oil phase 
of a therapeutic emulsion is generally of natural origin. Intralipid®, a fat emulsion formulated with 10, 
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20 or 30% (v/v) soybean oil, 1.2% egg phophatides and 2.5% glycerol, was the first fat emulsion for 
human intravenous injection that reached the market in 1962 (Hallberg et al., 1985).  A common oil 
phase used for therapeutic emulsion is long-chain triglycerides (LCT) from vegetable sources, 
including soybean, safflower and cottonseed oils (Davis et al., 1987). Medium-chain triglycerides 
(MCT), such as Miglyol® 812, have also been reported as the oil phase for therapeutic emulsion 
(Chuan et al., 2011, Kovacevic et al., 2011, Sanad et al., 2010, Zeng et al., 2013). Regardless of the 
origin, the oil phase needs to be purified to remove any known contaminants (oxidative decomposition 
products, herbicides, pesticides etc.) (Malmesten, 2002).  
 
The most common emulsifier used in parenteral emulsion formulations is phospholipids, especially 
those from egg or soybean sources. Such emulsifiers are relatively safe and stable (Floyd, 1999). 
Synthetic emulsifiers such as fatty acid esters of sorbitans (SpanTM) and polyoxyethylene sorbitans 
(TweensTM) are also considered or employed for use in parenteral emulsion drug delivery. One study 
has shown that an appropriately composed oil phase could aid in increasing the encapsulation rate of a 
drug due to the optimization of drug solubility within the inner oil phase (Klang et al., 1996). Another 
consideration regarding the excipient of an emulsion is the additives used. Electrolytes (e.g. NaCl), 
reducing sugars (e.g. glucose) and glycerol are sometimes needed to adjust the emulsion to 
physiological pH (Dawes and Groves, 1978, Kawilarang et al., 1980, Washington et al., 1990, 
Washington et al., 1989).  
 
2.6.2. Emulsion particle size  
Emulsion size is the main characteristic that governs interactions with the biological environment. 
Particles with diameters greater than 7 μm are clinically unacceptable as they will cause capillary 
blockage (Illum et al., 1987). Generally, particles with a larger size are more likely to be retained by the 
reticuloendothelial system (RES) after intravenous injection (Tamilvanan, 2004). Emulsions with a 
droplet size below 100 nm will escape from the vascular system via the capillary endothelium, thus 
making it difficult to reach any site of action in the extravascular space. One study has shown that 
emulsions with a droplet size larger than 200 nm could effectively inhibit the drug from entering the 
bone marrow, small intestine and other non-RES organs hence toxicities caused by many cytotoxic 
compounds can be avoided (Kurihara et al., 1996). However, therapeutic nanocarrier emulsions need to 
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be sterile before application to humans or animals. As most of the emulsion components are susceptible 
to heat sterilization, filter sterilization with a 0.22 μm filter device is more practical.  
 
2.6.3. Surface Characteristics 
The cellular uptake, biodistribution and stability of emulsions are also affected by their physiochemical 
characteristics, including surface charge and hydrophobicity/hydrophilicity. Emulsions with a neutral 
droplet surface are taken up by macrophages more slowly than those with a charged droplet surface 
(Stossel et al., 1972). Negatively charged emulsions are more easily cleared from the blood stream and 
distributed in the liver and spleen, while the positively charged emulsion droplets are expected to have 
high cell association as a result of electrostatic adhesion between the droplets and the negatively 
charged cell membrane (Nielloud and Marti-Mestres, 2000a). The hydrophobicity/hydrophilicity of 
emulsion oil droplets could also affect their uptake by MPS. A hydrophobic surface coating 
significantly reduces macrophage uptake as a result of decreased blood component opsonization onto 
the emulsion droplet surface, together with a steric stabilization effect from the hydrophobic surface 
coating (Illum et al., 1987). Coating emulsion droplets with hydrophilic polymers such as polyethylene 
glycol (PEG) has been found to improve emulsion stability in the plasma through steric stabilization 
and increased blood circulation time (Han et al., 2004).  
 
2.6.4. Administration route 
It is important to consider the route of administration for nanocarrier as this parameter will have impact 
on the drug delivery efficiency and safety. Intravenous (i.v.) injection still remains the standard form of 
application for formulations that require being bioavailable immediately or distribution to a biological 
site which is difficult to access by other means. However, i.v. injected nanocarrier need to escape the 
engulfment of the mononuclear phagocyte system (MPS) (Vonarbourg et al., 2006). Strategies that 
could improve the delivery efficiency of i.v. injected nanocarrier will be discussed in next section. In 
contrast to i.v. administration, intraperitoneal (i.p.) administration can directly delivers injected 
nanocarriers to peritoneal pathogenic-relevant macrophages and serves as a depot for subsequent 
systemic dissemination (Howard et al., 2008). PLGA particles i.p. injected to mice are found to be 
primary up-taken by macrophages, whereas intrademal injection (i.d.) of the same particles resulted in 
increased DCs association in draining lymph nodes (Newman et al., 2002). I.p. injection showed 
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reduced toxicity as the peritoneal cavity acts as a barrier to the injected nanocarrier entering the blood-
brain-barrier (Sadauskas et al., 2007). 
 
2.7. Targeting strategies 
Targeting therapeutic nanocarriers to an active biological site provides several advantages over their 
non-targeted counterparts. Targeted delivery of a therapeutic compound could potentially circumvent 
the side-effects on healthy tissues and enhance pharmaceutical efficiency (Minko et al., 2004). The 
current targeting strategies fall into two main areas: passive and active targeting. 
 
2.7.1. Passive targeting 
Passive targeting exploits the normal biodistribution that nanocarriers will take upon administration. In 
general, intravenously injected unadorned nanocarriers are rapidly removed from the circulation by 
opsonization and the mononuclear phagocytic system (MPS) and eventually accumulate within the 
spleen and liver (Owens Iii and Peppas, 2006). Hence, the rapid clearance of nanocarriers can be 
exploited for targeting professional antigen presenting cells (APCs) or treating hepatic disorders 
(Durand et al., 1997, Yekollu et al., 2011, Chuan et al., 2011). The potential of a passively targeted 
nanocarrier in cancer treatment has been well studied. Nanocarriers can passively accumulate within 
solid tumors due to the leaky vasculature network and aberrant lymphatic system that limits the 
drainage of molecules from tumor tissues (Matsumura and Maeda, 1986, Peer et al., 2007). 
 
Although rapid clearance by the MPS had been exploited as a passive targeting strategy, treatment of 
other diseases, like tumors, requires that drug loaded nanocarriers escape from opsonization and MPS 
arrest for drug delivery to non-MPS tissues. In addition, the non-specific uptake of nanocarriers 
prevents the use of emulsions for controlled release of the drug within the vasculature. To circumvent 
this, nanocarriers have been modified with polyethylene glycol (PEG), a process known as PEGylation; 
this has been widely investigated and shown to increase the bioavailability and biodistribution of 
nanocarriers (Gref et al., 2000, Kim et al., 2009). A corona of hydrophilic PEG on the surface of 
nanocarriers creates a repulsive barrier that prevents the absorption of opsonins (Klibanov et al., 1990, 
Maruyama et al., 1991). Therapeutics encapsulated in long-circulating nanocarriers can escape from 
MPS clearance and accumulate within the blood stream. Thus, the required therapeutic level can be 
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maintained (termed as enhanced permeability and retention effect, also known as the EPR effect or 
passive targeting) (Maeda et al., 2000). 
 
2.7.1.1. PEGylation 
Polyethylene glycol (PEG) is formed by linking repeating units of ethylene glycol in either linear or 
branched structures (Figure 2-9). The process of covalently coupling PEG to a carrier of choice is 
called PEGylation. Activated PEG, with a functional group at one or both termini can be coupled to a 
molecule via different chemistries. One should choose the functional group based on the type of 
available reactive amino acids on the molecule to which PEG is conjugated. Conjugating PEG to lysine 
and N-terminal amino acid groups is the most common route for the PEGylation of a protein or peptide 
(Roberts et al., 2002), since lysine is the most prevalent amino acid in proteins.  
 
Figure 2-9. Structural formulation of the polyethylene glycol (PEG) molecule (Harris and Chess, 
2003). 
 
PEGylation studies were initiated in the late 1970s by Davis and colleagues who succeeded in 
protecting proteins from enzymatic degradation during drug delivery by PEGylation (Abuchowski et al., 
1977a, Abuchowski et al., 1977b). The literature is now replete with reports on the PEGylation of 
various applications, namely increased stability and half-life, enhanced drug solubility, reduced toxicity 
and immunogenicity (Veronese and Pasut, 2005). PEG provides a steric barrier that surrounds its 
conjugated drugs or particles, which protect them from enzymatic degradation, excretion by the 
kidneys, MPS clearance, and cell surface protein interactions and thereby eliminating adverse allergic 
reactions (Harris and Chess, 2003, Davis et al., 1978). PEGylation also enhances the stability of DDS 
over a range of pH and temperature, compared to non-PEGylated counterparts (Monfardini et al., 1995).    
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It is worth noting that PEG derivatives with a molecular weight lower than 40 kDa can be excreted 
from the body via the kidneys (Caliceti and Veronese, 2003). The most commonly used PEG molecules 
for drug nanocarrier modification are those with a molecular weight from 1000 to 20,000 Da (Torchilin, 
2006). Owing to the above mentioned properties, the FDA has approved PEG for application in foods, 
cosmetics and pharmaceuticals (Harris and Chess, 2003). The first PEGylated protein to enter the 
pharmaceutical market was ADAGEN®, a PEGylated adenosine deaminase (ADA) for treating severe 
combined immunodeficiency disease (SCID).  
 
2.7.2. Active targeting 
Active targeting is a strategy that relies on specific interactions at target sites, such as antibody-antigen 
or ligand-receptor interactions. Inspired by Paul Ehrlich’s “magic bullet” theory back in the early 20th 
century (Strebhardt and Ullrich, 2008), the active targeting strategy involves modifying nanocarriers 
with a targeting moiety to facilitate the homing, binding and internalization of the therapeutic agent by 
cells at the biological site of action. Various moieties have been examined as targeting agents, 
including antibodies and their fragments (Fay and Scott, 2011, Han and Davis, 2013, Marega et al., 
2012), peptides (Agemy et al., 2011, Hansen et al., 2013, Stefanick et al., 2013, Choi et al., 2010), 
proteins (Huang et al., 2010, Wiley et al., 2013, Pitek et al., 2012, Carrillo-Conde et al., 2011), DNA 
aptamers (Boyacioglu et al., 2013, Yu et al., 2011, Li et al., 2012), and vitamins, in particular folate 
(Werner et al., 2011a, Werner et al., 2011b).  
 
The most common strategy for preparing targeting nanocarriers takes advantage of the well-known 
molecular recognition in antibody-antigen binding. Certain antigens are over-expressed in specific 
tumor cells and nanocarriers modified with monoclonal antibodies (mAbs) have been shown to 
effectively accumulate within tumor tissues. For instance, the use of anti-HER2 immunoliposomes 
leads to significantly higher drug accumulation within the tumor site compared to their non-targeting 
counterparts (Park et al., 2002, Reynolds et al., 2012, Nielsen et al., 2002). Nonetheless, the use of a 
full-length mAb as the targeting moiety for nanocarriers is limited by their relatively high molecular 
weight, which will potentially lead to poor quality control and incorrect orientation on the nanocarriers 
surface after conjugation. These shortcomings have led to a new trend of using targeting moieties, such 
as Fab fragments (Sapra et al., 2004) or single chain variable fragments (scFv) (Iyer et al., 2011) of 
antibodies, proteins over-expressed on tumor cells like transferrin (Iinuma et al., 2002, Li et al., 2009, 
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Ishida et al., 2001), DNA-based aptamers (Boyacioglu et al., 2013, Li et al., 2013, Xiong et al., 2013), 
and peptides such as arginine–glycine–aspartic acid (RGD) (Li et al., 2004, Danhier et al., 2009). The 
relatively smaller hydrodynamic radius of these targeting moieties enables higher ligand density and 
more flexible multivalent surface engrafting.  
 
2.7.2.1. Receptor mediated endocytosis 
Once the drug delivery nanocarriers have reached their target site and been taken up by cells, 
subsequent drug release may occur in the intracellular space. There are several cellular uptake 
mechanisms that depend on the cell type (e.g. phagocytic vs. non-phagocytic cells), physicochemical 
properties of the internalized entity and the mode of activation such as receptor-mediated endocytosis. 
 
Endocytosis is a process by which cells engulf macromolecules, which can be sub-divided into two 
categories, namely phagocytosis and pinocytosis depending on the physical state of the internalized 
objects (Xiao and Gan, 2013, Conner and Schmid, 2003). Phagocytosis corresponds to the uptake of 
large solid macromolecules, e.g. bacteria or dead cell debris; while pinocytosis is the uptake of a large 
volume of extracellular material or a small volume of fluids (Hansen and Nichols, 2009). Meanwhile, 
receptor-mediated or clathrin-dependent endocytosis is a specific process for cells to acquire bulk 
quantities of specific substances, including hormones, growth factors, and plasma proteins (Goldstein 
et al., 1979, Xiao and Gan, 2013). In receptor mediated endocytosis, extracellular molecules are 
recognized by specific receptors on the cell membrane. Interactions of these molecules with surface 
receptors lead to their internalization into cells by the engulfment plasma membrane vesicles through 
coated pits, a term that refers to a clustering of receptors in specific regions the cell membrane 
(Goldstein et al., 1979). Then, the coated pit pinches off from the cell membrane and forms an 
endosome for subsequent lysosomal degradation and drug release (Lodish, 2008). Meanwhile, 
endocytic receptor released from the endosome returns to the cell membrane to start a second round of 
receptor mediated endocytosis (Figure 2-10). 
 
Whether the targeting nanocarrier can be internalized after binding to target cells is an important 
criterion in the selection of targeting ligands. Drugs that enter the cytoplasm by means of receptor 
mediated endocytosis may avoid recognition by the P-glycoprotein efflux pump, which is known for 
being related to P-glycoprotein mediated drug resistance (Gottesman et al., 2002, Wong et al., 2006). 
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Encapsulating drugs within a nanocarrier engineered with a targeting moiety which specifically binds 
to an endocytic receptor can potentially overcome drug resistance in cancer.  
 
  
 
Figure 2-10. Schematic representation of receptor-mediated endocytosis of a targeting 
nanocarrier. Once the targeting nanocarriers reach the extracellular space of the target cells, (i) they 
bind to specific receptors; (ii) membrane invagination occurs and the targeting nanocarriers is engulfed 
by the cell through a coated pit; (iii) drug release is initiated by the acidic pH environment of the 
endosome; (iv) the drugs are released from the endosomal compartment into the cytoplasm. (v) 
Receptors then recycle back to the cell membrane. Meanwhile, efflux pumps express on the cell 
membrane may clear free drugs and leads to multidrug resistant (Kapse-Mistry et al., 2014).  
 
In summary, combining targeted ligands with protecting polymers such as PEG within a single 
nanocarrier platform will be beneficial for the following reasons: i) the presence of a sterically-
protecting polymer like PEG could compensate for MPS clearance caused by the attached ligands on 
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the nanocarrier surface and ii) the longevity of a ligand-bearing nanocarrier may allow for greater 
accumulation even at target sites expressing a low level of the receptor.  The rationale for combining 
passive and active targeting strategies in single nanocarrier platform to enhance drug delivery efficacy 
has been demonstrated by PEGylated liposomal doxorubicin (Yamada et al., 2008). The greatest 
antitumor efficacy was found in animals treated with PEGylated, folate-modified liposomal 
doxorubicin, compared to that of animal treated with untargeted PEGylated liposome or non-
PEGylated PEGylated liposomes modified with folate. However, one should also consider that the 
target recognition moiety may be shielded by the steric barriers created by the protective polymer. 
Studies in the field of targeting nanocarriers have shown that the particle size and surface ligand 
density are critical to their performance (Jiang et al., 2008, Huang et al., 2009, Wang et al., 2010, Elias 
et al., 2013, Bandyopadhyay et al., 2011). Hence, the optimization of these parameters, in combination 
with PEGylation and targeting moiety density, are crucial to ensure that the functionality of 
nanocarriers is not compromised. As stated in Section 1.4 of Chapter 1, Objective 5 of this PhD 
project was to investigate whether varied design parameters have an effect on eliciting an immune 
response, and to use the research outcome to design an optimized drug delivery vehicle with enhanced 
immunogenicity.      
 
2.8. Our body’s defense against foreign invaders 
The human immune defense is a complex system involving specialized lymphoid tissues and various 
types of cells, which closely interact with each other to defend the body against foreign invaders. There 
are three major defense mechanisms involved in the human immune system (Janeway, 2005, Moser 
and Leo, 2010). The first mechanism is comprised of external barriers, including physical (such as skin 
and mucous membranes) and chemical (such as stomach acids) barriers that provide the first line of 
defense against foreign intruders. The second mechanism is innate immunity, which is induced 
immediately once a pathogen enters the body. A range of cells are involved in innate immunity, 
including natural killer (NK) cells, macrophages, granulocytes and dendritic cells that are specialized in 
the recognition and destruction of common pathogens (Moser and Leo, 2010, Haaheim, 2009). Several 
receptors are also involved in the recognition of pathogens, such as pattern recognition receptors 
(PRRs), Toll-like receptors (TLRs) and NOD-like receptors (NLRs) (Janeway, 2005). Antigen 
presenting cells, including macrophages, dendritic cells and granulocytes, will take up, destroy and 
process the invading pathogen through these receptors. However, the innate immune system cannot 
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defend the body against all pathogens and is not capable of immunological memory. Thus, a more 
versatile means of defense, termed adaptive immunity, constitutes the third mechanism of defense. 
Immature dendritic cells encounter and capture pathogens in infected tissues and thereby initiate the 
adaptive immune response. Adaptive immunity consists of humoral and cell mediated immunity. 
Humoral immunity is mediated by B cell-secreted antibodies, while cell-mediated immunity is 
mediated by T lymphocytes which target and destroy pathogens that antibodies do not have access to.  
 
2.8.1. Dendritic cells in the immune system 
Dendritic cells (DCs) are a group of professional antigen presenting cells (APCs) specialized in 
capturing, processing and cross-presenting antigens (Banchereau and Steinman, 1998). DCs play a 
central role in regulating the innate and adaptive immune systems. As a key regulator of the immune 
response, DCs comprise a complex network of APCs that regulates T cell mediated immunity and 
tolerance. DCs are also responsible for inducing the differentiation of B cells into antibody-producing 
plasma cells. While B cells can directly recognize native antigen through their B cell receptors and 
secrete the corresponding antibody, T lymphocytes need the antigen to be processed and presented to 
them by APCs. In most tissue, DCs are present in their immature state and are incapable of stimulating 
T cell due to the lack of requisite accessory signals for T cell activation, e.g. CD40, CD54 and CD86. 
However, they are highly efficient in capturing antigens, which is essential for their full maturation and 
mobilization (Banchereau and Steinman, 1998). DCs take up particles and microbes by phagocytosis 
(Inaba et al., 1993, Moll et al., 1993), take in high volumes of fluid or solutes via macropinocytosis 
(Sallusto et al., 1995) and express receptors that mediate adsorptive endocytosis such as C-type lectin 
receptors (Sancho et al., 2009) and macrophage mannose receptor (Sallusto et al., 1995). An encounter 
with antigen stimulates the maturation and differentiation of DCs, which then rapidly lose their ability 
to capture antigen. On the other hand, this process up-regulates the antigen processing and presentation 
ability of DCs, as well as their expression of co-stimulatory molecules and the secretion of cytokines. 
DCs undergo a complex process of maturation into antigen-presenting cells. There are two types of 
major histocompatibility complexes (MHC) on the surface of APCs that can bind to the antigen: MHC 
class I and MHC class II, responsible for stimulating cytotoxic T cells (CTLs) and helper T cells 
respectively. To generate CTLs, mature DCs present intracellular MHC class I loaded with antigenic 
peptides. Extracellular antigens are processed within the APC endocytic pathway and presented by 
MHC class II to T helper cells to initiate an immune response (Banchereau and Steinman, 1998). In 
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summary, DCs are mobile sentinels that bring antigen to T cells and initiate the immune response 
(Figure 2-11). 
 
 
Figure 2-11. A brief illustration for antigen presentation in vivo. Immature DCs capture antigen in 
peripheral tissues followed by the formation of MHC-peptide complexes. After an encounter with 
antigen, immature DCs derived from proliferating DC progenitors begin to mature and express 
cytokines to stimulate and bind T cells. In cases where the antigen was bound to B cells, then both T 
cells (blue) and B cells (orange) can cluster with DCs and leave the T-cell area of the lymph nodes. 
Eventually, B cells will arrive at bone marrow and other lymphoid tissues, such as the medulla of 
lymph node. Figure taken from (Banchereau and Steinman, 1998). 
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2.8.2. Types of DCs in mice, CD8+ DC and cross presentation 
Numerous studies have shown that mouse DCs comprise several subsets with distinct phenotypes and 
functionalities (Ganguly et al., 2013b). DCs can be subdivided into two major subsets: conventional 
(myeloid) DC (cDC) and plasmacytoid DC (pDC) that differ in the expression of their Toll-like 
receptor (Shortman and Liu, 2002, Caminschi et al., 2012). In addition to cDCs and pDCs, two small 
subsets of DCs, namely monocyte derived DCs (moDCs) and langerhans cells (LCs) had also been 
reported (Chorro et al., 2009, Domínguez and Ardavín, 2010). 
 
In the steady-state, cDC progenitors in bone marrow migrate through the blood to non-hematopoietic 
tissues and secondary lymphoid organs. cDCs are dedicated in internalizing, processing and presenting 
antigen and the subsequent naïve T cell activation. The lymphoid-resident cDCs in the spleen and 
lymph nodes can be sub-categorized as CD8α and CD4. CD8+ DCs are the primary DCs found in the 
thymus which express CD8α but no CD4, while the CD4+ DCs express CD4 but not CD8α. In 
addition, there are double negative (DN) DC express neither CD8α nor CD4 surface molecules 
(Vremec et al., 2000). The CD8+ DCs subset is highly efficient at presenting exogenous antigen on 
MHC class I molecules to cytotoxic CD8+ T cells (Ganguly et al., 2013a). Such mechanism is called 
cross-presentation and is vital for the induction of cytotoxic T lymphocytes and efficient T-cell 
mediated anti-tumor immunity(Caminschi et al., 2009). The reason for CD8+ DCs superior to CD4+ 
DCs at cross-presenting exogenous antigen lies in the selective expression of phagocytics receptors and 
their endocytic pathways (Caminschi et al., 2012, Segura et al., 2013). In CD8+ DCs endocytotic 
pathway, proteolysis is limited different mechanisms, including the inhibition of acidification in 
endosomes and phagosomes through production of reactive oxygen species (ROS), by which 
degradation of potential epitopes can be avoided(Savina et al., 2009). CD4+ DCs are believed to be 
professional in presenting MHC class II-restricted antigens to CD4+ T cells (Ganguly et al., 2013a).  
 
2.8.3.  Targeting delivery to DCs via Clec9A 
As stated in the previous section, DCs are professional APCs that detect and destroy invading 
pathogens. Receptors such as Toll-like receptors (TLRs), nucleotide-binding oligomerization domain 
(NOD) proteins and C-type lectin receptors on the immature DCs surface are vital for the recognition, 
communication and activation of DCs (Villadangos and Schnorrer, 2007). C-type lectins (also known 
as C-type lectin receptors (CLRs) are a protein family involved in cell adhesion, endocytosis, natural-
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killer-cell target recognition and dendritic-cell activation (Robinson et al., 2006, Villadangos and 
Schnorrer, 2007). One of the C-type lectins, Clec9A (C-type lectin domain family 9A; also known as 
DNGR1) is the most recently identified receptor and is expressed in many tissues (Caminschi et al., 
2009, Huysamen et al., 2008, Sancho et al., 2009). In mouse, Clec9A is highly restricted to CD8+ 
dendritic cells (Sancho et al., 2009, Huysamen et al., 2008). The equivalent human ortholog of mouse 
Clec9a was found on the human dendritic cell subtype BDCA3+ (Huysamen et al., 2008). The 
cytoplasmic tail of Clec9A contains a tyrosine residue with a sequence similar to the immunoreceptor 
tyrosine-based activation motifs (ITAMs), allowing the recruitment and activation of spleen tyrosine 
kinase (Syk) by Clec9A (Sancho et al., 2009). Clec9A functions as an activation receptor that induces 
inflammatory cytokine production and signaling via Syk kinase (Huysamen et al., 2008).  
 
DCs play a central role in the immune system and orchestrate a wide repertoire of immune responses, 
ranging from resistance to infection and tolerance to self (Steinman and Banchereau, 2007). Being a 
key player in regulating immunity, DCs are the natural focus for immune therapy. Targeting an antigen 
to CLRs on DCs represents an attractive strategy to enhance vaccine efficacy. This is because most of 
the CLRs are endocytic receptors, i.e. they are highly specialized for the internalization of antigens and 
processing and influence antigen routing and presentation on MHC class I and II. Depending on the 
CLR targeted, either CD4+ or CD8+ T cell response can be specifically induced (Caminschi et al., 
2009). In order to facilitate highly specific targeting delivery, it is important to choose a CLR that is 
highly exclusive to a certain subset of DCs. Expression of Clec9A is highly restricted to certain DC 
subsets in both mice and humans compared to other C-type lectins. Antigen coupled to an mAb 
recognizing a DC surface molecule like Clec9A could potentially be cross-presented to the CD8+ DCs. 
Several studies have been done to show that Clec9A is an effective target for delivering antigen to DCs. 
Sancho et al have shown that along with adjuvant, targeting a tumor antigen conjugated to a mouse 
Clec9A specific antibody elicits a robust CTL response. In another study done by Caminschi et al, even 
without the presence of adjuvant, an antigen targeted to Clec9A produced a striking enhancement in 
antibody responses, and the required amount of antibody was much lower than that of the free antigen 
to preduce a positive titer (Caminschi et al., 2008). All these findings suggest that targeting DCs using 
Clec9A as a target could potentially enhance the effectiveness of vaccines. One of the reasons why 
Clec9A is such an effective target could be due to the fact that CD8+ DCs, which express Clec9A, are 
believed to be capable of recognizing necrotic cells and cross-presenting antigen to T cells via MHC 
class I molecules (Villadangos and Schnorrer, 2007). Antigens that target CD8+ via Clec9A seemed to 
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fall into the regular biological process of DCs for processing exogenous antigens (Caminschi et al., 
2009).  
 
2.9. Summary 
In this chapter, the literatures relating to this PhD projects were critically reviewed. Effective drug 
delivery is key to better disease treatment. With a high proportion of drug candidates characterized by 
poor bioavailability and biodistribution, there is a great need to develop new drug delivery systems that 
can improve the intrinsic adsorption, distribution, metabolism and excretion (ADME) of drugs. 
Nanocarriers are emerging as safer and more effective drug delivery options compared to the traditional 
counterparts, i.e. capsules and tablets. They have shown numerous favorable features including a long 
circulation halftime, target specificity, intracellular delivery through endocytosis, high drug loading 
capacity and co-delivery of multiple therapeutic substrates to cater personal medication needs. The 
delivery of therapeutic agents through nanocarriers diminishes the unfavorable site effect in healthy 
tissues and enables enhanced accumulation at the biological site of action. The use of antigens 
exclusive to certain subset of cells is an effective targeting strategy. However, current strategies for 
surface engineering with functional moieties usually required a stringent reaction environment, which 
is potentially compromising to the activity of the therapeutic payload. The search for new strategies for 
targeting and nanocarrier stabilization will advance our ability to improve delivery efficacy.  
 
The next chapter presents the study on constructing a PEGylated TNE with enhanced immune evading 
ability. It demonstrates a simple one-step PEGylation step for TNE using DAMP4 as anchor. The result 
from this part of the work provides a strong evidence base to support the hypothesis stated in Chapter 1 
that laid the foundation of this PhD project. Subsequent chapters develop the PEGylated nanoemulsion 
further to input targeting and to demonstrate desirable biological outcomes in vivo. 
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Chapter 3  Design, synthesis and characterization of a stealth 
nanocarrier emulsion using DAMP4 as an anchor  
3.1. Introduction 
The in vivo behavior of nanocarriers is dictated by their physical parameters such as size, surface 
charge and hydrophilicity (Laurent et al., 2009, Mornet et al., 2004) and any biological function 
encoded, for example, by antibodies on the nanocarrier surface. When nanocarriers enter the 
bloodstream, they encounter a complex environment filled with plasma proteins and immune cells. 
Based on their physiochemical nature, these nanocarriers in the blood stream will be captured by the 
mononuclear phagocyte system (MPS) and directed to clearance organs including the liver and spleen 
at various clearance rates. The capturing of nanocarriers by the MPS is known to be initiated by the 
electrostatic adsorption of plasma protein (opsonin) onto the surface of nanocarriers (Vonarbourg et al., 
2006). For a nanocarrier to escape MPS capture, that is to be a “stealth” nanocarrier, opsonin 
adsorption on the nanocarrier surface needs to be minimized (Dobrovolskaia et al., 2008). Thus 
nanocarriers with neutral zeta-potential or zeta-potential close to zero are expected to have a lower 
opsonization rate. Stealth nanocarriers are expected to circulate within the bloodstream for a longer 
time and accumulate in the desired biological site by the EPR effect (reviewed in Section 2.7). To aid 
this, the hydrodynamic diameter (DH) of nanocarriers is optimally between 100 to 200 nm (reviewed in 
Section 2.6).  
 
Modifying the surface of nanocarriers with a hydrophilic polymer is another effective way to increase 
“stealthiness”. PEG is a non-toxic, non-immunogenic, hydrophilic and highly elastic polymer approved 
by the FDA for pharmaceutical use. PEG is an attractive polymer for reducing opsonization due to its 
uncharged and hydrophilic nature (Harris and Chess, 2003, Harris et al., 2001). It has been shown that 
the presence of PEG chains on the nanocarrier surface increases both the colloidal stability in 
physiological conditions (Hervé et al., 2008) and the in vivo blood half-life (Krystek et al., 2011). The 
stealthiness of a PEGylated nanocarrier can also be affected by parameters such as the polymer 
molecular weight, as well as its density and conformation on the nanocarrier surface (Gref et al., 2000, 
Peracchia et al., 1997). Therefore it is important to understand hematocompatibility during initial 
biological evaluation for newly designed injectable nanocarriers.  
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As stated in Chapter 1, the goal of this research is to develop an efficient emulsion nanocarrier with 
immune evading and target-specific characteristics for cellular delivery. Here we decouple the 
biological and physical design criteria through a novel emulsion nano-engineering approach. This 
chapter aims to address Objective 1 stated in Section 1.4, which is devoted to PEG modified TNE 
development as the base platform having enhanced immune-evading ability. Under our first hypothesis 
(see Chapter 1), conjugation of a functional molecule to DAMP4 and addition of the conjugate to a 
pre-formed emulsion should functionalize the AM1-coated oil-water interface with this molecule. 
Figure 3-1 shows this idea schematically. PEG (white) chemically conjugated to DAMP4 (dark blue) 
is introduced to a solution containing pre-formed TNE oil core (light yellow) stabilized by AM1 (red), 
in aqueous buffer (light blue background). The chemical similarity of DAMP4 and AM1 allows non-
covalent interfacial coupling and hence integration of DAMP4 to the interface, with hydrophilic PEG 
projecting from its DAMP4 interfacial anchor into the aqueous phase surrounding the emulsion surface.  
 
 
 
Figure 3-1. Decoration of the nanoemulsion oil-water interface with PEG by simple addition of 
PEGylated biosurfactant protein DAMP4 to an oil droplet previously formed in the presence of 
peptide surfactant AM1. Schematic representation of PEG (white) chemically conjugated to DAMP4 
protein (dark blue) being introduced to a solution containing pre-formed nanoemulsion oil core (light 
yellow) stabilized by AM1 peptide (red), in aqueous buffer (light blue background). DAMP4 protein, 
which is chemically similar to AM1 peptide, is able to integrate into the oil-water interface formed 
between the core and the aqueous bulk. Prior conjugation of PEG to DAMP4 leads to its functional 
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display at the interface through non-covalent molecular self-assembly. Figure reproduced from Zeng et 
al, 2013 (Zeng et al., 2013). 
 
With reference to Figure 3-1, the addition of PEG to the interface will create a sheath at the interface 
which is expected to very significantly change the mechanical properties of the interface. By 
conducting a sudden contraction of the interface, we would expect the response to be quite different in 
the presence or absence of interfacially-anchored PEG. Thereafter, the effects of an anchored PEG 
coating on the in vitro hematocompatibility was assessed by comparison of TNE modified with various 
concentration of PEG. We showed that the conjugation of DAMP4 to PEG resulted in functional 
display of the molecule at the interface separating the oil droplet from the aqueous bulk.  
 
3.2. Materials and methods 
3.2.1. Materials 
AM1 (molar mass 2473 Da, 95 % purity) was custom synthesized by Genscript (Piscataway, NJ, USA) 
as reported previously (Dexter et al., 2006). Peptide concentration was determined by quantitative 
amino-acid analysis (Australian Proteome Analysis Facility, Sydney, NSW, Australia). Miglyol® 812 
was purchased from AXO Industry SA (Wavre, Belgium). 1,1′-dioctadecyl-3,3,3′3′-
tetramethylindocarbocyanine perchlorate (DiI), Phalloidin-AlexaFluor® 647, Hoechst 33342, 
CellTraceTM Violet and AlexaFluor® 700-anti-CD20 were purchased from Molecular Probes (Victoria, 
Australia). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and zinc chloride (ZnCl2) 
were purchased from Sigma-Aldrich (St Louis, MO, USA) and were reagent grade. mPEG-NHS (MW 
5000, PDI <1.08, purity >95 %) was purchased from Nanocs (Boston, MA, USA). RPMI-1640 and 
foetal calf serum (FCS) were purchased from GIBCO (Victoria, Australia). Anti-CD8-eFluor780 was 
purchased from eBioscience (San Diego, CA, USA). APC-ani-HLA-DR, FITC-anti-CD3, PerCP5.5-
anti-CD14, PE/Cy7-anti-I-A/I-E, PerCP5.5-anti-CD8, Pacific Blue-anti-CD19 and PE/Cy7-anti-CD11c 
were purchased from Biolegend (San Diego, CA, USA).  
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3.2.2. DAMP4 expression 
Protein surfactant DAMP4 sequence was cloned into pET48b vector and expressed in E. coli with high 
expression level and good solubility (conducted in Protein Expression Facility, The University of 
Queensland, Australia). Briefly, DAMP4 was expressed as a soluble protein in E. coli BL21 (DE3). 
Glycerol stock of the transformed cells was streaked onto an LB plate (15 g L -1 agar, 10 g L -1 peptone, 
5 g L -1 yeast extract, 10 g L -1 NaCl) containing kanamycin sulphate (50 mg L -1). A single colony from 
the plate was inoculated into 10mL LB media (10 g L -1 peptone, 5 g L -1 yeast extract, 10 g L -1 NaCl) 
and incubated for 16 h at 37 ºC as a seed culture. 400 μL of seed culture was inoculated into 400 mL LB 
media containing 50 mg L -1 of kanamycin and incubated at 37 ºC in an orbital shaker (BioLine, 
Alexandria, Australia) at 180 rpm. When the OD600 reached 0.5, cultures were induced with 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) (AMRESCO®, Solon, US) and incubated for another 5 
h at 37 ºC.  The cell pellet was collected by centrifugation for 15 min at 2000 g at 4 ºC (Beckman 
Coulter-Avanti® J-20 XPI) and stored at -80 ºC until further use.  
 
3.2.3. DAMP4 purification 
The purification of DAMP4 involved sequential chromatographic methods, specifically immobilized 
metal affinity chromatography (IMAC), ion exchange (IEX) and then reversed-phase HPLC (RP-
HPLC) polishing. In brief, cell pellets were re-suspended in lysis buffer (50 mM NaCl, 25 mM Na2PO4, 
2 mM MgCl2, 0.5 % v/v Triton X-100, pH 7.5) and disrupted by ultrasonication (4 cycles of 45 s each; 
Branson Ultrasonics Corporation, Connecticut, USA). Homogenate was centrifuged at 8000 xg 
(Avanti® J-26 XPI, Beckman Coulter) at 4 ºC for 30 min and the supernatant was filtered through a 
Millex® 0.45 μm syringe filte unit (Millipore, Vic, Australia). Clarified cell lysate was loaded onto to a 
Ni2+ charged 5 mL HisTrap FF IMAC column (GE Healthcare Life Sciences, NSW, Australia) using an 
ÄKTAexplorer™ 10 chromatography system (GE Healthcare Biosciences) pre-equilibrated with five 
column volumes (CV) of Buffer A (50 mM NaCl, 25 mM NaH2PO4, pH 7.5). Unbound sample was 
washed out by 4 CV of Buffer A. Pre-elution was performed with 3.8 CV at 6 % (v/v) Buffer B (50 mM 
NaCl, 25 mM NaH2PO4, 500 mM imidazole, pH 7.5) and DAMP4 was eluted from the column with 
80 % (v/v) Buffer B for 8 CV. Elution fractions were pooled and further purified on a HiTrap QFF 1mL 
column (GE Healthcare Life Sciences, NSW, Australia) coupled with a HiTrap SP FF 1 mL column 
(GE Healthcare Life Sciences, NSW, Australia). Only flow-through fractions were collected from this 
step. DAMP4 collected from IEX was further purified on semi-preparative RP-HPLC using a Jupiter 
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C5 10 μm 300 Å 250 mm × 10 mm column (Phenomenex, NSW, Australia). The solvent system 
comprised 99.9 % ultrapure water and 0.1 % (v/v) TFA as Buffer A and 90 % acetonitrile, 0.1 % (v/v) 
TFA as Buffer B. DAMP4-containing fractions were lyophilized and stored at -80 ºC until PEGylation. 
Quantification of DAMP4 was performed on RP-HPLC using a standard curve established in our lab 
previously.  
 
3.2.4. DAMP4 PEGylation 
Methyoxyl N-hydroxylsuccinamide (NHS) functionalized polyethylene glycol (mPEG-NHS) (average 
MW 5000, PDI <1.08, purity >95 %) was purchased from Nanocs (New York, USA).  Lyophilized 
DAMP4 was dissolved in 25 mM HEPES, pH 7.0 and a known amount of mPEG-NHS (molar ratio of 
mPEG : DAMP4 = 20 : 1) was added to the solution, and the conjugation reaction was performed for 
12 h at 4°C.  The reaction product, which contained PEGylated DAMP4 (PEG-DAMP4), unmodified 
DAMP4 and free PEG, was analyzed by SDS-PAGE using Novex® 10 % SDS-PAGE tricine gel (Life 
technologies, Vic, Australia).   
 
3.2.5. Sudden inverted oil drop contraction experiment 
A drop shape tensiometer (DSA-10, KRÜSS GmbH, Hamburg, Germany) was used to record images. 
An 8 mL quartz cuvette (Hellma GmbH, Mülheim, Germany) was filled with AM1 peptide (final 
concentration 5 µM) and zinc chloride (100 µM) in HEPES (25 mM, pH 7.0). An inverted needle fitted 
to a gas-tight glass syringe (SGE Analytical Science Pty Ltd, Ringwood, Australia) was submerged into 
the cuvette and Miglyol® 812 as injected to form a droplet. Miglyol® 812 droplets were first aged for 
10 min before PEGylated DAMP4 (10 µM) or an equivalent volume of HEPES buffer (25 mM, pH 7.0) 
was added. Droplets were then aged for another 30 min before a sudden reduction in droplet volume 
was performed by withdrawing Miglyol® 812 back into the syringe.  
 
3.2.6. TNE preparation 
To prepare TNE core, lyophilized AM1 (final concentration 400 µM) was dissolved in 980 µL HEPES 
(25 mM, pH 7.0) containing ZnCl2 (800 µM). Twenty microliters of Miglyol® 812 was added to give an 
oil volume fraction of 2 % (v/v). The mixture was homogenized using a Branson Sonifier 450 
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ultrasonicator for four 45 s bursts at 60 W. To prepare P20-TNE, TNE (500 µL) was added to 
PEGylated DAMP4 solution (500 µL, 40 µM) followed by 60 s of vigorous stirring using a magnetic 
stirrer. To prepare P200-P20-TNE, P20-TNE (500 µL) was added to PEGylated DAMP4 solution (500 µL, 
400 µM) followed by 60 seconds of vigorous stirring using a magnetic stirrer.  
 
3.2.7. Particle size and zeta potential analysis  
TNE was diluted 100-fold into water or phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) prior to analysis to avoid multiple scattering effects. Particle 
size and zeta potential measurements were performed using a Malvern Zetasizer Nano ZS (Malvern, 
Worcestershire, UK) equipped with a He-Ne laser (633 nm). Data analysis was with DTS software 
(Malvern, version 4.2), using a non-negatively constrained least squares (NNLS) fitting algorithm. 
Dispersant refractive index and viscosity of the dispersant were assumed to be 1.45 and 1.02 cP, 
respectively.  
 
3.2.8. Analysis of in vitro cell uptake  
RAW264.7 mouse macrophage cells were cultured in RPMI-1640 medium supplemented with FCS (5 
%, v/v). One day before the uptake experiment, cells  (2.5 × 105 cells per well) were seeded into a 24-
well flat bottom tissue culture plate (Greiner Bio-One, Frickenhausen, Germany) with 12-mm diameter 
glass slips and incubated at 37°C with 5 % (v/v) CO2 supplied. The following day, DiI labelled BSA-
TNE (25 µL) or P20-TNE (25 µL) or P200-P20-TNE (50 µL) was added to the corresponding well and co-
cultured with cells for 2 h at 37°C with 5 % (v/v) CO2 supplied. Cells were fixed with 4 % (v/v) 
paraformaldehyde. Cell nuclei were stained with Hoechst 33342 and cell membrane was stained with 
Phalloidin-AlexaFluor® 647. Mounted glass slips were imaged on an Apotome microscope (Carl-Ziess, 
Sydney, Australia). For in vitro uptake in human peripheral blood mononuclear cells (PBMC, collected 
from health donors with approval from the Human Research Ethics Committee of the Princess 
Alexandra Hospital), cells (5 × 105 cells per well) were seeded into a 24-well flat bottom tissue culture 
plate in 1 mL of RPMI-1640 medium supplemented with FCS (5 %, v/v). DiI labelled BSA-TNE (25 
µL) or P20-TNE (25 µL) or P200-P20-TNE (50 µL) was added to the corresponding wells and co-cultured 
with cells for 3 h at 37°C with 5 % (v/v) CO2 supplied. After washing with PBS, cells were stained 
with APC-anti-HLA-DR and PE/Cy7-anti-CD11c (DCs), FITC-anti-CD3 (T cells), PerCP5.5-anti-
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CD14 (monocytes) and Pacific Blue-anti-CD20 (B cells). Cell uptake was analyzed on a Beckman 
Coulter Gallios™ Flow Cytometer.  
 
3.3. Results and discussion 
3.3.1. DAMP4 PEGylation 
A variety of chemistries can be used for the covalent attachment of PEG to proteins and peptides 
(Veronese and Pasut, 2005, Roberts et al., 2002). The most common method is to conjugate PEG to the 
primary amino group of lysine using PEG modified with an active NHS ester. SDS-PAGE is a widely 
used method for PEG-protein characterization (Sun et al., 2003, Moosmann et al., 2009, Colonna et al., 
2008). Theoretically there are five NHS-reactive sites in the DAMP4 sequence (4 lysine residues plus 1 
N-terminus group per DAMP4 molecule). As shown in Figure 3-2, the additional band at size 17 kDa 
suggests that the majority of DAMP4 had been conjugated with PEG. However, the molecular mass of 
the PEGylated DAMP4 could not be determined due to the band broadening and, for most cases, the 
electrophoretic mobility of PEGylated proteins is not strictly related to their molecular weight (Kurfürst, 
1992). 
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Figure 3-2. Photographic representation of an SDS-PAGE gel showing samples from a PEGylation 
reaction of DAMP4.  Lane 1: Novex® Sharp Pre-stained Protein Standard (Novex®, Mulgrave, 
Australia); Lane 2: Lyophilized DAMP4 re-dissolved in HEPES (25 mM, pH 7.0); Lane 3: DAMP4 
PEGylation reaction mixture.   
 
3.3.2. DAMP4 carries its conjugated PEG onto an AM1 pre-adsorbed oil-water interface 
An inverted oil drop within an aqueous buffer solution comprising AM1 was formed and allowed to 
form a cohesive interfacial network at the oil-water interface.  PEGylated DAMP4 was then added to 
the buffer and aged for 30 min. When a sudden contraction of the oil drop interface was imposed, the 
oil-water-PEG interface wrinkled as the oil drop relaxed and the effect persisted for more than 10 min 
(Figure 3-3a). In the absence of PEGylated DAMP4, the oil drop relaxed to a spherical shape in less 
than 6 s (Figure 3-3b). The strikingly distinct interfacial behavior mediated by PEGylated DAMP4 is 
characteristic of an elastic interface (Malcolm et al., 2009), likely due to the presence of the additional 
elastic PEG film connected to the oil-water interface by DAMP4, in keeping with our hypotheses.  
 
 
 
Figure 3-3. Photographs of a 10 min old Miglyol 812 oil drop formed from an inverted needle in 
peptide AM1 solution, further aged for 30 min following the addition of either (a) PEGylated DAMP4 
or (b) HEPES buffer. The oil drops were subjected to a sudden contraction in volume and images were 
acquired using a drop shape tensiometer.  
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3.3.3. DAMP4 mediated TNE PEGylation 
Nanocarriers for intravenous administration should ideally have colloidal stability within a biological 
environment. AM1-stablized TNE core forms large flocculates rapidly when diluted in PBS as a result 
of removal of the electrostatic barrier by the high ionic strength of PBS. These then proceed to quickly 
coalesce at a rate dependent on the interfacial mechanical properties.(Chuan et al., 2011, Malcolm et al., 
2009). On the other hand, the anchoring of the polymer PEG at the interface would create a repulsive 
steric barrier thus imparting additional stability to the nanoemulsion even under conditions of high 
ionic strength. If DAMP4 really does integrate its conjugated PEG onto the AM1 stabilized oil-water 
interface as hypothesized, then the additional PEG layer should prevent the TNE core from flocculation 
and coalescence.  So first we evaluated whether the PEG-modified TNE oil core could stay stable 
under isotonic conditions. Serial additions of PEGylated TNE were prepared by adding a range of 
concentrations of PEGylated DAMP4 to a pre-formed 2 % (v/v) AM1 stabilized TNE oil core and the 
size distribution of the resulting PEGylated TNE in isotonic phosphate buffered solution (PBS) was 
measured by DLS.  
 
As shown in Figure 3-4, AM1-stabilized TNE core modified with PEGylated DAMP4 at a 
concentration ranging from 20 μM to 560 μM was flocculation-stable in PBS and maintained a Z-
average diameter of approximately 180 nm, even at low levels of added PEGylated DAMP4. Only 
when TNE core was mixed with PEGylated DAMP4 at a concentration lower than 20 µM was a 
polydispersed size distribution, with large droplets, observed. This result suggested that as little as 20 
μM of PEGylated DAMP4 was sufficient to create steric repulsion around the pre-formed AM1 
stabilized TNE oil core, preventing them from flocculating and coalescing under high ionic strength 
conditions. 
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Figure 3-4. The effect of concentration of PEGylated DAMP4 on TNE stability following dilution 
from water into isotonic buffer. 10 μL of freshly prepared TNE was diluted into 990 μL of PBS for DLS 
measurements. All measurements were done in triplicates. Data was shown as mean with SD.  
 
3.3.4. PEGylated TNE escapes APC phagocytosis 
We further tested the biological function of the TNE oil core modified with PEGylated DAMP4, by 
assessing whether the expected reduction in phagocytosis due to core PEGylation, indeed occurred. We 
constructed a PEGylated TNE by adding 20 µM of PEGylated DAMP4 to a pre-formed 2 % (v/v) AM1-
stabilized TNE oil core (termed P20-TNE, noting that the formulation comprises an AM1-stabilised 
core modified by addition of 20 µM PEG to the surrounding bulk aqueous phase). Further addition of 
200 µM PEGylated DAMP4 to P20-TNE created a modified TNE which notionally had a higher PEG 
surface coverage (P200-P20-TNE, i.e. P20-TNE with a further 200 µM of PEG added to the surrounding 
bulk aqueous phase after prior addition of 20 µM PEG). Size distribution and zeta-potential of the 
resulting TNE were measured by DLS. As shown in Table 3-1, following the addition of 20 µM of 
PEGylated DAMP4 to the pre-formed AM1 stabilized oil core, the emulsion size was slightly larger, 
but remained mono-dispersed at 174 ± 2.4 nm. The zeta potential of the emulsion surface decreased to 
30.2 ± 0.6 mV as a result of decoration of the PEG polymer shielding the effective positive charge of 
AM1 stabilized interface. Further addition of PEGylated DAMP4 to P20-TNE (P200-P20-TNE) did not 
increase the size significantly, but further decreased the Z-potential to 18.9 ± 0.7 mV as a consequence 
of more PEG being introduced to the oil core surface shielding the positively charged AM1 network.  
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Table 3-1 Size distribution and Z-potential of TNE measured. TNE was diluted 1 in 100 in ultra-pure 
water, size distribution and zeta potential were measured using a Malvern Zetasizer Nano ZS (Malvern, 
Worcestershire, UK). Data were collected from three experiments and expressed as average with 
Standard Deviation. 
 
The P20-TNE and P200-P20-TNE were co-cultured with RAW264.7 macrophages for 2 h. The 
previously-reported BSA-coated TNE (Chuan et al., 2011) was also incubated with the same cell line 
for comparison. Uptake of TNE was monitored with intensity of the DiI dye used to label the emulsion. 
Compared with uptake of a BSA-stabilized but non-PEGylated TNE, uptake of P20-TNE appeared to be 
reduced (Figure 3-5), although significant uptake occurred in both cases. Further addition of 200 µM 
PEGylated DAMP4 to P20-TNE created a modified TNE (P200-P20-TNE) which notionally had a higher 
PEG surface coverage. In vitro testing confirmed that P200-P20-TNE exhibited reduced uptake by 
macrophages compared to P20-TNE (Figure 3-5), providing evidence that the core TNE is amenable to 
successive PEGylation via simple, top-down sequential addition of PEGylated DAMP4.  
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Figure 3-5 Confocal images showing uptake of BSA-TNE (a negative control reported previously, 
lacking PEG), P20-TNE (an interface coated with a low amount of PEG) and P200-P20-TNE 
(nanoemulsion with a higher level of PEG interfacial coverage) by murine macrophage cell line 
(RAW264.7) after 2 h incubation and then washing to remove unbound TNE. Nanoemulsions were 
labeled with fluorescent dye DiI (red). Cell nuclei were stained with Hoechst 33342 (green) and cell 
membrane was stained with Alexa Fluor® 647 conjugated phalloidin (blue). Scale bar 20 µm; 
 
We then sought to evaluate the PEGylated TNE in a more complex system. To mimic injection of 
PEGylated TNE into the bloodstream, clearance by immune cells was investigated in vitro by co-
culturing the same set of TNEs with human peripheral blood mononuclear cells (hPBMC), 
predominantly comprising T and B cells, monocytes and dendritic cells (DCs). Figure 3-6 shows that 
uptake of P200-P20-TNE was consistently lower than that of the simple and previously-reported BSA-
TNE across all of these cell types, with 40 % and 20 % reduction in internalization by monocytes and 
HLA-DRhi CD11c+ DCs, respectively. This result shows that the nanoemulsion, when appropriately 
covered with self-assembled PEG, is able to avoid non-specific cell uptake. 
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Figure 3-6. Uptake of BSA-TNE, P20-TNE and P200-P20-TNE by cell sub-populations within human 
peripheral blood mononuclear cells (PBMC). Gating strategy: T cells: CD3+ CD20; B cells: CD20+ 
CD3; monocytes: CD14+, DCs: HLA-DRhiCD11c+. Percentage of cells with bound TNE (DiI positive 
cells) was calculated using baseline set against FMO. Results are expressed as mean with standard 
deviation (for N=2), and demonstrate a clear down-regulation of non-specific binding for PEGylated 
nanoemulsion versus BSA-TNE. 
 
3.4. Conclusions 
The goal of this Chapter was to address Objective 1 stated in Section 1.4, by using DAMP4 as anchor 
for TNE PEGylation based on the hypothesis stated in Section 1.3, which comprises three steps that are 
closely associated with each other: 1) DAMP4 four-helical bundle pre-conjugated to PEG unfolds in 
the sub-interfacial region; 2) The unfolded DAMP4 integrates into the AM1 pre-occupied interface and 
anchors its conjugated PEG molecule there, and 3) functionally displays PEG on the surface of TNE oil 
core. By conducting a sudden inverted oil drop contraction experiment, we demonstrated that the 
addition of PEGylated DAMP4 to an oil-in-water interface pre-adsorbed with AM1 created an elastic 
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PEG film connected to the interface, consistent with the first part of our hypothesis that the DAMP4 
bundle unfolds and integrates into the AM1-coated interface.  
 
In its unmodified form, the AM1 stabilized TNE core was not stable against flocculation in isotonic 
buffer as the positively-charged AM1 network will be neutralized eventually leading to emulsion 
destabilization through flocculation and coalescence under physiological levels of salt. We developed a 
simple sequential reagent addition approach for preparing PEGylated TNE that enables the non-
covalent attachment of PEG to the surface of the AM1-stabilized TNE core. We prepared a range of 
PEGylated TNEs formulated with a range of concentrations of PEG-DAMP4 conjugate. The addition 
of PEG-DAMP4 conjugate into the TNE system led to the formation of PEGylated TNE. PEGylation 
imparts steric stability to the TNE oil core in isotonic conditions, as can be seen from the consistent 
size distribution when PEGylated TNE was exposed in isotonic PBS (Table 3-1),  suggesting such 
formulation would be suitable for intravenous injection and intracellular delivery. Another consequence 
of PEGylation is partial charge screening. Unmodified TNE is positively charge due to the presence of 
positively charge amino acid residues R, H and K within the AM1 sequence (AM1 is reviewed in 
Section 2.4.2), as well as the presence of zinc ions in the interfacial network. The magnitude of 
positive charge reduces with the concentration of PEG-DAMP4 within the system as the non-covalent 
grafting of PEG-DAMP4 shields the positively charged AM1 network (Figure 3-4). This result further 
supports the second hypothesis, that DAMP4 brings PEG to the AM1 pre-occupied interface as evident 
by the reduction in PEGylated TNE surface charge.   
 
Armed with this PEGylated TNE, we proceeded to test the immune evading ability in vitro. The 
PEGylated TNE, P200-P20-TNE, showed reduced non-specific cell-association compared to its non-
PEGylated (BSA-TNE) or TNE with lower PEG content (P20-TNE) counterparts (Figure 3-5, 3-6). 
Others have already demonstrated that the rapid MPS clearance of nanocarriers can be significantly 
reduced by modifying their surface with a hydrophilic polymer such as PEG (topic reviewed in Section 
2.7.1). The presence of PEG on the TNE surface can protect a TNE from capture by macrophages 
(Gaur et al., 2000, Ozcan et al., 2010). Such a reduction in MPS clearance of the PEGylated 
nanocarrier is mainly due to reduced interactions between the nanocarrier and the protein opsonin 
within the blood stream. Consistent with literature, the presented results in this Chapter confirm that the 
cell-association of TNE is dependent on the PEG content within the TNE system, further proving the 
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third part of our hypotheis, that PEG was functionally displayed on the TNE oil/water interface by 
DAMP4. 
  
Results from this experimental chapter confirm the hypothesis that the integration of DAMP4 into the 
AM1 stabilized oil droplet surface would lead to the functional display of conjugated PEG at the 
interface of the TNE oil core. This was evidenced by the elastic properties of the film during inverted 
oil drop contraction. When appropriately covered with self-assembled PEG using DAMP4 as an 
anchor, nanoemulsion is able to avoid, almost completely, non-specific cell uptake.  
 
The long term goal of this PhD project was to develop an efficient emulsion nanocarrier for targeting 
intracellular delivery. However, the PEGylated TNE presented in this chapter does not contain any 
targeting ligand which is necessary for a nanocarrier to enter cancerous cells (reviewed in Section 
2.7.2). For nanocarrier to work for intracellular delivery, it must be internalized by the target cells in 
significant quantities. Hence in the next Chapter (Chapter 4), we further investigated whether the same 
process can be applied to functionalize a TNE with a receptor-specific homing device (an antibody), to 
simultaneously increase its target specificity while reducing clearance by immune cells through 
PEGylation as demonstrated in this Chapter.  
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Chapter 4  Design, synthesis and characterization of a TNE targeting 
dendritic cells  
4.1. Introduction 
In Chapter 3 we demonstrated that addition of PEG-DAMP4 conjugate to a pre-formed AM1-
stabilized TNE core resulted in an elastic layer being coated on the oil core, which creates a steric 
barrier for stabilizing the TNE under isotonic conditions. The PEGylated TNE, P200-P20-TNE, showed 
enhanced immune evading characteristics, compared to P20-TNE which had less PEG displayed on the 
TNE oil core. Reasons for the enhanced stealthiness, which is the ability of a nanocarrier to escape 
mononuclear phagocyte (MPS) capture, could be due to the possibility that DAMP4 carries its 
conjugated PEG and co-adsorbs at the AM1-stabilized TNE core interface, which then imparts a 
repulsive barrier that repels the attachment of opsonins onto the TNE surface. It has been demonstrated 
that PEGylation can increase the bioavailability and biodistribution of a nanocarrier, hence it is a 
common strategy for passive targeting (reviewed in Section 2.7.1). In Chapter 3, I accomplished 
Objective 1 as stated in Section 1.4, by demonstrating that DAMP4 could display its conjugated PEG 
on a TNE surface to achieve a PEGylated TNE having enhanced immune-evading ability.  
 
A novel drug delivery system (DDS) should not only have immune evading ability, but also have 
superior in situ targeting ability for precise intracellular delivery, which is the so called “active 
targeting” strategy (reviewed in Section 2.7.2). Take cancer treatment, for example; current cancer 
therapy usually involves the application of cytotoxic anti-cancer drugs. Systemic administration of 
these drugs leads to undesired site-effects; hence they are given to patients at sub-optimal dosages and 
potentially result in treatment failure (Allen, 2002). Concentrated dosage of these cytotoxic drugs can 
be given to patients by encapsulation into a nanocarrier, and a passive targeting strategy, e.g. 
PEGylation, can increase the circulation half time of the nanocarrier. Adding a targeting moiety to the 
long-circulating nanocarrier could further improve its “homing” ability, i.e. the ability to discriminate 
between healthy and malignant cells. Targeting moiety incorporation facilitates intracellular delivery 
via receptor-mediated endocytosis, whereby their drug payloads can be released to provide a 
therapeutic action.  
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Liposome nanocarriers and nanoparticles represent well-studied platforms for cell-specific delivery 
both in vitro and in vivo (Ashley et al., 2011, Hu et al., 2011, Kaaki et al., 2011, Kukowska-Latallo et 
al., 2005, Liu et al., 2010, Mathew et al., 2012, Reddy et al., 2006, Shroff and Kokkoli, 2012, Yoshida 
et al., 2012). These systems can encode complex functionality, for example immune targeting and 
immune evasion, but often suffer from a lack of stability, limited cargo capacity, cellular processing 
through non-functional pathways, or a general loss of intended function simply due to the complexity 
of the in vivo environment (Kim et al., 2009). In the last chapter, I demonstrated that PEGylation of a 
TNE can be achieved by non-covalent “click” chemistry by using DAMP4 as an anchor and a simple, 
sequential, reagent addition method. In this chapter, I aim to address Objectives 2 and 3 stated in 
Section 1.4, to construct a long circulating nanocarrier emulsion that has superior in situ targeting 
ability, by using the non-covalent TNE functionalization procedure I developed and demonstrated in 
Chapter 3. Although active targeting of the nanocarrier by engineering a site-specific moiety on a 
long-circulating nanocarrier’s surface can potentially increase intracellular delivery, exposure of the 
targeting moieties may counteract the shielding effect of the polymeric coating. Therefore it is vital to 
maintain a balance between these two categories of functional groups (Objective 3). Hence I also 
investigate the effect of tuning the ratio of PEG to targeting moiety on the in vitro target selectivity of 
the constructed TNE platform. 
 
For the targeting moiety, we choose dendritic cells (DCs) as the model target cell, and an antibody 
against the highly DC-restricted receptor Clec9A (Caminschi et al., 2008, Huysamen et al., 2008) as the 
homing device on the nanoemulsion (Clec9A was reviewed in Section 2.8.2). In this chapter, we 
demonstrate that the constructed P200-Ab-P20-TNE specifically targets Clec9A presented on the surface 
of Chinese hamster ovary (CHO) cells in vitro. In addition, we show superior in situ targeting with the 
constructed targeting TNE in comparison with its non-targeted counterparts.  
  
4.2. Materials and methods 
4.2.1. Materials 
Refer to Section 3.2.1. 
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4.2.2. Preparation of DAMP4 fused with antibody 
Preparation of antibody against Clec9A or an isotype antibody fused to DAMP4 was done by . Irina 
Caminschi in the Walter and Eliza Hall Institute, Melbourne, Australia. Briefly, the cDNA encoding 
heavy and light chains of (anti-Clec9A clone 24/04-10B4; rat IgG2a isotype control clone GL117) were 
amplified from the original hybridomas (Caminschi et al., 2008) and cloned by RACE amplification as 
previously described (Lahoud et al., 2011). The cDNA antibody heavy chains were subcloned into a 
pcDNA 3.1 vector modified to contain an Ala-Ala-Ala linker fused to DAMP4 cDNA. This construct 
enabled the generation of a single fusion protein where the C-terminal region of the heavy chain is 
fused to an alanine linker and then to DAMP4. The antibody light chains were cloned into pcDNA3.1. 
Plasmid DNA was prepared using the GigaPrep Plasmid DNA extraction kit (Qiagen, Hilden, 
Germany), and plasmids encoding the kappa chain, and the heavy chain linked to OVA were 
transiently co-transfected into freestyle 293F cells (Invitrogen) using 293Fectin transfection reagent as 
per manufacturer’s recommendations. Culture supernatant containing the recombinant antibodies was 
harvested, and antibodies purified by affinity chromatography using Protein G Sepharose. Recombinant 
antibodies were validated for their ability to bind Clec9A on transfectant cells as previously described 
(Caminschi et al., 2008). DAMP4 fused to anti-Clec9A mAb was termed as DAMP4-mAb, and 
DAMP4 fused to isotype mAb was termed as DAMP4-Isotype. 
 
4.2.3. TNE preparation 
P20-TNE was prepared following the protocol detailed in Section 3.2.6. For preparation of P200-Ab-P20-
TNE, mAb-DAMP4 (36 µL, 3 µM) was added to P20-TNE (200 µL) followed by 60 seconds of 
vigorous stirring using a magnetic stirrer to prepare Ab-P20-TNE; subsequently Ab-P20-TNE (200 µL) 
was added to PEGylated DAMP4 (200 µL, 400 µM), followed by 60 seconds of vigorous stirring. TNE 
size was measured by Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK) equipped with a He-
Ne laser (633 nm). Data analysis was with DTS software (Malvern, version 6.2), using a non-
negatively constrained least squares (NNLS) fitting algorithm. Dispersant refractive index and viscosity 
of the dispersant were assumed to be 1.45 and 1.02 cP, respectively. For each sample, 10 runs of 10s 
were performed.  
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4.2.4. CHO-Clec9A cells binding test 
Chinese hamster ovary (CHO)-Clec9A cell line, which was CHO-K1 cell line transfected with Clec9A, 
was provided by the Walter and Eliza Hall Institute (WEHI, NSW Australia). Cells were grown in 
RPMI 1640 medium supplemented with heat inactivated 5 % fetal calf serum. G418 antibiotic (500 µg 
mL-1) was added to medium to maintain selection pressure. One day before the binding experiment, 
cells  (2.5 × 105 cells per well) were seeded into a 24-well flat bottom tissue culture plate (Greiner Bio-
One, Frickenhausen, Germany) with 12-mm diameter glass slips and incubated at 37°C with 5 % CO2 
supplied. The following day, DiI labelled P20-TNE or Ab-P20-TNE (25 µL) or P200-P20-TNE or P200-Ab-
P20-TNE (50 µL) was added to the corresponding well and co-cultured with cells for 1 h at 4°C. Cells 
were fixed with 4 % paraformaldehyde. Cell nuclei were stained with Hoechst 33342 and cell 
membrane was stained with Phalloidin-AlexaFluor® 647. Mounted glass slips were imaged on an 
Apotome microscope (Carl-Ziess, Sydney, Australia).  
 
For testing the effects of PEG on TNE target specificity, CHO-Clec9A cells were first labeled with 
Hoechst 33342 before mixing with CHO-K1 cells at a ratio of 1:10 (CHO-Clec9A to CHO-K1). Fifty 
microliter of DiI TNE sample was added to 1 mL of mix cell population containing 2.5 × 105 of cells. 
Cells were kept at 4°C all the time to prevent internalization. Cells and TNE mixture were incubated 
for 1 h before acquiring data on a Gallios™ Flow Cytometer. Percentage of TNE bound cells was 
calculated from DiI positive cells from each cell population.  
 
4.2.5. Mouse splenocyte binding test 
Spleens from C57Bl/6 mice were harvested and digested with Collagenase Type III (Worthington) for 
25 min at room temperature. Digested tissue was passed through a cell strainer and then centrifuged at 
800 xg for 2 min before removing red blood cells by incubation in ACK lysis buffer (150 mM NH4Cl, 1 
mM KHCO3, 0.1 mM Na2EDTA). Cell pellet was re-suspended in RPMI1640 medium supplemented 
with 5 % FCS. Cells (106 in 1 mL) were added to tubes and co-cultured with 50 µL of P200-Isotype-P20-
TNE or P200-Ab-P20-TNE for 1 h at 4°C. Cells were washed with PBS and stained with anti-I-A/I-E-
PE/Cy7, anti-CD11c-PerCP5.5 and anti-CD8-eFluor780. Cells were analyzed on a Beckman Coulter 
Gallios™ Flow Cytometer. CD8+ DCs were gated as I-A/I-EhiCD11c+CD8+ and CD8- DCs were gated 
as I-A/I-EhiCD11c+CD8-. 
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4.2.6. Analysis of in vivo specificity  
Two hundred micro liters of DiI labelled P200-Ab-P20-TNE or P200-Isotype-P20-TNE was injected 
intraperitoneally into C57BL/6 mice. Twenty four hours post injection, spleens were removed and 
digested with Collagenase Type III (Worthington) for 25 min at room temperature. Digested tissue was 
passed through a cell strainer and then centrifuged at 800 xg for 2 min before removing red blood cells 
by incubation in ACK lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA). Single cell 
suspension was stained with anti-I-A/I-E-PE/Cy7, anti-CD11c-PerCP5.5 and anti-CD8-eFluor780. 
Cells were analysed on a Beckman Coulter Gallios™ Flow Cytometer. CD8+ DCs were gated as I-A/I-
EhiCD11c+CD8+ and CD8- DCs were gated as I-A/I-EhiCD11c+CD8-. 
 
4.3. Results and discussion 
4.3.1. Functionalized TNE with Clec9A mAb via DAMP4 
In this chapter we examined whether the top-down approach for sequential self-assembly of 
components of the oil-water interface of the nanoemulsion, which had been used to construct an 
immune-evading TNE in Chapter 3, could be applied to simultaneously down-regulate phagocytosis 
by generic immune cells via PEGylation, and up-regulate specific delivery to target cells. Here, the 
anti-Clec9A mAb was first fused to DAMP4 (mAb-DAMP4) at the DNA level (see Section 4.2.2). A 
self-assembled nanoemulsion bearing the anti-Clec9A mAb and PEG on its surface was then created by 
first adding 270 nM mAb-DAMP4 to P20-TNE to form Ab-P20-TNE. Further addition of 200 µM 
PEGylated DAMP4 Ab-P20-TNE led to the formation of P200-Ab-P20-TNE, enabling the sequence of 
additions to be easily identified. Table 4-1 shows the size distribution and zeta-potential of the 
constructed TNE measured by dynamic lights scattering. Addition of DAMP4-Ab conjugate to P20-
TNE did not cause an increase in size distribution, but decreased the Z-potential from 30.1 ± 0.7 mV to 
26.3 ± 2.4 mV. This reduction could due to the attachment of the negatively-charged DAMP4-Ab onto 
the oil droplet surface reducing the net positive charge on the AM1-stabilized oil-water interface. 
Further addition of PEGylated DAMP4 reduced the zeta-potential to 18.9 ± 0.7 mV, suggesting the 
additional attachment of neutral PEG to the interface shielded the positively-charged AM1 network.  
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Table 4-1 Size distribution of zeta-potential of TNEs measured by dynamic light scattering (DLS). 
TNE samples were 1 in 100 diluted in ultrapure water. Data were collected from three experiments and 
expressed as average with Standard Deviation. 
 
4.3.2. Effect of adding anti-Clec9A-mAb into TNE on binding to CHO-Clec9A cells 
After having constructed the P200-Ab-P20-TNE and characterizing its physicochemical properties, we 
next examined their targeting ability, particularly against Chinese hamster ovary (CHO)-K1 cells that 
were transfected to express surface Clec9A (CHO-Clec9A) (Caminschi et al., 2008) . TNE was labeled 
with a fluorescence dye (DiI) for in vitro tracking purpose. Labeled TNE was incubated with CHO-
Clec9A cells for 1 h at 4°C to allow association between TNE and cells. Isotype-P20-TNE and P200-
Isotype-P20-TNE, which were constructed using the same method as for Ab-P20-TNE and P200-Ab-P20-
TNE, but with a non-targeting mAb isotype, were used as negative controls. The binding profile was 
evaluated by confocal microscopy. The overlay of the red and blue fluorescence suggests that the TNE 
bound to the cell membrane. Figure 4-1 shows the confocal images of the binding of TNE to CHO-
Clec9A. As expected, the non-targeting, non-immune evading TNE, P20-TNE which carries the lowest 
amount of PEG on the surface, showed the strongest cell-association out of the all TNE constructs 
tested here. Addition of Clec9A targeting mAb to P20-TNE (Ab-P20-TNE) did not significantly affect 
the binding extent. Though slightly reduced binding was observed when cells were incubated with P200-
Ab-P20-TNE, suggesting that the addition of further PEG into the targeting but not immune evading 
Ab-P20-TNE aided in reducing non-specific cell interactions, meanwhile not compromising the Clec9A 
ligand mediated cell-TNE association. This was further proved by incubating cells with immune-
evading P200-P20-TNE, as a minimal level of DiI-labeled TNE was observed co-localizing with cell 
membrane (Figure 4-1a).  In contrast, the non-specific binding of Isotype-P20-TNE to CHO-Clec9A 
(Figure 4-1b) was significantly reduced by the further addition of PEGylated DAMP4 to the same 
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formulation (P200-Isotype-P20-TNE), as reduced DiI fluorescence was observed in cells incubated with 
P200-Isoype-P20-TNE (Figure 4-1c). This selective targeting could only be attributed to the 
complementary binding to the Clec9A antigens by the anti-Clec9A mAb on the surface of P200-Ab-P20-
TNE, as compared to the binding profile of the non-targeting TNE in the same cell line. Such a 
mechanism could potentially enhance drug delivery efficiency through receptor-mediated endocytosis 
which facilitates particle internalization (Goldstein et al., 1979, Jiang et al., 2008). After the TNE is 
taken up by the target cells, it may release its drug payload to show therapeutic activity, though this 
remains to be shown in later chapters.  
 
 
Figure 4-1. Confocal images showing binding of TNE to CHO-Clec9A cells which have been 
transfected to express a dendritic-cell ligand (Clec9A) on the cell surface. TNEs were labeled with 
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fluorescent dye DiI (red) for in vitro tracking. Cell membrane was stained with phalloidin (blue) and 
cell nuclei with Hoechst 33342 (green). a) Binding of targeting P200-Ab-P20-TNE to CHO-Clec9A cells; 
(b) Binding of non-targeting Isoypte-P20-TNE, and; (c) P200-Isoype-P20-TNE to CHO-Clec9A cells. 
Scale bar: 10 µm.  
4.3.3. Effect of PEG on TNE target specificity 
The generic binding of P200-Ab-P20-TNE was tested in a mixed cell population comprised of CHO-K1 
with (Clec9A+) and without (Clec9A-) surface-expressed Clec9A receptors in a 1:10 number ratio 
(Figure 4-2). P200-Ab-P20-TNE exhibited striking selectivity for Clec9A+ cells, binding to more than 
85% of this sub-population, which represented only 10 % of the total population. Binding to Clec9A- 
cells was significantly less (only 26 %), even though these cells dominated the culture numerically. 
This result shows clear ability to target cells in a mixed population and in a receptor-specific fashion. 
As expected, P20-TNE was present in over 95 % of both the Clec9A+ and Clec9A- cells, showing no 
cell selectivity. P200-P20-TNE, on the other hand, almost completely avoided cell binding, likely due to 
the high PEG surface coverage on the TNE. These findings provided evidence that the anti-Clec9A 
mAb was connected to the oil-water interface of P200-Ab-P20-TNE by DAMP4 in a functional manner, 
and that the presence of the mAb successfully up-regulated selectivity for targeted Clec9A-bearing 
CHO cells. These results suggest that cell selectivity could be adjusted by modifying the mAb to PEG 
ratio presented on the TNE surface. To test this theory, mAb-DAMP4 concentration was kept constant 
while varying the amount of PEGylated DAMP4 added in the sequential addition preparation method. 
Figure 4-2 shows that cell selectivity was increased for both P300-Ab-P20-TNE and P400-Ab-P20-TNE, 
with the non-specific binding to Clec9A- cells almost abrogated. However, enhanced selectivity was 
achieved at the expense of an overall reduction in binding, decreasing the binding to Clec9A+ cells to 
only 30-40 %. Nonetheless, these results provide a very clear demonstration that the targeted 
nanoemulsion was able to very selectively target a specific set of cells in a mixed population of very 
similar cells, in a receptor-specific fashion. The ability to control for non-specific binding by simple 
variation of the amount of PEG versus targeting antibody also provides an elegant nanotechnology 
strategy to tune specificity and thus to control bio-distribution and pharmacokinetics.                             
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Figure 4-2. a) FACS dot plots showing binding of DiI labeled TNE to Clec9A- (blue) and Clec9A+ 
(red) cells. DiI positive cells were gated against CTRL where no TNE was added.  b) The percentage of 
Clec9A- or Clec9A+ CHO-K1 cells bound with TNE calculated from flow cytometry results showing 
the effects of increased PEG content in the Ab-P20-TNE formulation. Results are shown as the mean of 
N=3 experiments with standard deviation. 
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4.3.4. TNE selectively binds to CD8+ DCs in vitro 
We also investigated the in vitro cell specific of P200-Ab-P20-TNE in a more complex cell population 
that mimics the in vivo environment that the i.v. injected TNE would encounter. Labeled emulsion was 
incubated with mouse splenic cells for 1 h at 4°C. Clec9A is highly restricted to DCs and is selectively 
expressed by CD8+ conventional DCs and plasmacytoid DCs in mice (Caminschi et al., 2008) therefore 
allowing the Clec9A+ cells among mouse splenocytes to be tracked using the CD8 marker. Figure 4-3 
shows that P200-Ab-P20-TNE selectively associated with the CD8+ DC sub-population. Emulsion was 
detected in close to 40% of the CD8+ DCs, while the non-targeting P200-Isotype-P20-TNE only bound to 
a minimum number of cells in the same population (< 5 %). This result further demonstrated the in 
vitro targeting capability of P200-Ab-P20-TNE in a highly-complex cell population. 
  
 
 
Figure 4-3. In vitro cellular binding of P200-Ab-P20-TNE and P200-Isotype-P20-TNE to CD8+ DC. 
Splenocytes (106 in 1 mL) were added to tubes and co-cultured with 50 µL of P200-Isotype-P20-TNE or 
P200-Ab-P20-TNE for 1 h at 4°C. Cells were washed with PBS and stained with anti-I-A/I-E, anti-
CD11c and anti-CD8. CD8+ DCs were gated as I-A/I-EhiCD11c+CD8+ and CD8- DCs were gated as I-
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A/I-EhiCD11c+CD8-. Cells did not incubated with TNE was used as control for baseline. Results shown 
are mean and standard deviation from N=3 experiments.  
 
4.3.5. TNE targets CD8+ DCs in vivo 
We also investigated the in vivo distribution of P200-Ab-P20-TNE by i.p. injecting labeled emulsion into 
mice, and harvested splenocytes after 24 h. Figure 4-4 shows that P200-Ab-P20-TNE associated 
selectively with the CD8+ DC sub-population; the emulsion was detected in >30 % of the CD8+ DCs 
but in <2 % of the CD8- DCs. This finding supports the in vitro data, demonstrating the excellent in situ 
targeted delivery capability of P200-Ab-P20-TNE. As expected, this level of striking cell selectivity was 
not exhibited by the control sample constructed in a similar way but using a non-specific isotype 
antibody instead of the anti-Clec9A mAb (P200-Isotype-P20-TNE). 
  
 
Figure 4-4. In vivo cellular uptake of P200-Ab-P20-TNE and P200-Isotype-P20-TNE in CD8+ DCs and 
CD8- DCs. Results shown are mean and standard deviation from N=2 experiments. 
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4.4. Conclusion 
The goal of this Chapter is to address Objective 2 and 3 stated in Section 1.4, by constructing a long-
circulating TNE that is capable of targeting Clec9A+ DCs in vivo. A long-circulating TNE, termed as 
P200-P20-TNE, was demonstrated in the last Chapter by using DAMP4 as an anchor to functionalize the 
nanoemulsion oil core with immune-evading polymer PEG. This initial result supports our hypothesis, 
that DAMP4 carries its conjugated PEG onto an AM1 pre-stabilized oil-water interface, leading to 
functional display of PEG on the nanoemulsion surface. PEGylation imparts steric stability of TNE in 
isotonic condition and creates a repulsive barrier that repels the attachment of opsonins which leads to 
clearance by the mononuclear phagocyte system (MPS).  In order to increase the intracellular delivery 
efficiency, P200-P20-TNE can benefit from being functionalized with a targeting moiety that enables 
receptor-mediated endocytosis. Targeting delivery of a nanocarrier loaded with therapeutic 
components, e.g. protein antigen, to DCs is a promising strategy to initiate antigen-specific immune 
response (reviewed in Section 2.8.2).  
 
The coupling of anti-Clec9A mAb to PEGylated TNE oil core is based on the non-covalent “click” 
chemistry we developed in Chapter 3, which uses DAMP4 as an anchor to display mAb on the TNE 
surface. This approach differs from procedures used by others, which normally involves covalent 
conjugation chemistry (Goldstein et al., 2007, Lundberg et al., 1999, Lundberg et al., 2004). Anti-
Clec9A mAb was fused to DAMP4 via molecular cloning, circumventing the potential of mAb 
deactivation by extreme physiochemical conditions required by covalent conjugation chemistry. Cell 
binding ability of targeting nanocarriers is governed by many factors, including shape, size and surface 
charge (Thorek and Tsourkas, 2008). Following functionalization of TNE oil core with DAMP4-PEG 
and mAb-DAMP4, we measured the size distribution and surface zeta-potential of each conjugate. 
Sequential addition of PEG-DAMP4 and DAMP4-mAb to positively-charged TNE oil core causes a 
decrease in the absolute value of the zeta potential (Table 4-1), probably due to a shielding effect from 
PEG-DAMP4 and the addition of negatively charged mAb-DAMP4 to the TNE system. The 
constructed P200-mAb-P20-TNE exhibits size distribution under 200 nm, which indicates it is suitable 
for i.v. injection.   
 
The cell-targeting capability of P200-Ab-P20-TNE was first assessed by conducting in vitro cell-binding 
assays using Clec9A-transfected CHO-K1 cells (CHO-Clec9A). To assess Clec9A-mediated 
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differential uptake, the CHO-Clec9A cells were incubated with TNEs functionalized with DAMP4-
PEG and/or Clec9A mAb-DAMP4 in 4  ͦC to prevent internalization. The cells from each sample were 
then washed, stained and analyzed using confocal microscopy (Figure 4-1). As expected, P20-TNE 
shows high levels of non-specific binding to cells, as there is not sufficient PEG content to create a 
repulsive barrier that prevents cell association. And such non-specific cell association can be 
diminished by further adding PEG into P20-TNE to create P200-P20-TNE. Compared to the non-targeting 
long circulating P200-P20-TNE, incubation of Clec9A targeting P200-Ab-P20-TNE resulted in a 
significantly high level of cell association, as evident by the co-localization of fluorescence dye labeled 
P200-Ab-P20-TNE with cell membrane, which indicated that the increased cell binding of P200-Ab-P20-
TNE was receptor-specific (Figure 4-1 a). To demonstrate that the targeting effects were exclusive to 
TNE functionalized with Clec9A mAb, CHO-Clec9A cells were also incubated with two TNEs that 
been functionalized with a non-targeting isotype mAb, which was termed as Isotype-P20-TNE and P200-
Isotype-P20-TNE. The non-specific binding of Isotype-P20-TNE was minimized by adding additional 
content of PEG to create P200-Isotype-P20-TNE, further suggesting that the cell-association observed in 
CHO-Clec9A cells incubated with P200-Ab-P20-TNE was mediated by Clec9A mAb that had been 
displayed on the TNE surface. Overall, these results confirm the receptor-specific targeting capability 
of Clec9A mAb functionalized TNE.  
 
PEG density on a nanocarrier is a crucial determinant of immune evading efficacy. Increasing PEG 
density can significantly reduce interactions of PEGylated nanocarriers with MPS and increase their in 
vivo half-life (Gref et al., 2000, Mosqueira et al., 2001). Increased density of PEG on the surface could 
affect the availability of targeting ligand and alleviate potential steric hindrances. We presented a 
method to tune the density of PEG presented on the TNE surface by producing them with adjusted 
amount of PEG-DAMP4. Not surprisingly, we found that an increased amount of PEG-DAMP4 reduce 
the non-specific cell association of P300-Ab-P20-TNE and P400-Ab-P20-TNE, but also reduced specificity 
towards target cells (Figure 4-2). Nonetheless, we demonstrated the ability to tune the target specificity 
by simple variation of TNE composition, and the superior targeting selectivity of P200-Ab-P20-TNE 
compared to their non-targeting counter parts both in vitro and in vivo (Figure 4-3 and 4-4).  
 
In summary, we have successfully synthesized a nanocarrier emulsion-based TNE platform specific to 
Clec9A-expressing dendritic cells. Through the aid of DAMP4, which acts as anchor for displaying 
immune evading polymer PEG and mAb targeting Clec9A using a non-covalent “click” chemistry, thus 
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circumventing the need to expose the biological moieties to chemical reactions designed to form 
irreversible bonds. The simplicity of this functionalization scheme can potentially enable a wide array 
of functionalized TNE for tailored disease treatments. The capability to control and adjust density of 
functional moieties through DAMP4 mediated functionalization also provides versatility for platform 
optimization. Future studies are warranted to examine the in vivo implications of ligand 
functionalization of TNE. The targeted P200-Ab-P20-TNE demonstrated in this Chapter possess 
significant potential for targeting delivery of delicate therapeutics, e.g. protein based therapeutics, as 
the platform integrates immune-evasive moieties with a DC-targeting ligand. DCs plays a central role 
in immune system and orchestrate a wide repertoire of immune responses (topic reviewed in Section 
2.9.2), thus targeting an antigen to DCs exclusive receptor, i.e. Clec9A, represents an attractive strategy 
to enhance vaccine efficacy. The following Chapters will demonstrate the process of loading a model 
protein antigen into P200-Ab-P20-TNE (Chapter 5), as well as the immune response and advantage of 
targeting antigen to DCs by P200-Ab-P20-TNE (Chapter 6) with the aim to address Objectives 4 and 5 
of this PhD project.  
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Chapter 5  Induction of potent CD8+ T cells response by TNE carrying 
model antigen using S/O/W emulsification method 
5.1. Introduction 
The two previous chapters of this thesis describe the design, construction and characterization of a 
nanocarrier emulsion capable of targeting a specific subset of DCs that express the C-type lectin 
receptor Clec9A. The targeting emulsion, P200-Ab-P20-TNE, was constructed using a new approach to 
the bottom-up self-assembly of nanoemulsion. Functional moieties such as immune evading PEG and 
the targeting antibody against Clec9A can be pre-conjugated to the biosurfactant (reviewed in Section 
2.4.2) DAMP4, and the simple top-down sequential addition of such a hybrid DAMP4 molecule to an 
AM1-pre-stabilized nanoemulsion leads to self-assembly of the functional moieties at the emulsion 
interface. These two previous chapters report successful outcomes that provide evidence in support of 
hypothesis stated in Chapter 1,  that DAMP4 could be used to engineer the interface of a TNE through 
non-covalent self-assembly. 
 
As mentioned in Chapter 1, biologics is a hot topic in the pharmaceutical industry. Advances in 
biotechnology have led to the development of new therapeutics for various disease treatments by 
delivering proteins and peptides into cells (Vlieghe et al., 2010, Leader et al., 2008). Alterations in 
intracellular protein functions are the main course of many diseases (Carter, 2011), making protein 
therapeutics a potential treatment. Biologics have opened a new door for treating diseases such as 
cancers (Foltopoulou et al., 2010, Yarden and Sliwkowski, 2001), inflammation (Jo et al., 2005) and 
cerebrovascular disorders (Ogawa et al., 2009). Since the first recombinant insulin was approved by the 
Food and Drug Administration (FDA) for clinical use over 30 years ago, biologics currently represent a 
significant proportion of biopharmaceutical market (Leader et al., 2008). For example, Humira®, an 
engineered human tumor necrosis factor (TNF) mainly prescribed for treating rheumatoid arthritis 
(Bain and Brazil, 2003), was the most top-selling biologic drug of 2012 (Huggett, 2013).  Compared to 
traditional small molecule drugs (SMDs), protein based therapeutics have higher intracellular activities 
and specificities, which could potentially provide more effective disease treatment. Moreover, biologics 
are relatively safer than alternative gene therapies, as no random or permanent genetic changes result, 
thus circumventing concerns of potential mutagenesis (Gu et al., 2011). 
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Despite their potential medical application, effective delivery of biologics to their site of action remains 
a challenge, due to intrinsic properties of most proteins, including high molecular weight, fragile 
tertiary structures and hydrophilicity (Leader et al., 2008). Moreover, the transportation of protein-
based drugs through compartmental barriers is ineffective due to their short in vivo half-life. 
Translation of biologics research to clinical application is restrained by the incapability of delivering 
functional proteins into cells. Native protein drugs administered intravenously can suffer from serum 
instability and be rapidly degraded or deactivated. Mechanical delivery methods such as microinjection 
have been investigated for decades, nevertheless are laborious and require specialized equipment to 
mechanically puncture membranes thereby limiting their in vivo application (Zhang and Yu, 2008). On 
the other hand, proper design of a transport system can greatly improve the pharmacokinetics of these 
drugs. In order to achieve effective intracellular protein release, drug delivery systems (DDS) capable 
of carrying their therapeutic payloads overcoming a range of biological barriers are needed. For 
example, such DDS need to escape from the rapid clearance by mononuclear phagocytic system 
(MPS), kidney filtration, aggregation and degradation by serum proteins. In addition, protein DDS need 
to help their protein cargo escape from early endosomal degradation to reach the desired subcellular 
compartments, such as the cytosol and nucleus (Bareford and Swaan, 2007). Therefore, development of 
efficient and safe protein DDS is vital for the translation of these drugs into clinical application.  
 
To date, many research groups have concentrated on the development of protein delivery systems 
(reviewed in Chapter 2). The enhanced ability to manipulate materials at the nanoscale enables the 
development of various nanocarriers for protein delivery. Protein cargos can be encapsulated in or 
adsorbed onto various nanocarriers to avoid premature degradation and denaturing interactions with the 
biological environment (Peer et al., 2007, Faraji and Wipf, 2009, Gao and Xu, 2009). The high surface-
to-volume ratio of nanocarriers can potentially improve the pharmacokinetics and biodistribution of the 
payload (Chou et al., 2011, Gaberc-Porekar et al., 2008, Peer et al., 2007). Moreover, nanocarrier-based 
DDS provide tailored chemical and physical properties to facilitate cell penetration, endosomal escape, 
enhanced stability, target specificity and controlled release, through controlled assembly and chemical 
modification (Kabanov and Vinogradov, 2009, Stuart et al., 2010, Solaro, 2008). An ideal nanocarrier 
should incorporate the drugs without compromising bioactivity. Once administered into the human 
body, these nanocarriers should protect the drug payload (by concealing immunogenic epitopes) and 
avoid capture by the host immune system. Most importantly, the drug must be shuttled into the 
particular cell compartments where it can exert its therapeutic activity (Torchilin, 2006). Nanocarriers 
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such as micelles (Lee et al., 2009, Gao et al., 2012, Ren et al., 2013), nanocapsules (Gu et al., 2009, 
Yan et al., 2010, Tang et al., 2013) and liposomes (Liguori et al., 2008, Zelphati et al., 2001, Dalkara et 
al., 2006) have been developed for intracellular protein delivery. However, there is not a single 
nanocarrier or platform that can be considered ideal for all types of biologics. For example, the use of 
organic solvents in the preparation of some of the polymeric formulations will potentially denature the 
protein payload; liposomal formulations mostly suffer from low drug loading capacity and inadequate 
stability; inorganic nanocarriers such as quantum dots and gold nanoparticles are non-biodegradable, 
causing huge safety concerns in relation to their clinical administration (Gu et al., 2011). Therefore new 
strategies need to be explored to expand the scope of nanocarriers for effective protein delivery.   
 
The ability of DCs to prime naïve T cells with antigens implies a critical role of DCs in mediating 
immunity against infectious diseases and cancers (Fonteneau et al., 2003). This thesis reports a simple 
method to produce a DC-targeting TNE in the last two chapters, by which stringent preparation steps 
are not involved. We have already shown the AM1 stabilized nanoemulsion is an ideal cargo carrier for 
delivering lipophilic drugs to cells (Chuan et al., 2011). Hence the TNE platform could potentially be 
an ideal system for intracellular protein delivery by addressing the aforementioned issues. It is possible 
that once P200-Ab-P20-TNE has been taken up by target DCs, its encapsulated protein will be released 
and processed by DCs and subsequently presented via the MHC class I molecules to CD8+ T cells 
through the antigen cross-presentation pathway.  
 
This chapter extends the previous studies into the application of TNE for intracellular delivery of 
protein. TNE was evaluated in vitro using ovalbumin (OVA) as a model antigen. Hydrophilic OVA 
was loaded into the oil core using the solid-in-oil (S/O) nanodispersion method (Tahara et al., 2008) 
(Figure 5-1). Briefly, an aqueous solution of protein was mixed with hexane solution of glycerol 
monooleate (CithrolTM GMO HP) to form a water-in-oil (W/O) emulsion. Then a S/O nanodispersion 
was prepared by lyophilizing the W/O emulsion before dissolving the lyophilized surfactant-protein 
complex in Miglyol® 812.  Subsequently protein S/O dispersion was used as the oil phase to prepare 
S/O/W emulsion following the same procedure for producing P200-Ab-P20-TNE which is described in 
Chapter 4. In this method, protein was first coated with hydrophobic surfactant molecules to form 
protein-surfactant complexes, to significantly increase its solubility in the oil phase and enable facile 
packaging into the TNE oil core. An in vitro cross-presentation assay was carried out as the first step to 
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evaluate whether antigen encapsulated within TNE could be correctly processed and cross-presented by 
DCs to antigen-specific T cells.  
 
 
Figure 5-1. Schematic illustration of the preparation of the surfactant protein complex prepared from a 
W/O emulsion (Tahara et al., 2008). 
 
5.2. Materials and methods 
5.2.1. Materials 
n-hexane and disodium salt of ethylenediaminetetraacetic acid (Na2EDTA) were purchased from Ajax 
Finechem (NSW, Australia). CithrolTM GMO HP was a gift from Croda Europe Ltd (Staffordshire, 
United Kingdom). Other materials were as detailed in Section 3.2.1 of Chapter 3.  
 
5.2.2. Mice 
Mice (C57Bl/6) were bred at the Diamantina Institute Biological Research Facility (BRF) at The 
University of Queensland under specific pathogen-free conditions. Experiments were approved by the 
UQ Animal Ethics Committee (ethics number 465/12). 
 
5.2.3. Preparation of OVA in oil dispersion 
OVA solution (8 mg mL-1) was prepared by dissolving OVA (80 mg) in ultrapure water (10 mL). 
CithrolTM GMO HP solution (1 %, w/v) was prepared by dissolving CithrolTM GMO HP (200 mg) in 
hexane (20 mL). OVA solution (1 mL) and CithrolTM GMO HP solution (2 mL) were transferred into a 
20 mL glass vial, and mixed by using the homogenizer at 24,000 rpm for 5 min to form stable water in 
oil (w/o) emulsion. The resulting emulsion was frozen rapidly on dry ice for 2 h before being 
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lyophilized for 24 h. The resulting OVA-CithrolTM GMO HP pellet was dissolved in Miglyol® 812 (3 
mL) to a final concentration of 2.7 mg mL-1 of OVA, and used as the oil phase for preparing OVA-P20-
Ab-P200-TNE and OVA-P20-Isotype-P200-TNE following the same procedures detailed in Section 4.2.3 
of Chapter 4.  
 
5.2.4. Dot blot assay 
Dot blot analysis was performed to determine if the OVA-surfactant complex could be recognized by 
commercial anti-OVA mAb. Briefly, 5 µL of each protein sample was dotted onto a nitrocellulose 
membrane before blocking with 5 % (v/v) skim milk powder in PBS buffer containing 0.1 % (w/v) 
Tween 20. Commercial mouse monoclonal antibody specific to OVA (clone OVA-14, Sigma-Aldrich, 
NSW, Australia), was used at 1 µg mL -1 to bind protein.  The commercial antibody was generated from 
mice immunized with OVA. Secondary HRP-conjugated goat anti-mouse antibody (A4416, Sigma-
Aldrich, MO, USA) was used for detection. Binding of antibody to protein was detected by 
chemiluminescence with the Novex® ECL chemiluminescent substrate reagent kit (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s protocol.  
 
5.2.5. In vitro cross-presentation assay 
To prepare splenocytes, spleen from C57BL/6 mouse was removed and digested with Collagenase 
Type III (Worthington) for 30 min at room temperature. Digested tissue was passed through a cell 
strainer and then centrifuged at 430 g for 5 min before removing erythrocytes by incubation in ACK 
lysis buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA). OT-I cells were isolated from spleen 
and lymph nodes (LNs) of OT-I mice and purified using Miltenyi CD8α+ T Cell Isolation Kit II 
(Miltenyi Biotec Australia Pty. Ltd., NSW, Australia).  Purified OT-I cells were stained with 
CellTraceTM Violet for in vitro tracking. 
 
Splenocytes were treated with Mitomycin C (Sigma-Aldrich, St Louis, MO, USA) to block cell 
division. Mitomycin C treated splenocytes (106 cells) were cultured with P200-Ab-P20-TNE, OVA-P200-
Ab-P20-TNE or OVA-P200-Isotype-P20-TNE (50 µL, equivalent to 0.6 µg of OVA) for 3 h at 37°C with 
5 % v/v CO2. As positive control, splenocytes were pulsed with 1 μg of SIINFEKL peptide. At the end 
of the incubation, splenocytes were washed three times with RPMI-1640 supplemented with FCS (5 % 
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v/v) before being added to wells of a 96-well tissue culture plate at 5 × 105 cells per well in 100 µL 
RPMI-1640 medium supplemented with FCS (5 %  v/v). OT-I cells (2.5 × 105) in 100 µL RPMI-1640 
medium supplemented with FCS (5 % v/v) were then added to each well and cultured for 4 days at 
37°C with 5 % v/v CO2 supplied. Cells were harvested from the 96-well plate and stained with 
PerCP5.5-anti-CD8. OT-I T cell proliferation was measured as a function of CellTraceTM Violet dye 
dilution after gating on CD8+ T cells. 
 
5.2.6. In vivo cross-presentation assay 
OT-I cells were isolated from lymph nodes (LNs) of OVA257-264 specific OT-I transgenic mice and 
purified using Miltenyi CD8α+ T Cell Isolation Kit II (Miltenyi Biotec Australia Pty. Ltd., NSW, 
Australia).  Purified OT-I cells were stained with CellTraceTM Violet (CTV) for in vivo tracking. Cells 
were washed three times with RPMI-1640 supplemented with FCS (5 % v/v) before re-suspending in 
sterile PBS. C57Bl/6 mice were adoptively transferred with CTV labeled OT-I cells (106). One day 
later, these mice were immunized intravenously with OVA-P200-Isotype-P20-TNE or OVA-P200-Ab-P20-
TNE. Mice were sacrificed 4 days later, and the CD3+MHCII-CD8+ OT-I T cell response was 
determined as the dilution in CTV fluorescence intensity. 
 
5.3. Results and discussions 
5.3.1. Preparation of OVA loaded TNE 
Figure 5-2 a represents the physical difference in appearance between native OVA and its S/O 
dispersion counterpart in Miglyol® 812. The surfactant–FITC labeled OVA complex was highly 
dissolved in oil phase to give a transparent solution. In contrast, native FITC-labeled OVA without 
surfactant exhibited low solubility in oil and precipitated over time. The surfactant–OVA complex 
solubilized Miglyol® 812 used to prepare OVA-P200-Ab-P20 TNE followed a published protocol (Zeng 
et al., 2013). OVA-P200-Ab-P20 had consistent size distributions when diluted in water and PBS, with 
mean sizes of 187.1 ± 2 nm and 189.3 ± 3.8 nm, respectively, suggesting good stability under 
physiological salt (Figure 5-2 b).  The co-localizing of FITC-labeled OVA with the DiI-labeled AM1 
stabilized TNE oil core under confocal microscopy suggested that the surfactant-OVA complex was 
well encapsulated within the TNE oil core (Figure 5-2 c). 
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Figure 5-2. Characterization of OVA loaded TNE: a) Comparison of solubility between native FITC 
labeled OVA (right) and its surfactant complex (left) in Miglyol® 812; b) Particle size distribution of 
OVA-P200-Ab-P20 TNE diluted in water and PBS measured by dynamic light scattering; c) Confocal 
images showing FITC labeled OVA (green) dissolved in oil (upper panel) or encapsulated within AM1 
stabilized TNE core (lower panel), where the oil phase was pre-labeled with DiI (red). Size bar: 10 µm. 
 
5.3.2. Dot-blot assay 
Figure 5-3 shows dot blot analysis of oil-solubilized OVA-surfactant complex against commercial 
antibody specific to OVA antigen. Native OVA dispersed in oil, surfactant solubilized oil and oil core 
from surfactant encapsulated TNE were dotted as negative control. OVA-surfactant complex was first 
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dissolved in Miglyol® 812 to produce an OVA solid in oil (S/O) dispersion, and subsequently used as 
the oil phase to prepare OVA-TNE. TNE oil core was separated from the aqueous phase by high speed 
centrifugation. The dot blot analysis shows that both OVA S/O dispersion and the oil core from OVA-
TNE were recognized by the commercial antibody, showing that the ability of OVA  within the OVA-
surfactant complex to be recognized by an antibody was retained. This result also demonstrated that 
once encapsulated within the TNE oil core, only a limited amount of lipophilic OVA-surfactant 
complex presented in the emulsion aqueous phase due to its limited solubility in water.  
 
 
Figure 5-3. Dot blot analysis using a commercial OVA-specific antibody. Tested samples include (1) 
OVA-surfactant complex dissolved in Miglyol® 812 (OVA S/O dispersion); (2) Native OVA protein 
dispersed in oil (after centrifugation to remove aggregates); (3) Surfactant dissolved in Miglyol® 812 
(negative control); (4) OVA-TNE oil core (negative control); (5) Aqueous phase of OVA-TNE (for 
testing residual OVA present in aqueous phase); (6) Oil phase of OVA-TNE. Only OVA S/O 
dispersion and OVA-TNE oil core were recognized by the commercial antibody specific to OVA, 
confirming appropriate loading of OVA into the oil phase of the TNE. 
 
5.3.3. Dendritic cells response to antigen-loaded TNE 
DCs are professional APCs capable of presenting exogenous antigens to cytotoxic T lymphocytes, a 
crucial step for the development of adaptive immunity towards infectious pathogens and tumors, which 
plays an important role in the elimination of cancerous cells and pathogens (Heath and Carbone, 2001). 
An OT-I CD8+ T cell proliferation assay was performed to determine if model antigen OVA 
encapsulated within TNE can be correctly processed and cross-presented on MHC I via P200-Ab-P20-
TNE, which been shown to target DCs in vivo (Chapter 4). OVA specific CD8+ T cells were isolated 
from transgenic OT-I mice, labeled with CTV and co-cultured for 3 d with splenocytes that had been 
pulsed with either OVA loaded P200-Ab-P20-TNE (OVA- P200-Ab-P20-TNE) or the non-targeting P200-
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Isotype-P20-TNE (OVA- P200-Isotype-P20-TNE). OT-I specific epitope OVA257-264 peptide (SIINFEKL) 
was also used as a positive control. Splenocytes pulsed with SIINFEKL or OVA-P200-Ab-P20-TNE 
induced similar levels of CD8+ T cell proliferation (71.4% and 77.2% T cells divided, respectively) 
(Figure 5-4). However, it is worth noting that although SIINFEKL was able to induce an OT-I T cell 
response, a similar level of T cell response was obtained only by using almost double the amount of 
native peptide (1 µg) to the one induced by OVA-P200-Ab-P20-TNE (containing 0.6 µg OVA protein). 
And as expected, splenocytes pulsed with the same amount of OVA-P200-Isotype-P20-TNE failed to 
induce T cell proliferation. These results suggest that as an antigen vehicle, P200-Ab-P20-TNE was 
superior in delivering its payload to the target subset of DCs compared to its non-targeting counterpart. 
 
 
 
Figure 5-4. In vitro T cell proliferation assay. Splenocytes were pulsed with OVA (0.6 µg) loaded P200-
Ab-P20-TNE (OVA-P200-Ab-P20-TNE) or P200-Isotype-P20-TNE (OVA-P200-Isotype-P20-TNE), or OVA 
peptide SIINFEKL (1 µg) and subsequently co-cultured with CTV labeled OT-I T cells for 4 days. T 
cell proliferation was assessed by dilution of CTV in the labeled T cells. Representative histogram 
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showing proliferation of OT-I T cells gated as MHCII-CD3+CD8+. Percentage of proliferated T cells is 
stated in cytograms.  
 
5.3.4. Activation of antigen-specific CD8+ T cells by OVA antigen-carrying P200-Ab-P20-
TNE in vivo  
Next we accessed whether OVA-P200-Ab-P20-TNE could induce an antigen-specific CD8+ T cells 
response in vivo. Mice were immunized once with OVA-P200-Ab-P20-TNE or OVA-P200-Isotype-P20-
TNE (both contained 2.5 µg of OVA), or left unimmunized one day after mice have been adoptively 
transferred with CTV-labeled OT-I T cells. Proliferation of OT-I cells was determined by the dilution 
of CTV fluorescence on day 4 after immunization using flow cytometry. Mice immunized with OVA-
P200-Ab-P20-TNE displayed a significant proliferation of OVA-specific CD8+ T cells (Figure 5-5), 
compared to mice that been immunized with non-targeting OVA-P200-Isotype-P20-TNE. In contrast, 
immunizing mice with OVA-P200-Isotype-P20-TNE did not induce noticeable OT-I T cell proliferation. 
Coupled with results from the in vitro cross presentation assay, these findings suggest that TNE was 
productively taken up by target CD8+ DCs in a receptor-targeted fashion,  and its encapsulated antigen 
was correctly processed and presented to CD8+ T cells. 
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Figure 5-5. Activation of antigen-specific CD8+ T cells by OVA-P200-Ab-P20-TNE in vivo. Mice were 
intravenously injected once with OVA-P200-Ab-P20-TNE or non-targeting OVA-P200-Isotype-P20-TNE, 
or left unimmunized one day after the mice had been adoptively transferred with CTV-labeled OT-I 
cells. Spleen cells were isolated from the mice on day 4 after immunization before staining with anti-
CD3, anti-MHC II and anti-CD8 mAb. Data are expressed as (a) Flow cytometry dot plots showing the 
percentage of CTV+ CD8+ OT-I cells among the gated CD3+MHC II- T cells as determined; The 
percentage of proliferated T cells is stated in each dot plot. (b) histogram showing CTV fluorescence of 
OT-I cells. Reduction of CTV fluorescence intensity (from right to left) depicts OVA-specific OT-I T 
cells proliferation.  
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5.4. Conclusions 
Dendritic cells are considered the most effective antigen presenting cells that are professionalized in 
antigen uptake, processing and presentation to antigen-specific T cells (Reviewed in Section 2.8). Even 
though DCs are capable of taking up soluble proteins, peptides or DNA to induce antigen-specific 
immunity, these antigens alone are not sufficient to induce a potent and broad immune response. 
Relatively high doses of soluble proteins are needed to induce a sufficient immune response. Common 
methods of conjugating protein antigen to cell penetration peptide by protein engineering for 
intracellular delivery will potentially jeopardize the intrinsic protein function (Tahara et al., 2008). 
Encapsulating protein drugs within nanocarriers is an alternative and effective method for protein 
intracellular delivery, however most procedures require stringent conditions that may potentially 
compromise protein activity and are limited by the diversity of protein physiochemical properties. In 
Chapters 3 and 4, P200-Ab-P20-TNE that selectively targets Clec9A-expressing cells in situ was 
developed. The platform was constructed using a simple top-down sequential reagent addition method 
whereby stringent physiochemical preparation conditions were not required, making it an ideal carrier 
for delivering delicate therapeutics, e.g. protein, in a cell-specific manner. Hence the aim of this 
Chapter was to evaluate the potential of P200-Ab-P20-TNE as a carrier for targeting delivery of protein 
to DCs.  
 
We firstly encapsulated native OVA within the TNE oil core using a S/O/W emulsification method 
(Tahara et al., 2008). Hydrophilic OVA was first coated with hydrophobic small molecule surfactants 
for increased solubility in the oil phase of emulsion. Encapsulation of protein into nanocarriers by such 
a method does not require any covalent conjugation that would damage the native properties. Results 
from dot blot assay showed that the immunogenicity of OVA protein was preserved after it had been 
complexed with surfactant (Figure 5-3). Encapsulation of OVA into TNE via S/O/W emulsification 
did not affect stability of the TNE in isotonic conditions (Figure 5-2), suggested OVA-P200-Ab-P20-
TNE was suitable for intravenous injection.  
 
The ability of OVA-surfactant to induce antigen specific T cell immunity was assessed first in vitro and 
then in vivo. We demonstrated that potent antigen presentation by DCs can be achieved, by 
encapsulating antigen within the DCs targeting P200-Ab-P20-TNE. This may be due to the unique nature 
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of CD8+ DCs subset targeted by P200-Ab-P20-TNE, which are efficient in taking up exogenous antigens 
and cross-presenting to MHC class I (den Haan et al., 2000, Pooley et al., 2001, Schnorrer et al., 2006). 
Consistent with these studies, we have already shown that engineering of an mAb against CD8+ DCs 
exclusive to surface receptor Clec9A with nanocarriers emulsion facilitating the in situ targeting 
delivery to DCs (Chapter 4). In this Chapter, we showed that antigen encapsulated within the targeting 
P200-Ab-P20-TNE could be correctly processed and cross-presented to antigen-specific T cells both in 
vitro and in vivo (Figure 5-4 and 5-5). As effective delivery of protein antigen is an important goal for 
developing vaccines for cancers and infectious disease, results in this chapter further support the 
hypothesis that TNE will serve as an effective DDS platform for targeting DCs. Hereby we address 
Objective 4 of this PhD project as stated in Chapter 1.  
 
Questions regarding whether the ability of antigen carrying TNE for inducing antigen specific T cell 
immunity is dependent of the TNE formulation or the amount of antigen being encapsulated and 
delivered to DCs is of interest of this PhD project, but yet to be addressed. Density of targeting 
moieties on a nanocarrier surface is important in designing effective DDS. For example, different 
densities of folate acid ligand on liposomal formulations have been reported in the literature for 
promoting association between liposome and folate receptor on cells (Shmeeda et al., 2006, Watanabe 
et al., 2012, Saul et al., 2003, Reddy et al., 2002, Kawano and Maitani, 2011). In the case of a TNE 
system, we showed the in vitro target specificity of TNE was decreased when increasing the PEG 
content on a TNE surface (Chapter 4), probably as the accessibility of Clec9A mAb was shielded by 
the increased steric hindrance of the PEG layer surrounding the TNE surface. Therefore it is important 
to establish the optimal density of Clec9A mAb on TNE surface in vivo, as such a parameter is not only 
crucial for designing an effective DDS, but is also important for subsequent industrial scale up as the 
production cost is highly related to the amount of targeting mAb required.  
 
Targeting different DC subsets normally results in different types of immune response, i.e. targeting 
CD8+ DCs is more likely to induce an antigen-specific CD8+ T cell response while antigen-targeting 
CD8- DCs are more likely to induce a CD4+ T helper cell response. However Caminschi et al. reported 
that OVA targeting to Clec9A on the CD8+ DCs subsets not only led to a strong CTL response, but also 
induce a strong humoral immune response as a result of prolonged and efficient presentation of Ag on 
MHC class II (Caminschi et al., 2008). CD4+ T cells play a crucial role in initiating adaptive immunity, 
therefore it is also worth investigating whether TNE could deliver antigen payload to DCs and induce a 
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comparable CD4+ T cell response. In order to address the aforementioned issues, the next Chapter 
focuses on investigating the potential of the TNE as a tunable platform for delivering protein antigen, 
by evaluating the effect of Clec9A mAb density on in vivo cross-presentation efficiency and the ability 
of OVA-P200-Ab-P20-TNE to induce humoral immunity, with the aim to address Objective 5 of this 
PhD project.  
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Chapter 6  Efficient Targeting of protein antigen to dendritic cells via 
receptor Clec9A with an engineered nanoemulsion promotes potent 
antibody and cytotoxic T cell responses 
 
Chapter 6 is comprised entirely of the manuscript written for the submission to Journal of Controlled 
Release. 
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Abstract Eliciting potent antibody production and an efficacious cytotoxic T cell response represent 
major challenges in the field of modern vaccine development. Nanocarrier-based antigen delivery 
systems have great potential as an effective strategy to improve the efficacy of vaccines in order to 
deliver protein antigen to dendritic cell targets. In the present study, we developed a tailorable 
nanocarriers emulsion (TNE) encapsulated with a model protein antigen ovalbumin (OVA), termed 
OVA-P200-Ab-P20-TNE. Soluble protein antigen was encapsulated within the oil core of the emulsion 
by using a solid-in-oil (S/O) nanodispersion method. The emulsion oil core of the TNE was 
functionalized with immune-evading polymer PEG and an antibody directed against the CD8+ dendritic 
cell-specific ligand, Clec9A, using a novel non-covalent click chemistry method involving molecular 
self-assembly at the oil-aqueous interface. Immunizing mice with OVA-P200-Ab-P20-TNE induced the 
proliferation of both CD4+ and CD8+ T cells in vivo and strong CTL and humoral responses, in the 
absence of adjuvant. These results suggest TNE is an ideal system for targeting delivery of protein 
antigen for induction of cell mediated immunity. 
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1. Introduction 
Dendritic cells (DCs) are the mobile sentinels of the immune system and specialize in the capture, 
processing and presenting antigen to T cells via MHC I or II pathway [1]. DCs play a central role in the 
induction and the regulation of T- and B-cell immunity. The interaction between DCs and T cells 
regulates the type and magnitude of the immune response [2, 3]. Increased understanding of DC 
biology has inspired novel vaccines using DCs as a target for antigen (Ag) delivery, and thereby 
manipulating T cell responses [4, 5].  Since different subsets of DCs have distinct patterns of surface 
markers [6, 7], current approaches for targeting DCs include ligating Ag to monoclonal antibodies 
(mAbs) that specifically recognize exclusive DC subsets in situ. Such approach relies on a choice of 
suitable DC surface receptors that mediate endocytosis of bound mAb, allowing Ag to be delivered to 
endosomal compartments and subsequently processed for MHC presentation. To date, several DC-
specific endocytic receptors have been identified, including DEC205, CD207, Clec9A and Clec12A [8-
11]. Among these receptors, Clec9A or DNGR is a C-type lectin receptor expressed by CD8α+ DCs in 
mouse and BDCA3+ DCs in humans. In vivo, Clec9A organizes the processing and cross-presentation 
of dead cell and viral antigens by MHC class I for efficient induction of cytotoxic T lymphocytes 
(CTLs) [12, 13]. DC-targeting using the anti-Clec9A mAb clone induces efficient antigen processing 
and presentation in the context of MHC class I and II to induce CD4 and CD8 proliferative responses, 
T follicular helper cell development and potent humoral immunity [10, 14-16]. 
 
While protein antigens ligated to Clec9A or DEC205 mAb enhanced vaccine immunogenicity, studies 
also found that such delivery of Ag to DCs failed to induce strong antigen-specific effector CTLs, 
which are essential for tumor- or infected cell-clearance, unless additional stimuli or adjuvant was 
applied to activate DCs for the production of co-stimulatory molecules for adequate CTL generation 
[11, 15, 17-19]. These findings led to the hypothesis that vaccine efficacy can be further improved by 
simultaneously delivering multiple vaccine components to DCs. However, options for linking a DC-
specific mAb to multiple vaccine components, e.g. antigen and immune modulators, are limited. To 
this end, nanotechnology provides a great tool for designing better vaccines. Nanocarrier systems 
loaded with multiple vaccine components provide an attractive alternative to overcome the limitations 
of current DC-based vaccine approaches. Several types of nanocarriers have been used as vaccine 
carriers to entrap antigens or as adjuvant alone [20-23]. Nanocarriers are considered to be an effective 
vehicle for delivering antigen and have been widely investigated for their biological potential [24, 25]. 
Compared to its soluble counterparts, concentrated antigen and immune modulatory factors can be 
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encapsulated within the internal compartment of nanocarriers to avoid in vivo enzymatic degradation 
and to allow controlled release; targeting delivery to DCs can be facilitated by surface engineering with 
a DC-specific ligand. Antigen encapsulated nanocarrier systems can mimic pathogens that are 
recognized by professional antigen presenting cells, such as DCs and macrophages, and their 
subsequent processing and cross-presentation for initiating T cell immunity more efficiently. 
 
Oil in water nanoemulsion systems have been widely used as clinical vaccine adjuvants [26-28]. 
Nanoemulsions have shown low toxicity and no significant adverse effect in humans [29, 30]. 
Nevertheless, wide adoption of nanoemulsion as a drug delivery system (DDS) into clinical 
applications requires these platforms to encode more sophisticated functions, such as combined long 
circulation half-life and in vivo targeting ability. The in vivo fate of intravenously injected nanocarriers 
is dictated by their physical parameters such as size, surface charge and coating [31, 32]. In particular, 
pharmacokinetics and bioavailability as well as the nanocarrier’s ability to target a biological site are 
highly influenced by their surface coating [33]. Nanocarriers in the blood stream will be rapidly 
captured by the mononuclear phagocyte system (MPS) and directed to clearance organs like the liver 
and spleen. Modifying the nanocarrier surface with hydrophilic polymer such as polyethylene glycol 
(PEG) is an effective way to increase stealthiness, which is the ability to escape capture by the MPS. as 
PEG can create a steric barrier to reduce opsonization [34].  In addition, target-specific molecules can 
be engineered onto the nanocarrier’s surface for enhanced cellular delivery. However, exposure of the 
targeting moieties on the nanocarrier’s surface may counteract the shielding effect of the polymeric 
coating. Therefore it is vital to maintain a balance between these two categories of functional moieties 
on the surface of the nanocarrier. 
 
We recently reported a tailorable nanocarrier emulsion (TNE) for target specific delivery of antigen to 
DCs [35]. Harnessing the chemical similarity between two surface active peptides and their self-
assemble properties, the reported TNE was grafted with immune evading polymer PEG, which 
provides a steric repulsive barrier protecting the TNE from non-specific cell association. To facilitate 
the target specificity, anti-Clec9A mAb was also grafted onto the nanoemulsion surface using the same 
non-covalent click self-assemble approach. Our studies show that intraperitoneally injected TNE was 
able to evade the non-specific phagocytosis in blood stream and renal clearance, and was well 
distributed within Clec9A expressing CD8+ cDCs in mouse. Moreover, OVA encapsulated within the 
TNE oil core induced OVA-specific CD8+ T cell responses in vitro [32].  
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The aforementioned results, besides a promising platform nanocarrier technology, raised the question 
of whether Ag encapsulated within TNE could be efficiently cross-presented in the more complicated 
in vivo environment, which is pivotal for success of protein-based vaccines. Nanocarriers that 
specifically target DC-specific receptors for improved in vitro uptake have been reported, however 
there are few comprehensive studies demonstrating enhanced in vivo CD8+ T cell activation and 
antigen-specific CTL responses [36, 37]. It is also been reported that the cellular association of DC-
targeting nanocarriers can be influenced by ligand density on surface, and cell association can be 
improved with an optimal surface density [38, 39]. In this study, we examined whether OVA antigen 
delivered to DCs via this TNE induces CD4+ and CD8+ CTL cell responses in vivo. We show that 
OVA-encapsulated TNE target the Clec9A+ DC subset, and effectively induce OVA-specific effector 
CTLs and Ab responses.  
 
2. Materials and methods 
2.1. Materials 
AM1 (molar mass 2473, 95% purity) was custom synthesized by Genscript (Piscataway, NJ, USA) as 
reported previously [40]. Peptide concentration was determined by quantitative amino-acid analysis 
(Australian Proteome Analysis Facility, Sydney, NSW, Australia). Miglyol® 812 was purchased from 
AXO Industry SA (Wavre, Belgium). CellTraceTM Violet (CTV) was purchased from Molecular Probes 
(Victoria, Australia). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), albumin from 
chicken egg white (OVA) and zinc chloride (ZnCl2) were purchased from Sigma-Aldrich (St Louis, 
MO, USA). mPEG-NHS (MW 5000, PDI <1.08, purity > 95%) was purchased from Nanocs (Boston, 
MA, USA). RPMI-1640 and fetal calf serum (FCS) were purchased from GIBCO (Victoria, Australia). 
FITC-anti-CD3, APC/Cy7-anti-CD8, PE-anti-CD45.2 and PerCP5.5-anti-MHCII and APC-anti-CD4 
were purchased from Biolegend (San Diego, CA, USA). CithrolTM GMO HP was a gift from Croda 
Europe Ltd (Staffordshire, United Kingdom). DAMP4 fused with antibody (mAb-DAMP4) was 
provided by Dr. Irina Caminschi and Dr. Mireille Lahoud at the Burnet Institute (Melbourne, Australia) 
and was prepared using published protocol [10, 15]. 
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2.2. Mice 
Mice were purchased from the Animal Research Centre (Perth, WA) or bred at the Diamantina Institute 
Biological Research Facility (BRF) at The University of Queensland under specific pathogen-free 
conditions. Experiments were approved by the UQ Animal Ethics Committee (ethics number 465/12). 
 
2.3. Preparation of OVA in oil dispersion 
OVA solution (10 mg mL-1) was prepared by dissolving endotoxin free OVA protein (MW 45 kDa, 100 
mg) in ultrapure water (10 mL). CithrolTM GMO HP solution (1%, w/v) was prepared by dissolving 
CithrolTM GMO HP (200 mg) in hexane (20 mL). OVA solution (1 mL) and CithrolTM GMO HP 
solution (2 mL) were transferred into a 20 mL glass vial, and mixed by using a sonicator (Branson 
Sonifier® S-450A, Danbury, United State) 1 min at 20 W to form stable water in oil (w/o) emulsion. 
The resulting emulsion was frozen rapidly in dry ice for 2 h before being lyophilized for 24 h. The 
resulting OVA-Cithrol GMO HP pellet was dissolved in Miglyol 812 (2 mL) to a final concentration of 
5 mg ml-1 of OVA, and used as oil phase for preparing OVA-P200-Ab-P20-TNE and OVA-P200-Isotype-
P20-TNE.  
 
2.4. TNE preparation and characterization 
To prepare TNE core, lyophilized AM1 (400 µM) was dissolved in 980 µL HEPES (25 mM, pH 7.0) 
containing ZnCl2 (800 µM). Twenty microliter of Miglyol 812 was added to give an oil volume fraction 
of 2% (v/v).  The mixture was homogenized using a Branson Sonifier 450A ultrasonicator for four 45 s 
bursts at 60 W. To prepare P20-TNE, TNE (500 µL) was added to PEGylated DAMP4 solution (500 µL, 
40 µM) followed by 60 s of vigorous stirring using a magnetic stirrer. For preparation of P200-Ab-P20-
TNE, mAb-DAMP4 (36 µL, 3 µM) was added to P20-TNE (200 µL) followed by 60 seconds of vigorous 
stirring using a magnetic stirrer, and subsequently Ab-P20-TNE (200 µL) was added to PEGylated 
DAMP4 (200 µL, 400 µM), followed by 60 seconds of vigorous stirring. The final concentration of 
OVA in OVA-P200-Ab-P20-TNE was 0.56 µM.  
 
TNE size was measured by Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK) equipped with 
a He-Ne laser (633 nm). Data analysis was with DTS software (Malvern, version 6.2), used the non-
negativity constrained least squares (NNLS) fitting algorithm. Dispersant refractive index and viscosity 
122 
 
of the dispersant were assumed to be 1.45 and 1.02 cP, respectively. For each sample, 10 runs of 10s 
were performed. 
 
2.5. In vivo proliferation assays of transgenic T cells 
B6.SJL-Ptprca mice were injected i.v. with 3 × 106 CTV labelled lymph node cells harvested from OT-I 
or OT-II transgenic mice. One day later, these recipient mice were injected i.v. with 200 µL of OVA-
P200-Ab-P20-TNE or OVA-P200-Isotype-P20-TNE (both formulated with 5 µg of OVA). 200 µL of empty 
P200-Ab-P20-TNE or 5 µg of soluble OVA protein were also injected i.v. into control mice. Mice were 
sacrificed 4 days later, and the proliferation of CD3+CD45.2+CD8+ OT-I or CD3+CD45.2+CD4+ OT-II 
T cells was visualized by dilution of CTV fluorescence.  
 
In the Tuneable CD8+ T cells Response experiment, TNE samples were prepared following the same 
protocol detailed in Section 2.4, with the modification of using different concentrations of mAb-
DAMP4 to prepare P200-Ab-P20-TNE. Serial dilutions of 3 µM mAb-DAMP4 stock solution were made 
to obtain mAb-DAMP4 at concentrations of 1.5, 0.75 and 0.38 µM individually. Thirty-six microliters 
of 3, 1.5, 0.75 or 0.38 µM mAb-DAMP4 was added to P20-TNE (200 µL) followed by 60 seconds of 
vigorous stirring using a magnetic stirrer, and subsequently Ab-P20-TNE (200 µL) was added to 
PEGylated DAMP4 (200 µL, 400 µM), followed by 60 seconds of vigorous stirring to obtain P200-Ab-
P20-TNE with mAb-DAMP4 content at 0.27, 0.14, 0.07 or 0.03 µM respectively (based on the overall 
solution volume). The ratio of Ag to mAb was calculated by using the molar concentration of OVA 
protein in P200-Ab-P20-TNE (0.56 µM) divided by the molar concentration of mAb-DAMP4 added to 
the individual P200-Ab-P20-TNE formulations. 
 
2.6. In vivo cytotoxic T lymphocyte (CTL) assay 
Recipient C57BL/6 mice were primed by i.v. injection of 200 µL of OVA-P200-Ab-P20-TNE or OVA-
P200-Isotype-P20-TNE (both formulated with 5 µg of OVA) five days earlier. Empty P200-Ab-P20-TNE 
and soluble OVA (100 µg) were also injected to control mice. To prepare CTL targets in our in vivo 
CTL assay, single cell suspensions of splenocytes from C57Bl/6 mice were depleted of red cells and 
divided equally into two parts. Half of the splenocyte suspension (CTVhigh population) was pulsed with 
OVA257-264 (1 µg mL-1) and labeled with CTV (5 µM); and the other half of the splenocytes (CTVlow 
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population) was labeled with CTV (0.5 µM). Equal numbers of cells from each population were pooled 
and 107 cells were injected i.v. into recipient mice. Twenty hours post injection, lymph nodes (LN) and 
spleens were harvested from the mice and the relative proportion of CTVhigh to CTVlow cells was 
determined by flow cytometry using a Beckman Coulter GalliosTM flow cytometer and analysed using 
Kaluza® software. Percentage (%) specific lysis in vivo was calculated by [1-(r unprimed/r primed)] × 
100, where r = % CTVlow / % CTVhigh for each mouse.  
 
2.7. Immunization using OVA-P200-Ab-P20-TNE and Clec9A-OVA 
Constructs of OVA conjugated to anti-Clec9A mAb (Clec9A-OVA) or isotype mAb (Isotype-OVA) 
were provided by Dr. Irina Caminschi and Dr. Mireille Lahoud at the Burnet Institute (Melbourne, 
Australia) and were prepared using published protocols[10, 15]. C57Bl/6 mice were injected i.v. with 5 
µg of Clec9A-OVA or OVA-P200-Ab-P20-TNE. Isotype-OVA, OVA-P200-Isotype-P20-TNE or PBS was 
also injected to control mice in the absence of adjuvant. Serum anti-OVA Ig reactivity was measured 1, 
2 and 3 wk later by ELISA as previously described [10]. 
 
3. Results  
3.1. Preparation and Characterization of OVA-encapsulated TNE  
We determined the particle size of the prepared OVA-P200-Ab-P20 by dynamic light scattering (DLS). 
Figure 1 shows OVA-P200-Ab-P20 had a similar size distribution of 187.1 ± 2 nm and 189.3 ± 4 nm, 
when diluted in water and isotonic PBS respectively. As stability of nanocarriers in physiological 
conditions is a pre-requisite for effective cellular targeting, this result suggests OVA-P200-Ab-P20 is 
stable in physiological environment and suitable for i.v. injection.   
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Figure 1. Particle size distribution of OVA-P200-Ab-P20 TNE diluted in water and PBS measured by 
dynamic light scattering (DLS). 
 
3.2. TNE delivers Ag to CD8+ T cells  
We demonstrated that OVA-P200-Ab-P20-TNE could induce CD8+ T cell proliferation in vitro [35]. 
Here we investigated whether an antigen encapsulated within P200-Ab-P20 could be delivered in vivo to 
Clec9A+CD8+ DCs with subsequent processing and cross-presentation to Ag-specific CD8+ T cells. 
B6.SJL-Ptprca mice were adoptively transferred with CTV-labelled lymph node cells from OVA257-264 
epitope-specific OT-I TCR transgenic mice. One day later, these mice were immunized i.v. with OVA-
P200-Isotype-P20-TNE or OVA-P200-Ab-P20-TNE. Empty P200-Ab-P20-TNE or soluble OVA protein (5 
µg) in an amount equivalent to that encapsulated in TNE were injected i.v. to control mice. Seven days 
later the CD8+ OT-I T cell response was determined as the dilution in CTV fluorescence intensity, and 
the expansion of CD8+ OT-I cells identified by CD45.2 staining. Substantial levels of OT-I T cell 
proliferation were observed both in LN and spleen from mice immunized with OVA-P200-Ab-P20-TNE 
or equivalent amounts of soluble OVA (Figure 2). Immunization of mice with OVA-P200-Ab-P20-TNE 
resulted in significantly higher levels of OT-I T cell proliferation relative to mice treated with 
equivalent amounts of soluble OVA without adjuvant (Figure 2b-d). In contrast, OVA-P200-Isotype-
P20-TNE, prepared using the same process but engineered with an isotype targeting mAb, and empty 
P200-Ab-P20-TNE, did not induce OT-I T cell proliferation (Figure 2b-d). This result indicates that the 
P200-Ab-P20 TNE effectively induce OVA-specific CD8+ T cell proliferation in a manner dependent on 
Clec9A targeting of APCs.  
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Figure 2. TNE induces CD8+ T cell proliferation in LN and spleen. CTV labeled LN cells from 
OVA257-264 specific OT-I transgenic mice were transferred to B6.SJL-Ptprca mice. One day later these 
mice were injected i.v. with 100 µg of soluble OVA, or 200 µL of P200-Ab-P20-TNE, OVA-P200-Ab-P20-
TNE or OVA-P200-Isotype-P20-TNE (formulated with 5 µg of OVA). Six days later, LN and spleens 
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were removed and cell suspension were stained with anti-CD3, CD8, CD45.2 and MHC-II mAb and 
analyzed by flow cytometry. CD3+CD8+CD45.2+MHCII- cells were gated. a) Dot-plots with rectangle 
gate A represent OVA-specific CTVhigh parent T cells while gate B represent proliferated daughter T 
cells. b) Histogram showing dilution in CTV fluorescence intensity depicts OVA-specific T cell 
proliferation in LN. c) Dilution in CTV fluorescence intensity depicts OVA-specific T cell proliferation 
in spleen. d) Mean values ± SD of percentage CD3+CD8+CD45.2+ proliferation. Statistical differences 
were determined by one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (n=8-10 from two 
individual experiments). 
 
3.3. CTL generation in vivo after Ag targeting 
We further investigated whether Ag delivered by P200-Ab-P20-TNE to the CD8+ DCs leads to the 
generation of effector CTLs. OVA257-264 (SIINFEKL) induces a strong CTL response in naïve mice and 
is commonly used to investigate CTL-mediated immune responses. We first immunized C57BL/6 mice 
with OVA-P200-Ab-P20-TNE or OVA-P200-Isotype-P20-TNE (both formulations contained a total of 5 
µg of OVA). Empty P200-Ab-P20-TNE or 5 µg of soluble OVA were injected to control mice. Five days 
later the mice were injected with an equal mix of syngeneic splenocytes pulsed with SIINFEKL and 
labelled with 5 µM of CTV (CTVhigh), together with unpulsed splenocytes labelled with 0.5 µM of CTV 
(CTVlow).  Twenty hours post injection, the residual SIINFEKL specific CTVhigh and control CTVlow 
cells remaining in the immunized mice were analyzed by flow cytometry, which represents the killing 
activity of SIINFEKL-specific effector CD8+ cytotoxic T lymphocytes (CTLs) in the recipient mice 
(Figure 3). Whereas no CTVhigh target cell loss was observed in mice immunized with empty P200-Ab-
P20-TNE, substantial loss of CTVhigh target cells was observed in mice immunized with OVA-P200-Ab-
P20-TNE. We found approximately 80% SIINFEKL-specific lysis in this group of mice (Figure 3b). In 
contrast, no significant increase in % specific lysis was detected in mice immunized with non-targeting 
OVA-P200-Isotype-P20-TNE or equal amount of soluble OVA (5 µg). These data indicate that OVA 
encapsulated within the targeting P200-Ab-P20-TNE effectively induces CTL with capacity to kill Ag-
specific targets. 
 
 
127 
 
 
Figure 3. Targeting OVA to Clec9A induces OVA-specific cytotoxic response. C57BL/6 mice were 
adoptively transferred with equal number of unpulsed CTVlow and OVA257-264 (SIINFEKL)-pulsed 
CTVhigh target cells 5 days after i.v. injection with OVA-P200-Ab-P20-TNE or OVA-P200-Isotype-P20-
TNE (both formulated with 5 µg of OVA). After 20h, spleen cells were analysed by flow cytometry to 
determine the ratio of CTVhigh to CTVlow target cells (specific killing of target). a) Representative 
histograms of splenocytes of individual mouse are shown. b) Graph represents the percentage of 
SIINFEKL peptide specific lysis in spleen. Results are expressed as mean ± SD. Statistical differences 
were determined by one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P < 0.0001. 
(n=5-9 from two experiment). 
 
3.4. Tuneable CD8+ T cell response 
We next investigated whether the CD8+ T cell response from mice immunized with OVA-P200-Ab-P20-
TNE was dependent on the mAb-DAMP4 within the formulation, and whether such responses could be 
tuned by simply changing the concentration of the targeting mAb. We generated a set of OVA-P200-Ab-
P20-TNE which comprised varied molar ratios of OVA payload to targeting mAb, while keeping the 
composition of other components constant. We injected these formulations to B6.SJL-Ptprca mice 
which been adoptively transferred with CTV-labelled OT-I cells one day before. PBS and the non-
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targeting OVA-P200-Isotype-P20 TNE were injected to control mice. Expansion of OVA specific OT-I T 
cells was evaluated by flow cytometry 3 days later. Mice immunized with different formulations of 
OVA-P200-Ab-P20-TNE displayed varied levels of CD8+ T cell response, expressed as OT-I cell 
expansion (Figure 4). Immunization with OVA-P200-Ab-P20-TNE formulated with lowest molar ratio 
of mAb (2:1) resulted in expansion of 17% of OT-I T cells in spleen and LN. Dilution of anti-Clec9A 
mAb 4 fold to increase in the ratio of Ag to mAb to 8:1 significantly reduced the T cell response, and 9 
fold dilution essentially eliminated the T cell response. Results were similar in spleen and LN. This 
result further supports the conclusion that the antigen was correctly delivered and cross-presented to 
CD8+ T cells, and this target specificity was partly dependent on the targeting Ab concentration within 
the TNE formulation. These data indicated that Ag-specific responses after delivery of OVA via P200-
Ab-P20-TNE were mAb concentration dependent.  
 
Figure 4. Tuneable CD8+ T cells response by varying the concentration of targeting Ab within the 
TNE formulation. B6.SJL-Ptprca mice were adoptively transferred with CTV labelled lymph node 
cells from OT-I transgenic mice. One day later, the mice were injected with OVA-P200-Ab-P20-TNE 
formulated with a varied molar ratio of Ag to targeting mAb. Three days later, spleens and inguinal LN 
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were harvested and cells were stained with mAb against CD45.2, CD3 and CD8. Proliferation of OT-I 
cells (CD3+CD8+CD45.2+) in LN (a) and spleen (b) were determined by flow cytometry. Proliferation 
of OT-I (CD45.2+CD8+) cells in LN (c) and Spleen (d) were enumerated. Results are expressed as 
mean ± SD from two separate experiments (n=8). Statistical differences were determined by one-way 
ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001, ****, P < 0.0001. 
 
3.5. Proliferation response of CD4+ T cells in vivo after targeting Ags to Clec9A by 
TNE 
We next assessed the delivery of Ag by means of OVA-P200-Ab-P20-TNE to induce CD4+ Ag-specific 
responses in vivo. CTV-labeled LN cells from transgenic OT-II mice specific for OVA323-336 presented 
in the context of MHC class II were adoptively transferred into B6.SJL-Ptprca mice. One day later, 
mice were injected i.v. with OVA-P200-Ab-P20-TNE or the non-targeting OVA-P200-Isotype-P20-TNE. 
An equivalent amount of soluble OVA or empty P200-Ab-P20-TNE was injected into control mice. Six 
days later the proliferation of OT-II T cells was analyzed by flow cytometry (Figure 5). Mice 
immunized with OVA-P200-Ab-P20-TNE, which encapsulated low dose of soluble OVA (5 µg), induced 
vigorous OT-II cells proliferation in LN and spleen. By contrast, immunizing mice with the non-
targeting OVA-P200-Isotype-P20-TNE, which contained the same amount of OVA, induced a 
significantly lower OT-II T cell response, similar to the response level from mice that had been 
immunized with empty P200-Ab-P20-TNE. Notably, mice immunized with an equivalent amount of 
soluble OVA alone did not induce a comparable OT-II T cell response. These data indicate that P200-
Ab-P20-TNE delivers OVA protein effectively to APC for presentation to CD4+ T cells. 
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Figure 5. TNE delivery of OVA to Clec9A+ DC elicits CD4+ T cell proliferation. LN cells from 
transgenic OT-II mice (3 × 107) labeled with CTV were adoptively transferred to B6.SJL-Ptprca mice. 
One day later, mice were immunized i.v. with 200 µl of OVA-P200-Ab-P20-TNE or non-targeted control 
OVA-P200-Isotype-P20-TNE. Empty P200-Ab-P20-TNE and equivalent amount of soluble OVA were 
also injected i.v. to control mice. Six days later, LNs and spleens were harvested and cells were stained 
with mAb against CD45.2, CD3 and CD4. Proliferation of OT-II cells (CD3+CD4+CD45.2+) was seen 
as the dilution of CTV fluorescence by flow cytometry. a) Histogram showing dilution in CTV 
fluorescence intensity depicts OVA-specific OT-II T cell proliferation in LN and spleen. b) Mean 
values ± SD of percentage CD3+CD4+CD45.2+ proliferation. Statistical differences were dete  rmined 
by one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (n=8-10 from two experiment). 
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3.6. Ab responses induced by targeting Ags to Clec9A by TNE 
It has been reported that targeting OVA conjugated to anti-Clec9A mAb can induce strong Ab 
responses in mice [10]. We tested wether Ab delivered by P200-Ab-P20-TNE could induce comparable 
anti-OVA responses to those induced by OVA conjugated to anti-Clec9A mAb (Clec9A-OVA). Mice 
were injected i.v. with 5 µg of OVA-P200-Ab-P20-TNE or Clec9A-OVA. Serum anti-OVA Ab response 
was quantitated over 3 consective weeks after immunization. In the absence of adjuvant, OVA-P200-
Ab-P20-TNE induced similar anti-OVA response to that induced by Clec9A-OVA over 3 weeks post 
immunization (Figure 6). On the other hands, OVA delivered by the non-targeting P200-Isotype-P20-
TNE or conjugated to an isotype mAb (Isotype-OVA), induced significantly lower anti-OVA 
responses, similar to the reponses in mice injected with PBS. 
.  
Figure 6. OVA delivered by TNE to Clec9A+ DC induced humoral response. C57Bl/6 mice were 
injected i.v. with 5 µg of OVA in the form of either conjugate to anti-Clec9A mAb (Clec9A-OVA) or 
OVA-P200-Ab-P20-TNE. OVA conjugated to an isotype mAb (Isotype-OVA), OVA-P200-Isotype-P20-
TNE was also injected to control mice in the absence of adjuvant. Serum anti-OVA Ig reactivity was 
measured in 1, 2 and 3 wk later by ELISA. Each group consists of 5 mice. Each symbol represents the 
individual response and the bar represents the geometric mean. n=10 from two individual experiments. 
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4. Discussion and conclusion 
Currently clinical applications of native protein antigen based vaccines are hampered by the lack of an 
effective delivery platform and their inability to initiate strong T cell immunity, a process that is vital 
for the development of immunity against evading pathogens. Encapsulation of protein antigen into a 
delivery vehicle to target specific DC for efficient induction of CTL and antibody would provide 
opportunities for further development of protein antigens in anti-viral vaccines and tumor 
immunotherapy [41]. Here, we report a novel TNE engineered with anti-Clec9A mAb to deliver 
antigen payloads for induction of CD8+ and CD4+ mediated immunity. We previously reported the 
design and construction of TNE, which we showed targeted CD8+ DCs selectively in vivo by means of 
the Clec9A targeting mAb [35]. In this study, hydrophilic OVA was loaded into the oil core using the 
solid-in-oil nanodispersion method [42]. In this method, protein was first coated with hydrophobic 
surfactant molecules to form protein-surfactant complexes, which significantly increased its solubility 
in the oil phase, thus enabling its facile packaging into the TNE oil core by the time of emulsification. 
The particle size of OVA encapsulated TNE was under 200 nm. PEGylation imparted steric stability to 
the TNE oil core in isotonic conditions, as observed from the consistent size distribution when the same 
structure was exposed to isotonic PBS,  indicating suitability for i.v. injection and intracellular delivery 
[43]. Moreover, OVA-encapsulated TNE (OVA-P200-Ab-P20-TNE) effectively mediated OVA 
presentation and cross-presentation, leading to antigen-specific CD8+ and CD4+ T cell proliferation and 
CTL activity, even when the delivered dose of OVA was only 5 µg and in the absence of adjuvant. 
Indeed delivery of 5 µg of OVA by P200-Ab-P20-TNE induced greater levels of T cell proliferation 
compared to the same amount of soluble OVA. OVA delivered by P200-Ab-P20-TNE induced 
significantly enhanced anti-OVA response over three weeks post immunization. Although native 
protein based vaccines generally induce strong humoral immune responses, cellular immune responses 
are often relatively poor. By encapsulating protein antigens into nanoparticulate vehicles we could 
induce both Ab and CTL responses.  We observed that OVA-encapsulated nanoemulsion (OVA-P200-
Ab-P20-TNE) induced substantial levels of CTL in vivo, while the same amount of soluble OVA did 
not. Previously, OVA-specific CTL, albeit at lower levels, were induced after i.v. or i.d. injection of 
OVA-conjugated nanoparticles without targeting Ab but not low doses of soluble OVA [44]. DCs are 
the major antigen presenting cells through both MHC class I and II pathways. We previously showed 
that OVA-P200-Ab-P20-TNE was efficiently taken up by CD8+ DCs and that its encapsulated antigen 
was subsequently cross-presented by MHC class I molecules to CD8+ T cells [35]. 
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Previously, antigen targeting to mouse Clec9A+ DCs via anti-mClec9A mAb led to antigen-specific 
CD4 and CD8 T cell proliferation [10, 15, 45-47]. The current data demonstrate an alternate method to 
deliver Ag to CD8+ DCs with similar outcomes for cross presenting to CD8+ T cells. Targeting antigen 
specifically to the Clec9A DC receptor using anti-Clec9A mAb modified P200-Ab-P20-TNE has 
manufacturing advantages over construction of recombinant Ag-mAb constructs and in the flexibility 
of the TNE system for addition of excipients such as immunomodulatory adjuvants or drugs. 
Importantly, the efficiency of TNE for cross-presentation was dependent on the density of Clec9A 
mAb that been engineered on the TNE surface. Therefore there exists an optimal density for targeting 
mAb below TNE surface-saturation levels, suggesting that formulation optimization would be 
important for translation of this technology to clinically-relevant antigens. The ability to optimize DC 
targeting TNE platforms by controlling targeting moiety density could have significant benefit to future 
clinical applications, especially in chronic viral infections, intracellular bacterial infections and tumors 
where CD4+ and CD8+ cell-mediated immunity are critical for disease control, and to extend 
applicability to patients with multiple MHC types where CTL peptide epitopes are not known.  
 
Overall, the results presented here demonstrate that antigen delivered by TNE can be presented by both 
MHC I and II molecules, leading to CD4 and CD8 T cell activation in vivo. Our work lays a foundation 
on which to develop the TNE platform for vaccines to deliver both humoral and T cell mediated 
immunity.  
  
134 
 
[1] J. Banchereau, R.M. Steinman, Dendritic cells and the control of immunity, Nature, 392 (1998) 
245-252. 
[2] I. Mellman, R.M. Steinman, Dendritic Cells: Specialized and Regulated Antigen Processing 
Machines, Cell, 106 (2001) 255-258. 
[3] A. Lanzavecchia, F. Sallusto, Regulation of T Cell Immunity by Dendritic Cells, Cell, 106 (2001) 
263-266. 
[4] R.M. Steinman, J. Banchereau, Taking dendritic cells into medicine, Nature, 449 (2007) 419-426. 
[5] I. Caminschi, M.H. Lahoud, K. Shortman, Enhancing immune responses by targeting antigen to 
DC, Eur. J. Immunol., 39 (2009) 931-938. 
[6] K. Shortman, S.H. Naik, Steady-state and inflammatory dendritic-cell development, Nat Rev 
Immunol, 7 (2007) 19-30. 
[7] J.A. Villadangos, P. Schnorrer, Intrinsic and cooperative antigen-presenting functions of dendritic-
cell subsets in vivo, Nat. Rev. Immunol., 7 (2007) 543-555. 
[8] W. Jiang, W.J. Swiggard, C. Heufler, M. Peng, A. Mirza, R.M. Steinman, M.C. Nussenzweig, The 
receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen 
processing, Nature, 375 (1995) 151-155. 
[9] J. Idoyaga, N. Suda, K. Suda, C.G. Park, R.M. Steinman, Antibody to Langerin/CD207 localizes 
large numbers of CD8α+ dendritic cells to the marginal zone of mouse spleen, Proceedings of the 
National Academy of Sciences, 106 (2009) 1524-1529. 
[10] I. Caminschi, A.I. Proietto, F. Ahmet, S. Kitsoulis, J.S. Teh, J.C.Y. Lo, A. Rizzitelli, L. Wu, D. 
Vremec, S.L.H. van Dommelen, I.K. Campbell, E. Maraskovsky, H. Braley, G.M. Davey, P. Mottram, 
N.V. De Velde, K. Jensen, A.M. Lew, M.D. Wright, W.R. Heath, K. Shortman, M.H. Lahoud, The 
dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement, Blood, 112 
(2008) 3264-3273. 
[11] M.H. Lahoud, A.I. Proietto, F. Ahmet, S. Kitsoulis, L. Eidsmo, L. Wu, P. Sathe, S. Pietersz, H.-W. 
Chang, I.D. Walker, E. Maraskovsky, H. Braley, A.M. Lew, M.D. Wright, W.R. Heath, K. Shortman, I. 
Caminschi, The C-Type Lectin Clec12A Present on Mouse and Human Dendritic Cells Can Serve as a 
Target for Antigen Delivery and Enhancement of Antibody Responses, The Journal of Immunology, 
182 (2009) 7587-7594. 
[12] S. Zelenay, A.M. Keller, P.G. Whitney, B.U. Schraml, S. Deddouche, N.C. Rogers, O. Schulz, D. 
Sancho, C. Reis e Sousa, The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic 
cell antigens to favor cross-priming of CTLs in virus-infected mice, The Journal of Clinical 
Investigation, 122 (2012) 1615-1627. 
[13] J.-G. Zhang, Peter E. Czabotar, Antonia N. Policheni, I. Caminschi, S. San Wan, S. Kitsoulis, 
Kirsteen M. Tullett, Adeline Y. Robin, R. Brammananth, Mark F. van Delft, J. Lu, Lorraine A. 
O'Reilly, Emma C. Josefsson, Benjamin T. Kile, Wei J. Chin, Justine D. Mintern, Maya A. Olshina, W. 
Wong, J. Baum, Mark D. Wright, David C.S. Huang, N. Mohandas, Ross L. Coppel, Peter M. Colman, 
Nicos A. Nicola, K. Shortman, Mireille H. Lahoud, The Dendritic Cell Receptor Clec9A Binds 
Damaged Cells via Exposed Actin Filaments, Immunity, 36 (2012) 646-657. 
[14] C. Huysamen, J.A. Willment, K.M. Dennehy, G.D. Brown, CLEC9A is a novel activation C-type 
lectin-like receptor expressed on BDCA3(+) dendritic cells and a subset of monocytes, Journal of 
Biological Chemistry, 283 (2008) 16693-16701. 
[15] M.H. Lahoud, F. Ahmet, S. Kitsoulis, S.S. Wan, D. Vremec, C.N. Lee, B. Phipson, W. Shi, G.K. 
Smyth, A.M. Lew, Y. Kato, S.N. Mueller, G.M. Davey, W.R. Heath, K. Shortman, I. Caminschi, 
Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased 
toward a Follicular Helper Phenotype, J. Immunol, 187 (2011) 842-850. 
135 
 
[16] D. Sancho, Mour, xE, S. o, xE, Diego, O.P. Joffre, O. Schulz, N.C. Rogers, D.J. Pennington, J.R. 
Carlyle, C. Reis e Sousa, Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type 
lectin, The Journal of Clinical Investigation, 118 (2008) 2098-2110. 
[17] L.C. Bonifaz, D.P. Bonnyay, A. Charalambous, D.I. Darguste, S.-I. Fujii, H. Soares, M.K. 
Brimnes, B. Moltedo, T.M. Moran, R.M. Steinman, In Vivo Targeting of Antigens to Maturing 
Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination, The Journal of Experimental 
Medicine, 199 (2004) 815-824. 
[18] T.S. Johnson, K. Mahnke, V. Storn, K. Schönfeld, S. Ring, D.M. Nettelbeck, H.J. Haisma, F. Le 
Gall, R.E. Kontermann, A.H. Enk, Inhibition of melanoma growth by targeting of antigen to dendritic 
cells via an anti-DEC-205 single-chain fragment variable molecule, Clinical cancer research : an 
official journal of the American Association for Cancer Research, 14 (2008) 8169-8177. 
[19] J. Idoyaga, A. Lubkin, C. Fiorese, M.H. Lahoud, I. Caminschi, Y.X. Huang, A. Rodriguez, B.E. 
Clausen, C.G. Park, C. Trumpfheller, R.M. Steinman, Comparable T helper 1 (Th1) and CD8 T-cell 
immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and 
Clec9A, Proceedings of the National Academy of Sciences of the United States of America, 108 (2011) 
2384-2389. 
[20] P. Muttil, C. Prego, L. Garcia-Contreras, B. Pulliam, J. Fallon, C. Wang, A. Hickey, D. Edwards, 
Immunization of Guinea Pigs with Novel Hepatitis B Antigen as Nanoparticle Aggregate Powders 
Administered by the Pulmonary Route, AAPS J, 12 (2010) 330-337. 
[21] H.Y. Chou, X.Z. Lin, W.Y. Pan, P.Y. Wu, C.M. Chang, T.Y. Lin, H.H. Shen, M.H. Tao, 
Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the 
recruitment and activation of dendritic cells, Journal of immunology (Baltimore, Md. : 1950), 185 
(2010) 5468-5475. 
[22] S. Raman, G. Machaidze, A. Lustig, U. Aebi, P. Burkhard, Structure-based design of peptides that 
self-assemble into regular polyhedral nanoparticles, Nanomedicine : nanotechnology, biology, and 
medicine, 2 (2006) 95-102. 
[23] S. Babapoor, T. Neef, C. Mittelholzer, T. Girshick, A. Garmendia, H. Shang, M.I. Khan, P. 
Burkhard, A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian 
Influenza Infection, Influenza Research and Treatment, 2011 (2011). 
[24] Y.Y. Hwang, K. Ramalingam, D.R. Bienek, V. Lee, T. You, R. Alvarez, Antimicrobial Activity of 
Nanoemulsion in Combination with Cetylpyridinium Chloride in Multidrug-Resistant Acinetobacter 
baumannii, Antimicrobial Agents and Chemotherapy, 57 (2013) 3568-3575. 
[25] K. Matsuo, H. Koizumi, M. Akashi, S. Nakagawa, T. Fujita, A. Yamamoto, N. Okada, Intranasal 
immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent 
tumor immunity, Journal of Controlled Release, 152 (2011) 310-316. 
[26] D. O’Hagan, T. Tsai, S. Reed, Emulsion-Based Adjuvants for Improved Influenza Vaccines, in: R. 
Rappuoli, G. Del Giudice (Eds.) Influenza Vaccines for the Future, Springer Basel, 2011, pp. 327-357. 
[27] S. Calabro, M. Tortoli, B.C. Baudner, A. Pacitto, M. Cortese, D.T. O’Hagan, E. De Gregorio, A. 
Seubert, A. Wack, Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and 
monocytes that participate in antigen transport to draining lymph nodes, Vaccine, 29 (2011) 1812-
1823. 
[28] A. Seubert, E. Monaci, M. Pizza, D.T. O’Hagan, A. Wack, The Adjuvants Aluminum Hydroxide 
and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation 
toward Dendritic Cells, The Journal of Immunology, 180 (2008) 5402-5412. 
[29] L.R. Stanberry, J.K. Simon, C. Johnson, P.L. Robinson, J. Morry, M.R. Flack, S. Gracon, A. Myc, 
T. Hamouda, J.R. Baker Jr, Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant 
W805EC combined with approved seasonal influenza antigens, Vaccine, 30 (2012) 307-316. 
136 
 
[30] T.G. Boyce, H.H. Hsu, E.C. Sannella, S.D. Coleman-Dockery, E. Baylis, Y. Zhu, G. Barchfeld, A. 
DiFrancesco, M. Paranandi, B. Culley, K.M. Neuzil, P.F. Wright, Safety and immunogenicity of 
adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults, 
Vaccine, 19 (2000) 217-226. 
[31] S. Laurent, S. Boutry, I. Mahieu, L. Vander Elst, R.N. Muller, Iron Oxide Based MR Contrast 
Agents: from Chemistry to Cell Labeling, CURRENT MEDICINAL CHEMISTRY, 16 (2009) 4712-
4727. 
[32] S. Mornet, S. Vasseur, F. Grasset, E. Duguet, Magnetic nanoparticle design for medical diagnosis 
and therapy, Journal of Materials Chemistry, 14 (2004) 2161-2175. 
[33] S.M. Moghimi, A.C. Hunter, J.C. Murray, Long-Circulating and Target-Specific Nanoparticles: 
Theory to Practice, Pharmacological Reviews, 53 (2001) 283-318. 
[34] D. Peer, J.M. Karp, S. Hong, O.C. FaroKhzad, R. Margalit, R. Langer, Nanocarriers as an 
emerging platform for cancer therapy, Nat. Nanotechnol., 2 (2007) 751-760. 
[35] B.J. Zeng, Y.P. Chuan, B. O'Sullivan, I. Caminschi, M.H. Lahoud, R. Thomas, A.P.J. Middelberg, 
Receptor-Specific Delivery of Protein Antigen to Dendritic Cells by a Nanoemulsion Formed Using 
Top-Down Non-Covalent Click Self-Assembly, Small, 9 (2013) 3736-3742. 
[36] W.W.J. Unger, A.J. van Beelen, S.C. Bruijns, M. Joshi, C.M. Fehres, L. van Bloois, M.I. 
Verstege, M. Ambrosini, H. Kalay, K. Nazmi, J.G. Bolscher, E. Hooijberg, T.D. de Gruijl, G. Storm, 
Y. van Kooyk, Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-
SIGN on dendritic cells, Journal of Controlled Release, 160 (2012) 88-95. 
[37] J.J. García-Vallejo, M. Ambrosini, A. Overbeek, W.E. van Riel, K. Bloem, W.W.J. Unger, F. 
Chiodo, J.G. Bolscher, K. Nazmi, H. Kalay, Y. van Kooyk, Multivalent glycopeptide dendrimers for 
the targeted delivery of antigens to dendritic cells, Molecular Immunology, 53 (2013) 387-397. 
[38] K. Kawano, Y. Maitani, Effects of polyethylene glycol spacer length and ligand density on rolate 
receptor targeting of liposomal doxorubicin in vitro, J. Drug Deliv., 2011 (2010) 6. 
[39] A. Yamada, Y. Taniguchi, K. Kawano, T. Honda, Y. Hattori, Y. Maitani, Design of folate-linked 
liposomal doxorubicin to its antitumor effect in mice, Clinical Cancer Research, 14 (2008) 8161-8168. 
[40] A.F. Dexter, A.S. Malcolm, A.P.J. Middelberg, Reversible active switching of the mechanical 
properties of a peptide film at a fluid-fluid interface, Nat Mater, 5 (2006) 502-506. 
[41] C.L. Hutchings, S.C. Gilbert, A.V.S. Hill, A.C. Moore, Novel Protein and Poxvirus-Based 
Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity, The 
Journal of Immunology, 175 (2005) 599-606. 
[42] Y. Tahara, S. Honda, N. Kamiya, H. Piao, A. Hirata, E. Hayakawa, T. Fujii, M. Goto, A solid-in-
oil nanodispersion for transcutaneous protein delivery, Journal of Controlled Release, 131 (2008) 14-
18. 
[43] R. Agarwal, K. Roy, Intracellular delivery of polymeric nanocarriers: a matter of size, shape, 
charge, elasticity and surface composition, Therapeutic delivery, 4 (2013) 705. 
[44] P.J. White, F. Anastasopoulos, J.E. Church, C.Y. Kuo, B.J. Boyd, P.L.C. Hickey, L.S. Tu, P. 
Burns, A.M. Lew, W.R. Heath, G.M. Davey, C.W. Pouton, Generic construction of single component 
particles that elicit humoural and cellular immune responses without the need for adjuvants, Vaccine, 
26 (2008) 6824-6831. 
[45] J.M. den Haan, S.M. Lehar, M.J. Bevan, CD8(+) but not CD8(-) dendritic cells cross-prime 
cytotoxic T cells in vivo, The Journal of Experimental Medicine, 192 (2000) 1685-1695. 
[46] J.L. Pooley, W.R. Heath, K. Shortman, Cutting edge: intravenous soluble antigen is presented to 
CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells, 
Journal of immunology (Baltimore, Md. : 1950), 166 (2001) 5327-5330. 
137 
 
[47] P. Schnorrer, E. Maraskovsky, G.T. Belz, F.R. Carbone, K. Shortman, W.R. Heath, J.A. 
Villadangos, G.M.N. Behrens, N.S. Wilson, J.L. Pooley, C.M. Smith, D. El-Sukkari, G. Davey, F. 
Kupresanin, M. Li, The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by 
antigen capture, Proceedings of the National Academy of Sciences of the United States of America, 
103 (2006) 10729-10734. 
 
 
  
138 
 
Chapter 7  Conclusions and future directions 
 
Rational design of drug delivery system (DDS) has provided a solution to overcome the problems that 
many drugs have, such as poor water-solubility, rapid blood clearance and severe side effect. The 
application of nanotechnology to DDS has exerted tremendous impact on medicine in the past few 
decades. Nanocarriers hold great potential as drug delivery vehicles as they can be tailored to deliver 
unique drug combinations needed for personalized medical interventions, with a concurrent 
minimization of side effects in a cell-specific manner. There are over twenty nanocarrier-based 
therapeutic in clinical use, and numerous others are at various stage of development. Nanocarrier-based 
therapeutics, or nanomedicine, is expected to play increasingly important role in modern medicine 
landscape.  
 
However, the development of nanocarriers to date still has drawbacks including low drug loading 
capacity and laborious manufacturing process and low in therapeutic efficiency. To this end, this 
doctoral work aims to develop a tailorable nanocarrier emulsion (TNE) through an entirely novel nano-
engineering approach based on non-covalent self-assembly at the oil-water interface. A completely new 
concept of using a surface active protein surfactant DAMP4 as an anchor to display functional moieties 
on the surface of nanoemulsion was explored and developed in this doctoral project, by which the use 
of stringent chemistry that required for surface functionalization was substantially minimized. Surface 
active peptide AM1 stabilized oil-in-water emulsion provides a well-defined interface to facilitate self-
assemble surface functionalization mediated by DAMP4. Meanwhile, incorporation of active 
components into the oil phase at the time of emulsion formation enables facile packaging. The TNE 
platform developed from this doctoral work was functionalized with PEG and a mAb against DCs 
specific receptor Clec9A. At the physiological level, PEGylation of nanocarrier increases in vivo half-
life and enhance accumulation through passive targeting. Nanocarriers functionalized with site specific 
ligand increased target specificity and assisted in overcoming multiple cellular barriers through 
receptor-mediated endocytosis. At the molecular level, nanocarriers loaded with various drug 
combinations can further improve treatment efficacy by targeting multiple molecular pathways. 
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The experimental works discussed in this thesis were designed to explore the hypothesis of DAMP4 
mediating TNE functionalization and solve obvious challenges along the way, through achieving the 
following aspects: 
 
(i) Utilization of DAMP4 modified with polyethylene glycol (PEG) to investigate whether 
DAMP4 can display PEG at the interface and impart altered cell association to the 
nanoemulsion – This preliminary study evaluated the hypothesis stated in Chapter 1 and high-
lighted the potential of using DAMP4 for TNE surface functionalization  (Chapter 3); 
(ii) Utilization of DAMP4 modified with monoclonal antibody (mAb) against the CD8+ DCs 
specific receptor Clec9A to design a nanocarrier emulsion that able to target Clec9A+ DCs – 
This study evaluate the robustness and effectiveness of Clec9A mAb functionalized TNE. The  
in vivo target specificity of Clec9A+ DC targeting TNE was investigated (Chapter 4); 
(iii) Targeting antigen to DCs by TNE – A model antigen was encapsulated into the oil core of TNE 
and the efficiency of TNE in delivering its payload to DCs was evaluated by measuring antigen-
specific immune response (Chapter 5 and 6). The impact of Clec9A mAb molecule numbers 
presented on the TNE surface was also evaluated (Chapter 6). 
 
The following sections will reiterate the important conclusions from this dissertation and give some 
prospective points for the future work of this research.  
 
7.1. Summary of research findings 
In Chapter 3, I described the design and development of PEGylated nanocarrier emulsion with 
enhanced immune evading ability through a simple top-down sequential addition of PEG modified 
DAMP4. This chapter aimed at evaluating the hypothesis of DAMP4 mediating TNE functionalization 
(introduced in Chapter 1 in detail) through the construction of a PEGylated TNE. Here, we showed 
that simple mixing of AM1 stabilized TNE core with PEG-DAMP4 conjugate led to the non-covalent 
attachment of PEG to the surface of emulsion droplet. Addition of PEG-DAMP4 conjugate into the 
TNE system imparts steric stability to the TNE oil core in isotonic conditions, which enables 
intravenous injection and intracellular delivery application. PEGylation is a common strategy to 
increase “stealthiness” of nanocarrier by creating a steric barrier around the nanocarrier which against 
non-specific association with opsonins (Harris and Chess, 2003, Harris et al., 2001, Krystek et al., 
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2011). An effective shielding of the nanocarrier with a PEG layer is of important to increase in vivo 
half-life. PEGylation of TNE through addition of PEG-DAMP4 to the TNE system reduces non-
specific cell association compared to its non-PEGylated counterpart in vitro. In light of the results 
shown in this chapter, we confirmed the hypothesis that the integration of DAMP4 into the AM1 
stabilized oil droplet surface would lead to the functional display of conjugated PEG at the interface of 
the TNE oil core. Non-specific cell association of TNE can be down-regulated to a minimum with 
appropriate shielding from self-assembled PEG using DAMP4 as an anchor. However, whether the 
PEG layer present on the TNE oil core surface reduce opsonins adsorption, and thereby complement 
activation and MPS clearance, need to be performed in vivo and I addressed this issue in the following 
chapters.  
 
For therapeutic nanocarrier to maximize their efficacy, they need to arrive at the specific biological 
locations to release their payload. The active targeting of nanocarrier can be achieved by 
functionalization of a site specific ligand or mAb. The realization of the DCs are critical for initiation 
and control of innate and adaptive immune response, give rise to a number of strategies for target 
delivery antigen to DCs. Several studies have shown the delivery efficacy and efficiency of nanocarrier 
can be improved by engineering with a DCs targeting moiety on surface (Sehgal et al., 2014, 
Bandyopadhyay et al., 2011, Unger et al., 2012, Tel et al., 2013). To achieve targeting delivery, 
different DCs specific receptors had been studied with special interest to C-type lectin receptors 
(CRLRs), e.g. Clec9A (Caminschi et al., 2008, Huysamen et al., 2008, Idoyaga et al., 2011, Lahoud et 
al., 2011, Sancho et al., 2009, Schreibelt et al., 2012, Zelenay et al., 2012, Zhang et al., 2012). 
Chemical methods that most of the current Clec9A targeting strategies used for conjugating with 
vaccine antigen cannot guarantee site-specific conjugates and led to poor stoichiometry. In this PhD 
project, Clec9A mAb was conjugated to DAMP4 via genetic fusion approach and expressed as a 
recombinant fusion protein to eliminate the risk of mAb deactivation by extreme chemical conjugation 
condition. Leveraging the findings and method developed in Chapter 3, the design and development of 
Clec9A+ DC targeting TNE (P200-Ab-P20-TNE) through the non-covalent “click” chemistry was 
discussed in Chapter 4. Using DAMP4 as an anchor to display mAb on the TNE surface, I was able to 
construct Clec9A targeting TNE for in vitro and in vivo study. The functionalization of TNE with anti-
Clec9A mAb increased cell association to Clec9A-expressing cell line. With the array of Clec9A-
targeted TNE formulated with different concentration of PEG, I evaluated the target specificity in 
relation to PEG density on TNE surface to Clec9A-expressing cell lines. As expected, increased PEG 
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density on TNE surface reduces the non-specific cell association and increases specificity towards 
Clec9A+ DCs. These results not only demonstrating the ability of the developed production method is 
capable of manipulating the target specificity by simple variation of TNE composition, but also showed 
the importance of maintaining an optimal balance of functional moieties on TNE surface.  
 
Motivated by the need of developing an effective delivery system for biologics and vaccine, Chapter 5 
extended the studies in Chapter 3 and 4 into the application of TNE for intracellular delivery of 
protein antigen. DCs are the most effective antigen-presenting cells that initiate and regulate antigen-
specific immune responses. DCs internalize, process and present antigens to naïve T cells, therefore 
researchers have exploited DCs in an attempt to improve vaccine efficacy. In our study, hydrophilic 
ovalbumin (OVA) was loaded into the oil core using the solid-in-oil (S/O) nanodispersion method for 
enhanced solubility, which does not require any covalent conjugation that would damage the native 
properties of protein. OVA has been studied as a model antigen for a long time since many analysis 
tools have been developed, for example transgenic OT-I and OT-II mice which bear CD8+ and CD4+ T-
cells respectively recognizing epitopes of the OVA (Hogquist et al., 1994, Barnden et al., 1998). 
Presentation of OT-I T cell specific OVA epitode (OVA257-264, SIINFEKL) by DCs to OT-I T cells 
leads to proliferation and differentiation of cytotoxic CD8+ T cells, while presentation of OT-II specific 
OVA epitode (OVA323-339) to OT-II T cells results in proliferation and differentiation of cytokine 
producing CD4+ T cells. By using dot-blot assay, we showed that immunity of OVA protein was well 
preserved after it had been encapsulated within the TNE oil core. Exogenous antigens need to be cross-
presented on MHC I molecules to CD8+ T-cells for their activation. As an initial test, here we showed 
that OVA-P200-Ab-P20-TNE was able to elicit antigen-specific OT-I T cell proliferation both in vitro 
and in vivo. In addition, results in this chapter further support the hypothesis that TNE will serve as an 
effective DDS platform for targeting DCs. 
 
In Chapter 6, we examine the potential of TNE as vehicle for targeting antigen to Clec9A+ DCs in 
vivo. DC-based immunotherapy has been developed to the point where it is currently in the clinical trial 
phase (Apostolopoulos et al., 2014). However, such strategy also comes with problems such as the 
plasticity and complexity of DC maturation, shelf-life, high cost which restrict the translation of this 
therapeutic approach (Giannoukakis et al., 2011, Waeckerle-Men and Groettrup, 2005). Instead of 
manipulating DCs ex vivo, here we use a DCs targeting nanocarrier approach to apply the “in situ DC 
conditioning” concept to modulate immune response.   
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We analysed the immune response to model protein antigen OVA encapsulated within TNE (OVA-
P200-Ab-P20-TNE). The primary activation of T-helper and cytotoxic T-cells (CTL) following 
immunization with OVA-P200-Ab-P20-TNE was studied in vivo by adoptive transfer OT-I and OT-II T 
cells into naïve mice. We showed that TNE is an effective antigen delivery system for induction of both 
CD4 and CD8 T cell immunity. Mice immunized with Clec9A+ DCs targeting OVA-P200-Ab-P20-TNE 
showed enhanced antigen-specific CD4+ and CD8+ T cells response in spleen and lymph nodes, as 
compared to mice immunized with OVA encapsulated within the non-targeting TNE. Notably, 
targeting OVA to Clec9A+ DCs via TNE resulted in sustained and enhanced anti-OVA response in 
three weeks post immunization. Whilst soluble OVA is weak at activating CD8 T cell or CTL response 
(Ke et al., 1995), herein we demonstrated that immunization with OVA-P200-Ab-P20-TNE in naïve mice 
leads to generation of functional effector CTL that selectively killed antigen-specific target cells, even 
when low dose of soluble OVA was delivered and in the absence of adjuvant. Both humoural and cell-
mediated immune responses are essential elements required by novel vaccine design. Results from 
Chapter 6 demonstrate potential of TNE in efficient induction of T cell immunity. More importantly, 
we showed that strong CD8+ T cell response can be activated by antigen delivered by TNE, without the 
need for any chemical-based adjuvant, therefore circumventing any potential tolerability and safety 
issues. Questions regarding whether the ability of antigen carrying TNE for inducing antigen specific T 
cell immunity is dependent of the TNE formulation or the amount of antigen being encapsulated and 
delivered to DCs is of interest of this PhD project. We addressed this question by generating a panel of 
OVA-P200-Ab-P20-TNE which comprised varied molar ratios of OVA payload to targeting mAb, while 
keeping the composition of other components constant, and tested their efficacy in inducing OVA-
specific T cell proliferation. We showed that the target specificity was partly dependent on the targeting 
mAb concentration within the TNE formulation, and the immunity responses could potentially be tuned 
by simply changing the concentration of the targeting mAb. Taken together, this chapter highlights the 
TNE platform as an effective antigen-delivery system to enhance CD8+ and CD4+ T cell immunity, 
hereby prove targeting delivery of protein antigen by TNE potentially an effective, adjuvant-free and 
simple platform for use as therapeutic vaccines to deliver both humoral and T cell mediated immunity. 
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7.2. Future direction 
Evidently, this project is still at a nascent stage. Nonetheless, given the promising results thus far it 
should be worth to further explore and optimize the TNE platform for translation to clinical application 
in human. To accomplish this distant goal we will first have to improve the efficiency of the current 
TNE formulation. Reliable drug adsorption, distribution, metabolism, excretion and toxicity (ADME/T) 
are important properties critical for any drug development. Thus comprehensive pharmacokinetics and 
pharmacodynamics studies including an extensive toxicity analysis are required to evaluate and 
optimize the TNE delivery regime in vivo. In the studies described in the thesis, the dose of antigen 
was matched to a previously reported Clec9A targeting antigen that has been shown to stimulate a 
response (Caminschi et al., 2008, Lahoud et al., 2011). The relatively larger payload that is possible 
with TNE may allow for a reduced dose regime; therefore, a dose optimization study should be 
performed. In addition, by injecting mice with TNE that have been decorated with various amounts of 
anti-Clec9A mAb, we demonstrated that the efficiency of TNE for cross-presentation was partly 
dependent on the density of targeting moieties that been engineered on the TNE surface. Therefore 
there is an optimal density for targeting mAb below TNE surface-saturation levels that needs to be 
determined in the future studies.  
 
Although TNE have been shown to be an effective vehicle for targeting antigen to Clec9A+ DCs, those 
results were demonstrated by monitoring only cellular assays, e.g. antigen–specific CTL. In order to 
demonstrate translational significance of this delivery system, testing TNE in a disease model to show 
proof of concept will be essential. Clec9A have been shown to be a promising target for in vivo antigen 
delivery in human to increase the efficiency of vaccines against cancerous or infectious disease, 
targeting tumor antigen to Clec9A with adjuvant induced antitumor immunity in a mouse melanoma 
model (Schreibelt et al., 2012, Sancho et al., 2008). The TNE platform developed from this PhD project 
that is capable of highly specifically delivering protein antigen would potentially be a significant 
breakthrough in cancer treatment. 
 
7.3. Conclusion thoughts 
The results presented in this thesis add significant contributions to the continuing development of 
therapeutic nanocarriers. While functionally distinct, each of the aforementioned developments is 
structurally compatible with one another. The techniques for decorating TNE with PEG and mAb are 
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also compatible with other nanostructures, providing additional toolkit to the fledging field of 
nanotechnology and nanomedicine. The most significant results associated with this thesis centre 
around the exploitation of the application of protein surfactant DAMP4 as anchor for nanocarrier 
emulsion functionalization. This is the first time, to our best knowledge, that surface active peptide and 
protein has been utilized to prepare a nanoemulsion DDS with highly efficacious in vivo target 
specificity.   
145 
 
7.4. References APOSTOLOPOULOS, V., PIETERSZ, G. A., TSIBANIS, A., TSIKKINIS, A., STOJANOVSKA, L., MCKENZIE, I. F. C. & VASSILAROS, S. 2014. Dendritic cell immunotherapy: clinical outcomes. Clin Trans Immunol, 3, e21. BANDYOPADHYAY, A., FINE, R. L., DEMENTO, S., BOCKENSTEDT, L. K. & FAHMY, T. M. 2011. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials, 32, 3094-3105. BARNDEN, M. J., ALLISON, J., HEATH, W. R. & CARBONE, F. R. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based [agr]- and [bgr]-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol, 76, 34-40. CAMINSCHI, I., PROIETTO, A. I., AHMET, F., KITSOULIS, S., TEH, J. S., LO, J. C. Y., RIZZITELLI, A., WU, L., VREMEC, D., VAN DOMMELEN, S. L. H., CAMPBELL, I. K., MARASKOVSKY, E., BRALEY, H., DAVEY, G. M., MOTTRAM, P., DE VELDE, N. V., JENSEN, K., LEW, A. M., WRIGHT, M. D., HEATH, W. R., SHORTMAN, K. & LAHOUD, M. H. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood, 112, 3264-3273. GIANNOUKAKIS, N., PHILLIPS, B., FINEGOLD, D., HARNAHA, J. & TRUCCO, M. 2011. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes 
care, 34, 2026-2032. HARRIS, J. M. & CHESS, R. B. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov, 2, 214-221. HARRIS, J. M., MARTIN, N. E. & MODI, M. 2001. Pegylation - A novel process for modifying pharmacokinetics. Clinical Pharmacokinetics, 40, 539-551. HOGQUIST, K. A., JAMESON, S. C., HEATH, W. R., HOWARD, J. L., BEVAN, M. J. & CARBONE, F. R. 1994. T cell receptor antagonist peptides induce positive selection. Cell, 76, 17-27. HUYSAMEN, C., WILLMENT, J. A., DENNEHY, K. M. & BROWN, G. D. 2008. CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3(+) dendritic cells and a subset of monocytes. Journal of Biological Chemistry, 283, 16693-16701. IDOYAGA, J., LUBKIN, A., FIORESE, C., LAHOUD, M. H., CAMINSCHI, I., HUANG, Y. X., RODRIGUEZ, A., CLAUSEN, B. E., PARK, C. G., TRUMPFHELLER, C. & STEINMAN, R. M. 2011. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proceedings of the National Academy 
of Sciences of the United States of America, 108, 2384-2389. KE, Y., LI, Y. & KAPP, J. A. 1995. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. European Journal of Immunology, 25, 549-553. KRYSTEK, P., OOMEN, A. G., RAYAVARAPU, R. G., LEEUWEN, V. T. G., JONG, D. W. H., MANOHAR, S., LANKVELD, D. P. K. & VERHAREN, H. W. 2011. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. 
Nanomedicine, 6, 339-349. LAHOUD, M. H., AHMET, F., KITSOULIS, S., WAN, S. S., VREMEC, D., LEE, C. N., PHIPSON, B., SHI, W., SMYTH, G. K., LEW, A. M., KATO, Y., MUELLER, S. N., DAVEY, G. M., HEATH, W. R., SHORTMAN, K. & CAMINSCHI, I. 2011. Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype. 
J. Immunol, 187, 842-850. 
146 
 
SANCHO, D., JOFFRE, O. P., KELLER, A. M., ROGERS, N. C., MARTINEZ, D., HERNANZ-FALCON, P., ROSEWELL, I. & SOUSA, C. R. E. 2009. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature, 458, 899-903. SANCHO, D., MOUR, XE, O, S., XE, DIEGO, JOFFRE, O. P., SCHULZ, O., ROGERS, N. C., PENNINGTON, D. J., CARLYLE, J. R. & REIS E SOUSA, C. 2008. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. The Journal of Clinical Investigation, 118, 2098-2110. SCHREIBELT, G., KLINKENBERG, L. J. J., CRUZ, L. J., TACKEN, P. J., TEL, J., KREUTZ, M., ADEMA, G. J., BROWN, G. D., FIGDOR, C. G. & DE VRIES, I. J. M. 2012. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 119, 2284-2292. SEHGAL, K., RAGHEB, R., FAHMY, T. M., DHODAPKAR, M. V. & DHODAPKAR, K. M. 2014. Nanoparticle-Mediated Combinatorial Targeting of Multiple Human Dendritic Cell (DC) Subsets Leads to Enhanced T Cell Activation via IL-15–Dependent DC Crosstalk. The 
Journal of Immunology, 193, 2297-2305. TEL, J., SITTIG, S. P., BLOM, R. A. M., CRUZ, L. J., SCHREIBELT, G., FIGDOR, C. G. & DE VRIES, I. J. M. 2013. Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion. The Journal of Immunology, 191, 5005-5012. UNGER, W. W. J., VAN BEELEN, A. J., BRUIJNS, S. C., JOSHI, M., FEHRES, C. M., VAN BLOOIS, L., VERSTEGE, M. I., AMBROSINI, M., KALAY, H., NAZMI, K., BOLSCHER, J. G., HOOIJBERG, E., DE GRUIJL, T. D., STORM, G. & VAN KOOYK, Y. 2012. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of 
Controlled Release, 160, 88-95. WAECKERLE-MEN, Y. & GROETTRUP, M. 2005. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Advanced Drug Delivery Reviews, 57, 475-482. ZELENAY, S., KELLER, A. M., WHITNEY, P. G., SCHRAML, B. U., DEDDOUCHE, S., ROGERS, N. C., SCHULZ, O., SANCHO, D. & REIS E SOUSA, C. 2012. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. The Journal of Clinical Investigation, 122, 1615-1627. ZHANG, J.-G., CZABOTAR, PETER E., POLICHENI, ANTONIA N., CAMINSCHI, I., SAN WAN, S., KITSOULIS, S., TULLETT, KIRSTEEN M., ROBIN, ADELINE Y., BRAMMANANTH, R., VAN DELFT, MARK F., LU, J., O'REILLY, LORRAINE A., JOSEFSSON, EMMA C., KILE, BENJAMIN T., CHIN, WEI J., MINTERN, JUSTINE D., OLSHINA, MAYA A., WONG, W., BAUM, J., WRIGHT, MARK D., HUANG, DAVID C. S., MOHANDAS, N., COPPEL, ROSS L., COLMAN, PETER M., NICOLA, NICOS A., SHORTMAN, K. & LAHOUD, MIREILLE H. 2012. The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments. Immunity, 36, 646-657. 
 
 
 
  
147 
 
Appendix A 
Receptor-Specific Delivery of Protein Antigen to Dendritic Cells 
by a Nanoemulsion Formed Using Top-Down Non-Covalent Click 
Self-Assembly 
 
The entire Appendix A consists of the journal article published as: 
 
ZENG, B. J., CHUAN, Y. P., O'SULLIVAN, B., CAMINSCHI, I., LAHOUD, M. H., THOMAS, 
R. & MIDDELBERG, A. P. J. 2013. Receptor-Specific Delivery of Protein Antigen to Dendritic 
Cells by a Nanoemulsion Formed Using Top-Down Non-Covalent Click Self-Assembly. Small, 9, 
3736-3742.  
 
The following modifications were made to the article: 
- Page numbers of the original article were crossed out; and 
- Page numbers consistent with those on the remainder of the thesis pages were inserted. 
  
         

        
       
  
                                 
         
        
       
          
       
              
       
          
       
           
              
        
          
         
           
             
         
        
         
          
            
        
          
          
          
         
       
       
       
       
       
         
      
      
            
           
        
        
           
         
           
          
            
       
        
      
  
        
        
             
         
           
       
           
        
        
        
           
         
       
       
        
           
           
         
         
            
          
            
 
            
    
    
  
     
  
      
    
  
   
    
       
         
    
       
   
      
     
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      
        
         
          
           
         
       
         
      
           
         
      
            
       
         
         
        
           
       
          
                         
                    
                     
                      
                       
                      
                        
           
     
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    
 

        
     
       
     
      
    
       
     
      
      
       
     
        
      
        
         
       
     
        
          
       
        
           
     
      
         
        
      
      
      
         
     
     
      
      
        
      
        
     
       
         
     
     
        
         
      
       
              
         
             
           
                  
          
              
          
             
         
      
          
        
       
            
             
        
          
           
       
          
  
         
        
        
       
               
              
               
                  
            
               
             
                      
                    
                             
               
      
     
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      
        
         
           
        
              
         
           
         
        
        
         
         
          
           
      
         
            
             
      
       
         
          
      
      
        
     
             
      
            
        
        
      
         
        
      
      
        
       
          
            
          
      
        
       
      
      
          
       
    
     
      
        
       
     
      
      
     
        
         
          
           
         
            
         
        
            
           
          
          
         
      
         
            
         
            
             
             
               
          
                 
                  
                  
                    
                
                   
                          
               
                   
                    
     
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    
 

        
        
             
         
           
           
        
               
      
            
            
          
           
        
       
          
                
          
            
       
           
        
  
       
         
       
       
          
          
        
        
        
          
         
          
          
              
        
         
   
           
        
         
       
        
        
    
       
        
   
            
         
              
          
       
           
         
       
       
    
      
         
           
 
           
         
         
    
         
         
      
              
       
              
               
              
           
           
           
           
          
          
            
            
            
           
            
           
          
        
           
         
        
      
           
      
           
       
         
          
          
                  
               
         
           
             
              
             
           
       
               
                
                
          
              
               
     
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      
        
                 
                  
               
          
                   
                
              
                
          
         
          
         
         
           
           
          
         
                    
                     
              
           
         
              
            
        
               
                  
                 
                 
           
        
          
         
            
             
           
                      
             
                  
       
       
           
     
              
              
        
          
          
               
           
                    
       
        
                     
                    
                 
            
          
             
             
            
            
             
           
            
           
         
         
          
          
            
                      
           
                 
          
          
         
          
              
                       
             
         
                 
             
                  
            
                
         
           
           
  
         
       
        
         
          
        
         
       
    
                              
                            
                          
                             
                       
         
                             
                             
                              
                            
                          
                                 
                            
     
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    
 

        
                         
                        
                          
                              
                                     
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Appendix B 
Co-delivery of antigen and a lipophilic anti-inflammatory drug to 
cells via a tailorable nanocarrier emulsion 
 
The entire Appendix B consists of the journal article published as: 
 
CHUAN, Y. P., ZENG, B. Y., O'SULLIVAN, B., THOMAS, R. & MIDDELBERG, A. P. J. 2011. Co-
delivery of antigen and a lipophilic anti-inflammatory drug to cells via a tailorable nanocarrier 
emulsion. Journal of Colloid and Interface Science, 368, 616-624. 
 
The following modifications were made to the article: 
- Page numbers of the original article were crossed out; and 
- Page numbers consistent with those on the remainder of the thesis pages were inserted. 
 
         
    
                 
               
                     
   
          
 
   
   
    

 





       
               
               
                
               
              
            
                 
            
             
                
              
               
              
 
     
 
          
         
        
        
         
           
        
            
       
          
      
       
        
       
        
           
         
        
       
         
         
      
        
       
          
 
       
        
          
          
         
          
       
          
       
           
       

      
           
       
          

       
         
        
    
        
     
     
 
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        
        
        
         
         
       
         
           
        
        
        
        
        
         
       
         
        
      
       
        
     
          
        
           
          
         
       
         
          
          
         
           
            
       
      
           
       
       
        
       
         
        
        
        
         
        
          
      

   
     
         
         
        
        
           
         
     
         
       
         
      
          
     
       
       
       
          
         
            
        
       
           
         
         
     
                        
   
              
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       
        
       
         
        
         
          
          
         
            
          
        
         
           
      
          
         
   
           
        
           
        
          
         
            
            
        
         
              
           
           
         
         
          
         
         
         
         
        
        
         
       
        
        
        
           
            
        
          
            
          
            
            
        
         
          
        
        
          
       
            
            
           
           
            
           
         
           
            
         
          
         
          
          
         
      
        
           
         
       
        
            
           
           

           
             
             
       
              
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    
         
       
            
             
       
        
          
              
        
           

         
           
       
        
          
         
          
          
          
       
          
       
        
        
          
           
            
         
           
         
     
         
          
              
         
          
          
          
            
        
          
           
        
        
         
             
        
         
           
            
         
         
          
         
         
          
       
      
         
          
         
          
          
          
            
          
          
         
             
          
         
     
        
           
          
         
       
        
         
          
             
       
         
            
              
      
              
159
           
         
          
       
           
           
          
         
         
           
          
          
         
         
      
          
       
     
           
         
         
         
       
            
          
           
         
          
               
  
                          
                             
                       
          
              
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       
          
         
         
         
          
      
   
       
         
       
          
         
         
        
        
       
        
       
        
        
        
        
          
          
         
         
        
      
       
         
        
                       
                         
                              
                      
                 
              
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         
        
           
          
       
         
         
         
            
        
  
      
     
            
           
        
           
            
          
             
       
          
          
          
         
       
      
         
        
        
          
         
      
        
      
        
        
          
        
       
        

          
             
          
        
         
         
          
            
        
         
           
         
         
       
          
           
          
 
 
          
        
      
                          
                             
                         
    
              
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         
         
      
      
         
         
         
         
         
        
           
          
       
           
      
 
 
         
       
      
      
         
       
        
         
        
       
       
       
    
          
        
        
        
         
     
       
  
        
          
            
           
        
            
        
           
           
          
           
        
            
    
      
        
           
          
        
        
          
       
      
         
         
          
     
 
        
       
          
          
            
       
         
        

   
         
          
      
        
            
         
          

  
       
        
         
     
          
            
           
          
       
       

  
       
           
         
              
           
    
     
        
             
           
       
          
         
         
            
           
          
              
163
           
         
         
            
          
           
         
      
        
   
       
          
      
         
           
          
          
  

                
          
         
        
         
              
   
           

           
        
             
             
 
           

          
           
             
     
             

          
           
    
          
      
               
   
             
        
        
            
             
           
            

          
              
  
            

             
      
           
             
             
      
             
             
         
           
             
   
            
                
    
              
 
              
 
        
    
              
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